Targeted Limb Heating Augments the Actions of IGF1 in the Growth Plate and Increases Bone Elongation in Growing Mice by Racine, Holly Lyn
Marshall University 
Marshall Digital Scholar 
Theses, Dissertations and Capstones 
2018 
Targeted Limb Heating Augments the Actions of IGF1 in the 
Growth Plate and Increases Bone Elongation in Growing Mice 
Holly Lyn Racine 
tamski@marshall.edu 
Follow this and additional works at: https://mds.marshall.edu/etd 
 Part of the Animal Experimentation and Research Commons, Animal Sciences Commons, 
Musculoskeletal, Neural, and Ocular Physiology Commons, and the Physiology Commons 
Recommended Citation 
Racine, Holly Lyn, "Targeted Limb Heating Augments the Actions of IGF1 in the Growth Plate and 
Increases Bone Elongation in Growing Mice" (2018). Theses, Dissertations and Capstones. 1326. 
https://mds.marshall.edu/etd/1326 
This Dissertation is brought to you for free and open access by Marshall Digital Scholar. It has been accepted for 
inclusion in Theses, Dissertations and Capstones by an authorized administrator of Marshall Digital Scholar. For 
more information, please contact zhangj@marshall.edu, beachgr@marshall.edu. 
TARGETED LIMB HEATING AUGMENTS THE ACTIONS OF IGF1 IN THE GROWTH 






A dissertation submitted to  
the Graduate College of  
Marshall University  
In partial fulfillment of  
the requirements for the degree of  
Doctor of Philosophy  
in Biomedical Sciences  
by  
Holly Lyn Racine  
Approved by  
Dr. Maria A Serrat, Committee Chairperson 
Dr. Richard Egleton 
Dr. John Kopchick 
Dr. Travis Salisbury 

















We, the faculty supervising the work of Holly Lyn Racine, affirm that the dissertation, 
Targeted Limb Heating Augments the Actions of IGF1 in the Growth Plate and 
Increases Bone Elongation in Growing Mice, meets the high academic standards for 
original scholarship and creative work established by the Biomedical Sciences program 
and the Graduate College of Marshall University. This work also conforms to the 
editorial standards of our discipline and the Graduate College of Marshall University. 
With our signatures, we approve the manuscript for publication. 
/lld__Qj- i 0if)Or8 
Dr. Maria Serrat Committee Chairperson Date 





Dr. John Kopchick Committee Member Date 
ci!�mber 
gJt,/)'6 
Dr. Travis Salisbury Date 
/hi}-(.-., v� v+-vc c'o r iolq 















































Holly Lyn Racine 




 I would like to dedicate this work to my family who have supported me through 
the continuous ups and down along the journey to earn my PhD. I am thankful for my 
grandmother, Punky, she was always a call away to be my human thesaurus when I hit 
a mental roadblock in my writing. I would also like to specifically thank my mother, and 
best friend, she was there to listen to both my frustrations and excitement, provide 
professional advice, and also aided in giving me the time I needed to focus on my work 
(in other words, entertained my children). I am especially grateful to my husband 
Christopher. He guided me through it all and was always my biggest cheerleader. Last 
but not least, I want to dedicate this work to my daughters, Teegan and Milena, 





I would like to thank Maria Serrat for being inspirational in this area of research 
and establishing the unilateral heating model fundamental to my study. I am also 
grateful to my collegues, G. Ion and C. Meadows that were instrumental to the unilateral 
heating trials and assisting with data collection. I would also like to thank the VA Medical 
Center and CEB staff for their support throughout this project. I am grateful to Dr. 
Howard and the Marshall Animal Resource Facility for animal husbandry, assistance 
with equipment setup, and room temperature monitoring. This work was aided by the 
use of the facilities at the Huntington, West Virginia VA medical center. Research was 
made possible by the National Institute of Arthritis and Musculoskeletal and Skin 
Diseases of the National Institutes of Health (1R15AR067451-01). The content is solely 
the responsibility of the author and does not necessarily represent the official views of 




TABLE OF CONTENTS 
 
 






List of Tables……………………………………………………………………………………xii 
 




Chapter I: In Depth Review into Longitudinal Bone Growth…………………………...…...1 
  
1.1 Postnatal Longitudinal Bone Growth Through Endochondral Ossification…...1 
1.1.1 Endochondral Ossification and Growth Plate Morphology…….…...1 
1.1.2 Differential Growth of Long Bones………….…………………………4 
1.1.3 Age Comparison of Mouse and Man………………………...............6 
1.1.4 Limb Length Discrepancy……………………………………………..10 
1.2 Regulation of Growth Plate During Postnatal Linear Growth..……………….14 
1.2.1 Endocrine Regulation of Linear Growth……………………………..14 
1.2.2 Autocrine/Paracrine Regulation of Linear Growth………………….15 
1.3 Growth Hormone and Insulin-Like Growth Factor Regulate Linear 
Growth……………………………………………………………..……..………...16 
1.3.1 Evolution of the Somatomedin Hypothesis………………………….16 
1.3.2 IGF Induced Signaling Pathway……………………………………...21 
1.3.3 GH and IGF1 Distinct and Overlapping Functions on Linear 
Growth…………………………………………………………………..23 
 vii 
1.3.4 GH and IGF1 Treatment of Hormonal Deficiencies……..………...24 
1.4 IGF1 as a Primary Mediator of Longitudinal Bone Growth…..……………….26 
1.4.1 Function of Locally Expressed IGF1…………………………………26 
1.4.2 IGF1 Antagonists………………………………………………………28 
1.5 Regulation of Linear Growth by Temperature………………………….………33 
1.5.1 Temperature Regulates Linear Growth in Nature………………….33 
1.5.2 Temperature Regulates Linear Growth in Laboratory Setting……33 
1.5.3 Unilateral Heating Model Enhances Bone Lengthening…………..34 
1.5.4 Potential Function of IGF1 in Heat-Enhanced Linear Growth…….35 
1.6 Role of Vasculature in Promoting Longitudinal Bone Growth………………..36 
1.6.1 Vascular Supply of the Growth Plate………..………………………36 
1.6.2 Transport of Systemic IGF1 into the Growth Plate……………...…38 
1.6.3 Chondrocyte Expression of Angiogenic Factors……………………39 
1.7 Scope of Current Work…………………………..……………………………….40 
Chapter II: Functional Impact of Targeted Limb Heating in Mice…………..…………….44 
 2.1 Introduction………………………………………………………………………...44 
 2.2 Material and Methods……………………………………………………………..45 
  2.2.1 Animals and Experimental Design…………………………………….45 
  2.2.2 Tibial Radiographs………………………………………………………49 
  2.2.3 Hindlimb Weight Bearing……………………………………………….51 
  2.2.4 Tissue Collection………………………………………………………..51 
  2.2.5 Tibial Elongation Rate Analysis and Long Bone Measurements..…52 
  2.2.6 Statistical Analysis and Sample Size…………………………………53 
 viii 
 2.3 Results……………………………………………………………………………...54 
  2.3.1 Unilateral Heating Parameters………………………………………...54 
  2.3.2 Bone Length and Tibial Elongation Rate……………………………..54 
  2.3.3 Hindlimb Weight Bearing……………………………………………….57 
 2.4 Discussion………………………………………………………………………….59 
 2.5 Conclusion…………………………………………………………………………60 
Chapter III: Chondrocyte Proliferation and Hypertrophy in Tibial Growth Plates 
Increases After 7 Days of Targeted Limb Heating…………………………………………62 
 3.1 Introduction………………………………………………………………………...62 
3.2 Material and Methods……………………………………………………………..63 
  3.2.1 Animals and Experimental Design…………………………………….63 
  3.2.2 Tissue Collection………………………………………………………..66 
  3.2.3 Tibial Elongation Rate Analysis and Long Bone Measurements..…66 
  3.2.4 Growth Plate Morphometry………………………...…………………..67 
  3.2.5 Immunohistochemistry…………………………………………….……68 
  3.2.6 Statistical Analysis and Sample Size…………………………………71 
 3.3 Results……………………………………………………………………………...71 
  3.3.1 Unilateral Heating Parameters………………………………………...71 
  3.3.2 Bone Length and Tibial Elongation Rate……………………………..74 
  3.3.3 Growth Plate Morphometry…………………………………………….77 
  3.3.4 PCNA Expression……………………………………………………….80 
 3.4 Discussion………………………………………………………………………….82 
 3.5 Conclusion…………………………………………………………………………85 
 ix 
Chapter IV: Subcutaneous Injections of Low Dose IGF1 in Conjunction with Targeted 
Limb Heating Can Augment Heat-Enhanced Bone Growth………………………………87 
 4.1 Introduction………………………………………………………………………...87 
4.2 Material and Methods……………………………………………………………..89 
  4.2.1 Animals and Experimental Design…………………………………….89 
  4.2.2 Tissue Collection and Sample Analysis………..…………………….92 
4.2.3 Immunohistochemistry………………………………………….….…..92 
  4.2.4 Statistical Analysis and Sample Size..………………………………..92 
 4.3 Results……………………………………………………………………………..93 
  4.3.1 Unilateral Heating Parameters………………………………………..93 
  4.3.2 Length of Long Bones and Tibial Elongation Rate………………….96 
  4.3.3 Growth Plate Morphometry…………………………………………...100 
  4.3.4 PCNA Expression……………………………………………………..103 
  4.3.5 IGF1R and pIGF1R Expression in Proliferating Chondrocytes…..105 
 4.4 Discussion………………………………………………………………………..108 
 4.5 Conclusion………………………………………………………………………..115 
Chapter V: IGF1 Is Essential For Heat-Enhanced Bone Elongation……………….…..116 
 5.1 Introduction……………………………………………………………………….116 
5.2 Material and Methods……………………………………………………………118 
  5.2.1 Animals and Experimental Design…………………………………..118 
  5.2.2 Tissue Collection and Sample Analysis…………...…..……………121 
  5.2.3 Immunohistochemistry…………………………………………….….121 
  5.2.4 Statistical Analysis…………………………………………………….121 
 x 
 5.3 Results…………………………………………………………………………….122 
  5.3.1 Unilateral Heating Parameters……………………………………….122 
  5.3.2 Length of Long Bones and Tibial Elongation Rate…………………124 
  5.3.3 Growth Plate Morphometry…………………………………………...127 
  5.3.4 PCNA Expression……………………………………………………..127 
  5.3.5 IGF1R, pIGF1R and pAkt Expression……………………………....131 
  5.3.6 GHR-/- Growth Parameters…………………………………………..137 
 5.4 Discussion………………………………………………………………………..140 
 5.5 Conclusion………………………………………………………………………..145 
Chapter VI: Differential Limb Length is Maintained Throughout Skeletal Development 
After End of Treatment………………………………………………………………………146 
 6.1 Introduction……………………………………………………………………….146 
6.2 Material and Methods……………………………………………………………147 
  6.2.1 Animals and Experimental Design…………………………………..147 
  6.2.2 Tissue Collection and Long Bone Measurements…………………150 
  6.2.3 Statistical Analysis…………………………………………………….150 
 6.3 Results…………………………………………………………………………….150 
  6.3.1 Unilateral Heating Parameters……………………………………….150 
  6.3.2 Length of Long Bones Following 7 Days of Heating………………154 
  6.3.3 Length of Long Bones Following 14 Days of Heating………….….157 
 6.4 Discussion………………………………………………………………………..159 
 6.5 Conclusion………………………………………………………………………..161 
 xi 
Chapter VII: Thermal Imaging Reveals Temperature Retention in Hindlimbs of Mice 
After Targeted Intermittent Limb Heating…………………...…………………….……….163 
 7.1 Introduction……………………………………………………………………….163 
7.2 Material and Methods……………………………………………………………164 
  7.2.1 Infrared Thermal Imaging……………………………………………..164 
  7.2.2 Statistical Analysis and Sample Size....………………………….….167 
 7.3 Results…………………………………………………………………………….167 
  7.3.1 Temperature Retention in Hindlimbs Post-Heating………………..167 
 7.4 Discussion……………………………………………………………………..…170 
 7.5 Conclusion……………………………………………………………………….174 
Chapter VIII: Concluding Remarks and Future Directions………………………………175 
References…………………………………………………………………………………...184 
Appendix A: Institutional Review Board Approval………………………………………..215 
Appendix B: List of Abbreviations………………………………………………………….216 







LIST OF TABLES 
Table 1 Mouse Models With Disrupted IGF1 Regulation…………………………..18 
Table 2 Summary Of IGF1 Antagonists In Inhibiting Overall Growth……………..31 
Table 3 Comparison of Hindlimb Weight Bearing and Tibial Length Measured by      
X-Rays…………………..…………………….………………………………..56 
Table 4 List of Primary Antibodies and Secondary Antibody Kits Used in the 
Study…………………………………………………………………………....70 
Table 5 Comparison of Non-Treated and Heat-Treated Sides of Saline-Injected 
Experimental Mice Bone Parameters………………………….....…………75 
Table 6 Comparison of Growth Plate Morphometry Between Non-Treated and 
Heat-Treated Sides of Saline-Injected Experimental Mice…….…..……..78 
Table 7 Comparison of Non-Treated And Heat-Treated Sides of IGF1-Injected 
Experimental Mice Bone Parameters………………………………………..98 
Table 8 Comparison of Growth Plate Morphometry Between Non-Treated and 
Heat-Treated Sides of IGF1-Injected Experimental Mice………………..101 
Table 9 Comparison of Non-Treated and Heat-Treated Expression of Markers for 
IGF1 Activation In Proliferative Zone of Tibial Growth Plates in Saline and 
IGF1-Injected Mice…………………………………………………………...106 
Table 10 Comparison of Non-Treated and Heat-Treated Bone Parameters of 4-
Week Old Saline- and JB1-Injected Mice Following 7 Days of Heat-
Treatment……………………………………………………………………..125 
 xiii 
Table 11 Comparison of Non-Treated and Heat-Treated Expression of PCNA in 
Proliferative Zone of Tibial Growth Plates in Saline and JB1-Injected 
Mice……………………………………………………………………………128 
Table 12 Comparison of Non-Treated and Heat-Treated Expression of Markers for 
IGF1 Activation in Proliferative Zone of Tibial Growth Plates in Saline and 
JB1-Injected Mice………………………………………….…..…………….133 
Table 13 Comparison of Non-Treated and Heat-Treated Expression of Markers for 
IGF1 Activation in Hypertrophic Zone of Tibial Growth Plates in Saline and 
JB1-Injected Mice…………………………………………………………….134 
Table 14 Comparison of Non-Treated and Heat-Treated Bone Parameters of 5-
Week Old Wild-Type and GHR-/- Mice………………………………..…..138 
Table 15 Comparison of Mass Between Heat-Treatment Groups at The Start of 
Treatment and at Skeletal Maturity………………………………..……….152 
Table 16 Comparison of Non-Treated and Heat-Treated Sides of Experimental Mice 
Bone Parameters Following 7 Days of Limb Heating………………….…155 
Table 17 Comparison of Non-Treated and Heat-Treated Sides of Experimental Mice 
Bone Parameters Following 14 Days of Limb Heating………………..…158 
Table 18 Summary of Concluding Remarks…………………………….…………...182 
Table 19 Summary of Future Directions………………………..…………………….183 
  
 xiv 
LIST OF FIGURES 
 
Figure 1 Diagram of a Growth Plate……………………………………………………..2 
Figure 2 Developmental Stages During Postnatal Linear Bone Growth Compared 
Between Mouse and Man………………………………………………………8 
Figure 3 GH/IGF1 Axis in Postnatal Limb Elongation……………….……………….20 
Figure 4 IGF1 Induced Intracellular Signaling Pathway…………..…………………22 
Figure 5 JB1 Blocks IGF1R Signaling…………..……………………………………..32 
Figure 6 Diagram of the Unilateral Heating Method……………..…….……..….…..48 
Figure 7 Radiographs Collected Before and After Unilateral Heat-Treatment…….50 
Figure 8 Extremities are Lengthened on the Heat-Treated Side ………….……..…55 
Figure 9 Increase In Weight Bearing and Tibial Elongation Rate are Correlated 
After 7 Days of Unilateral Heat-Treatment……………………...…….…….58 
Figure 10 Unilateral Heating Schematic …………...…………………………………...65 
Figure 11 Majority of Body Mass Gained During 14 Days of Unilateral Heat-
Treatment Occurs During the First 7 Days..………………………………..73 
Figure 12 Extremities are Lengthened on the Heat-Treated Side …………………..76 
Figure 13 When Normalized to Total Proximal Tibial Growth Plate Height, PZ is 
Reduced on the Heat-Treated Side and HZ is Enlarged..………...………79 
Figure 14 Expression of PCNA, Marker for Cell Proliferation, Increased with Heat-
Treatment in the PZ of the Proximal Tibial Growth Plate……….…………81 
Figure 15 Unilateral Heating Schematic ………………………………………………..91 
Figure 16 Overall Change in Mass was not Impacted by IGF1 Injections at Either 
Length of Heat-Treatment…………………………………….………..…….95 
 xv 
Figure 17  Extremities are Lengthened on the Heat-Treated Sides when Injected 
with Saline and IGF1………………………………………….……………….99 
Figure 18 Proximal Tibial Growth Plate Morphometry After Administration of Low 
Dose IGF1 with Targeted Heating…………………………………..……..102 
Figure 19 Expression of PCNA in the PZ of Proximal Tibial Growth Plates After 
Administration of Low Dose IGF1 with Targeted Heating…...…………..104 
Figure 20 Heat-Induced Effect on IGF1 Activity in the PZ of the Tibial Growth Plate 
with IGF1 Administration…………………………………………………….107 
 Figure 21 Unilateral Heating Schematic ………………..……………………………..120 
 Figure 22 Total Body Mass Gained in Mice Treated for 7 days from 3-4 weeks of 
Age did not Differ Between Saline Controls and JB1-Injected Mice……123 
 Figure 23 Heat-Enhanced Growth Effects are Attenuated when IGF1 is Blocked..126 
 Figure 24 Expression of PCNA in the PZ of Proximal Tibial Growth Plates 
Decreased when IGF1 is Blocked………………………...………………..129 
Figure 25 Expression of Markers of IGF1 Activation Decreases in Heat-Treated 
Proximal Tibial Growth Plates when IGF1 is Inhibited………….…..……135 
Figure 26 Heat-Induced Effect on IGF1 Activity in the Tibial Growth Plate is Evident 
in the PZ and HZ……………………….………………………..……..…….136 
Figure 27 Extremities of Growth-Hormone Receptor Knockout (GHR-/-) Mice are not 
Lengthened with Unilateral Heat-Treatment………………………………139 
 Figure 28 Unilateral Heating Schematic ………………………………………………149 
 xvi 
 Figure 29 Mass did not Differ Between Non-Treated Controls, Heat-Treated Saline 
Control Mice, and Heat-Treated IGF1-Injected Mice at Either Duration of 
Limb Heating…………………………………………………….……………153 
Figure 30 Extremities Remained Longer on the Heat-Treated Sides at Skeletal 
Maturity when Limb Heating was Coupled with IGF1 Administration..…156 
 Figure 31 Infrared Thermal Imaging Schematic……………………………..……….166 
Figure 32 Thermal Imaging Shows Hindlimb Surface Temperature Remains 
Elevated up to 4 Hours Post-Heating……………….……………………..169 
Figure 33 Expression of VEGF and CD31 Appeared to Increase in the Growth Plate 
on the Heat-Treated Sides…………….……………..……………………..173 
Figure 34 Diagram Summarizes the Action of Important Factors in the Different 





Bone elongation disorders can lead to painful musculoskeletal disabilities in adulthood. 
Existing treatment options to correct left-right asymmetry in limb length include invasive 
surgeries and/or drug regimens. These are often only partially effective. Previous 
studies in weanling mice have shown that a daily application of mild heat (40°C) to limbs 
on one side of the body could be used to noninvasively enhance bone elongation. 
However, the impact of heat-treatment on bone at the cellular level remains elusive. The 
epiphyseal growth plate, the band of cartilage located at each end of long bones, is the 
main site of longitudinal growth and is regulated by local and systemic growth factors. 
Insulin-like growth factor 1 (IGF1) is the major regulator of growth and controls bone 
elongation by promoting chondrocyte proliferation and hypertrophy. The objective of this 
study was to build upon an established method of targeted limb heating to determine 
how heat-treatment influences IGF1 action in the growth plate. This study tests the 
hypothesis that exposure to warm temperature augments the actions of IGF1 in 
the growth plate and permanently increases length of the extremities. This 
dissertation demonstrates that differences of less than 1.5% are functionally significant 
measured by a nearly 20% increase in hindlimb weight bearing on heat-treated sides. 
Heat-enhanced bone elongation is documented in female C57BL/6 mice after 7 days of 
heat-treatment during the most active period of growth from 3-4 weeks of age. This 
increase in bone elongation is accompanied by increased chondrocyte proliferation and 
hypertrophy in the proximal tibial growth plate. Moreover, this study is the first to show 
that targeted limb-heating impacts local action of IGF1 in growth plate chondrocytes. 
Results suggest that heat-induced limb length is IGF1 dependent since the growth 
 xviii 
effects are attenuated when IGF1 activity is blocked. Administration of a low dose of 
IGF1 (2.5mg/kg) was found to augment heat enhanced bone elongation and effects 
were sustained to skeletal maturity (12 weeks of age). These studies help contribute to 
the ultimate goal of developing a noninvasive method for lengthening bones that may 


















CHAPTER I: IN DEPTH REVIEW INTO LONGITUDINAL BONE GROWTH 
 
1.1  POSTNATAL LONGITUDINAL BONE GROWTH THROUGH ENDOCHONDRAL 
OSSIFICATION 
1.1.1 Endochondral Ossification and Growth Plate Morphology 
The skeleton develops by means of two different mechanisms: (1) 
Intramembranous ossification, involving direct differentiation of mesenchyme cells to 
bone as with the development of the flat bones of the skull and (2) Endochondral 
ossification, occurring when mesenchyme cells condense and differentiate into cartilage 
tissue, which then is replaced by bone forming the vertebrae, ribs and limbs (Gilbert, 
2014). Endochondral ossification is initiated during fetal life but continues from infancy 
through adolescence (transitional period from childhood to adulthood). Cartilaginous 
growth plates found at each end of developing long bones are responsible for 
longitudinal bone growth (or linear growth). Longitudinal bone growth increases the 
length of long bones during postnatal development and is mediated by the growth plate. 
Growth plate cartilage is composed of cells known as chondrocytes that secrete 






Figure 1. Diagram of a Growth Plate  
Illustration represents the different cellular zones of the cartilaginous growth plate (dark 
gray). Arrows indicate the different zones within the growth plate. The vertical yellow 
line denotes the proliferative zone (PZ) and the green line denotes the hypertrophic 
zone (HZ). The PZ is a region of actively dividing chondrocytes stacked and flattened in 
multicellular columns. The HZ is a region of enlarged chondrocytes. Epiphyseal and 
metaphyseal bone on each end of the growth plate contain blood vessels (red lines) that 
supply each region of bone. Illustration based on Mackie, Ahmed, Tatarczuch, Chen, 




The cartilaginous growth plate functions as the command center of longitudinal bone 
growth. Understanding the general morphology of the growth plate is beneficial for 
appreciating its overall function. The end portion of the long bone is referred to as the 
epiphysis and the shaft of each long bone is termed the diaphysis. Directly between the 
epiphysis and the diaphysis is metaphysis, which contains the growth plate. The region 
adjacent to the epiphysis is the first zone of the growth plate, or the reserve zone (RZ). 
The RZ consists of round quiescent chondrocytes. The role of the RZ has been debated 
but is most commonly reported to act as the coordinator for the organization and 
orientation of the neighboring proliferative zone (PZ) (Abad et al., 2002). It has been 
suggested that the RZ contains stem-like cells that promote the production of 
proliferative chondrocytes and that this proliferative capacity decreases with age aiding 
to the closure of the growth plate associated with skeletal maturity (Abad et al., 2002; 
Hunziker, 1994b; Raimann, Javanmardi, Egerbacher, & Haeusler, 2017; Schrier et al., 
2006). Adjacent to the RZ is the PZ containing rapidly dividing chondrocytes stacked 
and flattened in multicellular columns. The PZ is a region of actively dividing cells that 
directs longitudinal growth along the long axis by which the cells line up in their 
arranged columns.  
The proliferating chondrocytes at the base of the columns make the transition from 
the PZ to the hypertrophic zone (HZ) where chondrocytes behave as terminally 
differentiated cells that begin to enlarge, secrete extracellular matrix and ultimately 
undergo physiological death (Kronenberg, 2003; Mackie et al., 2008; Shapiro, Adams, 
Freeman, & Srinivas, 2005; Ulici, Hoenselaar, Gillespie & Beier, 2008). Hypertrophic 
chondrocytes induce vascular invasion and recruit osteogenic cells in the process of 
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endochondral ossification and the replacement of cartilage with bone at the chondro-
osseous junction (region of growth cartilage between the growth plate and the newly 
mineralized bone). A majority of the bone-forming osteoblasts are said to be 
differentiated from bone marrow stromal cells. However, current research in the 
mammalian growth plate suggests that not all hypertrophic chondrocytes undergo 
apoptosis but instead transdifferentiate into osteoblasts during both bone development 
and repair (Bahney et al., 2014; Enishi et al., 2014; Hu et al., 2017; Zhou et al., 2014). 
Studies by Bahney et al. (2014) used cartilage grafts to promote bone regeneration 
through endochondral ossification (analogous to long bone development), and results 
from lineage tracing experiments showed chondrocytes differentiated into osteoblasts 
during bone repair. It is suggested that transdifferentiation occurs adjacent to the 
vasculature at the chondro-osseous junction and that the vasculature may have a 
signaling role in the transformation of chondrocytes to osteoblasts (Hu et al., 2017). It is 
not yet known if these chondrocytes undergo the same process of transdifferentiation 
during development as they do during repair.  
 
1.1.2  Differential Growth of Long Bones 
While the anatomical structure of the cartilaginous growth plate is comparable 
between the developing long bones, the rate at which these growth plates contribute to 
longitudinal bone growth differs from bone to bone, and from proximal end to distal end. 
This phenomenon is referred to as differential growth (Digby, 1916; Payton, 1932). The 
humerus, radius and ulna are the major long bones of the upper limb (excluding the 
hand and foot), and the lower limb includes the femur and tibia. When comparing 
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proximal to distal ends of these bones, the faster-growing sites are located at the 
proximal humerus (shoulder), distal radius and ulna (wrist), and distal femur and 
proximal tibia (knee) (J. Bisgard & M. Bisgard, 1935; Farnum, 2007; Kember, 1972; 
Pritchett, 1992; Raimann et al., 2017; Serrat, Lovejoy, & King, 2007; Wilsman, Farnum, 
Green, Leiferman, & Clayton, 1996a; Wilsman, Farnum, Leiferman, Fry, & Barreto, 
1996b; Wilsman, Bernardini, Leiferman, Noonan, & Farnum, 2008). Based on peak 
growth rates, the most rapid developing growth plate in humans and rodents is at the 
proximal end of the tibia followed by the distal femur (knee), distal radius (wrist), and 
proximal humerus (shoulder) (Rolian, 2008). Wilsman et al. (2008) have shown in rats 
that the proximal tibial growth plate (growth rate of 396 μM/day) is nearly nine times 
faster than the much slower proximal radial growth plate (growth rate of 47μM/day). 
The main factors contributing to increasing length of long bones and differential 
growth are the number of columnar cells in the PZ, the rate of proliferation, and the size 
of expanded cells in the hypertrophic zone (Hunziker, Schenk, & Cruz-Orive, 1987; 
Hunziker, 1994b; Kember, 1993; Lupu, Terwilliger, Lee, Segre, & Efstratiadis, 2001; 
Walker & Kember, 1972). Investigators have observed increased numbers of 
proliferative chondrocytes, increased rates of proliferation, and hypertrophic 
chondrocyte expansion in the faster-growing sites (Cooper et al., 2013; Farnum, 2007; 
Hunziker & Schenk, 1989; Kember, 1972; Raimann et al., 2017; Rolian, 2008; Serrat et 
al., 2007; Wilsman et al., 1996a, 1996b, 2008). Therefore, the cellular components of 
the growth plate are involved in regulating the process of endochondral bone 




1.1.3  Age Comparison of Mouse and Man  
A common model organism in the study of bone growth is the rodent, particularly 
the house mouse (Mus musculus). The murine model is beneficial because the mouse 
is small in size, cost-effective, easily available, and shares physiological similarities to 
humans making the mouse the most widely used animal (~59% of total animals used) in 
biomedical research (Dutta & Sengupta, 2016). However, mice have a shorter lifespan 
(~24 months) compared to humans (~80 years) (Dutta & Sengupta, 2016). While there 
may be a momentous difference in lifespan between mice and humans, it allows for 
accelerated projects when following the mouse throughout stages of development.  
Mouse age during different phases of postnatal growth is comparable to human 
age (Fig. 2). At birth, until approximately 2-3 weeks of age, mice rely completely on their 
mother for temperature regulation and food. At 3-4 weeks of age, pups will wean and 
become independent (Dutta & Sengupta, 2016; Latham & Mason, 2004). This phase of 
natural weaning that is the transition from exclusive nursing to nourishment by other 
food, is comparable to a 6-month-old infant (Dutta & Sengupta, 2016; Sengupta, 2013; 
Vail et al., 2015). While longitudinal growth is rapid during early postnatal stages of 
development, there is a progressive decline in this rate of active growth with 
approaching maturity. In mice, the accelerated rate of post weaning bone growth is from 
3-4 weeks of age, then gradually decelerates from 4-8 weeks of age, and significantly 
slows between 8-12 weeks of age (Callewaert et al., 2010; Li et al., 2017; Lui, Nilsson, 
& Baron, 2011) (Fig. 2). In humans, rapid linear growth is observed from infancy to 
childhood (6 months-3 years), decelerates from childhood through adolescence (3-16 
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years), and stops at adulthood (18-20 years) (Armstrong, 2007; Dutta & Sengupta, 






Figure 2. Developmental Stages During Postnatal Linear Bone Growth Compared 
Between Mouse and Man 
Diagram follows the appropriate age ranges of a human with the comparative ages of a 
mouse during stages of linear growth. Rates of longitudinal bone growth are also noted 
during each developmental stage. Both human and mouse follow similar trends in linear 
growth with the exception of epiphyseal closure (indicated by the blue boxes). At the 
end of puberty, cessation of growth at the human growth plate is accompanied by 
epiphyseal fusion. No epiphyseal fusion is observed in the mouse. There is also an 
early pubertal growth spurt specific to humans that interrupts the decline in linear growth 

































Puberty, when reproduction becomes possible, is reached in mice at 6-8 weeks 
(Jilka, 2013; Latham & Mason, 2004; Dutta & Sengupta, 2016) and 11-16 years in 
humans on average (Chirwa, Griffiths, Maleta, & Cameron, 2014; Dutta & Sengupta, 
2016; Lee, 1980; Kelly & Diméglio, 2008). Although linear bone growth progressively 
slows with age, this decline in growth rate is interrupted by an early pubertal growth 
spurt in humans (Li et al., 2017; Lui et al., 2011; Nilsson & Baron, 2004; Shim, 2015). 
During this time, increased rates of chondrocyte proliferation and hypertrophy within the 
growth plate are observed. This growth spurt is one reason why there is concern for 
childhood sport related physeal injuries, which are most common between 10-16 years 
of age (Grimmer, Jones, & Williams, 2000; Schwab, 1977) and account for 6-15% of 
youth fractures (Hunt & Amato, 2003). Disturbances during this period of developing 
growth cartilage can result in growth deformities (Caine, DiFiori, & Maffaulli, 2006; Mirtz, 
Chadler, & Eyers, 2011).  
Eventually a cessation of growth plate activity occurs as final adult height is 
reached. The cessation of longitudinal bone growth, also referred to as growth plate 
senescence, involves decreased rates of chondrocyte proliferation and hypertrophy 
(Forcinito et al., 2011; Lui et al., 2011; Nilsson & Baron, 2004; Nilsson et al., 2014; 
Walker & Kember, 1972). There is variation in time of closure between bones, but 
faster-growing sites such as in the proximal tibia close later (16-18 years of age in a 
human) than slower growing sites such as in the proximal radius (14-16 years of age in 
a human) (Schwab, 1977; Zoetis, Tassinari, Bagi, Walthall, & Hurtt, 2003). The process 
of growth plate senescence varies from species to species (Geiger, Forasiepi, Koyabu, 
& Sánchez-Villagra, 2014; Kilborn, Trudel, & Uhthoff, 2002). In humans, growth plate 
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cessation at the end of puberty is accompanied by epiphyseal fusion and the formation 
of a bony union (Geiger et al., 2014; Nilsson & Baron, 2004; Parfitt, 2002). In mice, 
there is not a complete closure of the growth plate (Dawson, 1925, 1935; Geiger et al., 
2014). The lack of complete epiphyseal fusion in mice contributes to complications in 
forming a direct comparison to humans. However, research has shown that even 
without complete closure, growth plate senescence still occurs at comparable 
developmental periods with similar cellular kinetics (Dawson, 1925, 1935; Geiger et al., 
2014; Walker & Kember, 1972). Skeletal maturity, not to be confused with sexual 
maturity, is similar between mice (8-12 weeks of age) (Kilborn et al., 2002; Li et al., 
2017; Serrat et al., 2007; Stempel, Fritsch, Pfaller, & Blumer, 2011; Zoetis et al., 2003) 
and humans (18-20 years of age) (Duren, Seselj, Froehle, Nahhas, & Sherwood, 2013; 
Dutta & Sengupta, 2016; Schwab, 1977) in regard to the proportion of their lifespan 
(Kilborn et al., 2002). When skeletal maturity is reached, chondrocyte proliferation, 
hypertrophy and longitudinal growth essentially stops despite the presence of a 
previously active growth plate.  
 
1.1.4  Limb Length Discrepancy 
 An orthopedic condition that is characterized by asymmetric length of lower 
extremity pairs is referred to as anisomelia, or limb length discrepancy (LLD) (Baker, 
Liu, Robertson, & Efstratiadis, 1993; Gurney, 2002). LLD usually emerges during 
childhood but the etiology varies and may be congenital, acquired or idiopathic. Prior to 
the development of the polio vaccine in the 1960s, the most common cause of LLD in 
children was poliomyelitis (viral infection causing paralysis) that resulted in leg 
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shortening (Morscher, 1977; Wilson & Thompson, 1939). While polio has been 
eliminated from the United States, treatment options are still studied for middle-aged 
patients suffering from long-term LLD as a result of poliomyelitis developed during their 
childhood (Kirienko et al., 2011; Sonekatsu, Sonohata, Kitajima, Kawano, & Mawatari, 
2018). Aside from paralysis, other acquired causes of LLD include infection, tumors, 
and trauma (Morscher, 1977; Shapiro, 1982; Wilson & Thompson, 1939).  LLDs caused 
by trauma most commonly involve epiphyseal fractures (shortening on the fractured 
side) and meta- and diaphyseal fractures (lengthening on the fractured side) (Hansson, 
Stenström, & Thorngren, 1976; Morscher, 1977; Shapiro, 1982; Togrul, Bayram, 
Gulsen, Kalaci, & Ozabarlas, 2005; Truesdell, 1921; Wilson & Thompson, 1939; Wray & 
Goodman, 1961). Regardless of the cause of the LLD, untreated inequalities into 
adulthood have been associated with painful musculoskeletal disorders (Campbell, 
Ghaedi, Ghongomu, & Welch, 2018; Gurney, 2002) including lower back pain (Friberg, 
1983; Defrin, Ben Benyamin, Aldubi, & Pick, 2005), gait abnormalities (Aiona, Do, 
Emara, Dorociak, & Pierce, 2015; Kaufman, Miller, & Sutherland, 1996; Khamis & 
Carmeli, 2017; Mahmood, Huffman, & Harris, 2010; Song, Halliday, & Little, 1997), 
scoliosis (abnormal curvature of the spine) (Papaioannou, Stokes, & Kenwright, 1982), 
and osteoarthritis of the hip and knee (Golightly, Tate, Burns, & Gross, 2007a; Golightly  
et al., 2007b; Harvey et al., 2010; Resende, Kirkwood, Deluzio, Morton, & Fonseca, 
2016). 
 The severity of limb length discrepancy varies depending on the condition, as 
well as the onset of acquired cases. Limb length inequalities of 2 cm or more involve 
surgical methods of treatment with intentions of permanently correcting unequal length 
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of limbs (Gurney, 2002; Stevens, 2016; Vitale et al., 2006; Zhang, Hamamura, Turner, & 
Yokota, 2010). Limb shortening is recommended for limb length inequalities of 2-5 cm 
using epiphysiodesis procedures (Stevens, 2016). This method involves shortening the 
longer limb by either permanently halting growth from a surgically formed bony bridge 
(Phemister, 1933) or temporarily slowing of growth using guided growth techniques 
(Pendleton, Stevens, & Hung, 2013; Sabharwal, Nelson, & Sontich, 2015; Stevens, 
2016). Limb lengthening is recommended for those with limb length inequalities over 5 
cm (Stevens, 2016) and includes methods based off the traditional Ilizarov technique 
using external fixators (Ilizarov, 1988) or by mechanical bone guidance (Hasler & Krieg, 
2012). The aforementioned surgical interventions involve a variation of percutaneous 
drilling and use of external and internal fixation devices (including a cortical screw 
surgically placed through the epiphysis, across the growth plate, and into the 
metaphysis). In addition to the high cost of these invasive procedures, they are also 
often associated with complications including pain, implant failure, angular deformities 
and infection (Hasler & Krieg, 2012; Wilson & Thompson, 1939). 
 For relative comparison, a 2 cm discrepancy is roughly equivalent to a 2.8-2.4% 
difference using a reference limb length of 72-82.5 cm (total height minus sitting height 
averaged from mean male and female reference data) corresponding to a 10-16 year 
old adolescent (Fredricks et al., 2005; McDowell, Fryar, & Ogden, 2009) during the 
period of sexual maturity/puberty (Fig. 2) when still growing but approaching final height. 
A 5 cm discrepancy is therefore roughly equivalent to a 6.9-6.1% difference. It is 
important to note that these percent differences based on total limb length vary through 
development until final height is reached. At final height (reference limb length of 85 cm 
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for a young adult), a 2 cm discrepancy is a difference of 2.4%, while a 5 cm discrepancy 
is a difference of 5.9% (Fredricks et al., 2005; McDowell et al., 2009; Racine, Meadows, 
Ion, & Serrat, 2018). 
The projected limb length discrepancy at the point of maturity varies between 
congenital cases (based on a fixed limb length inequality) and acquired cases (based 
on how much limb growth remains) (Kelly & Diméglio, 2008). There have been 
numerous methods of predicting final limb length including the Green-Anderson method 
(Anderson, Green, & Messner, 1963), Menelaus method (Menelaus, 1966), Moseley 
method (Moseley, 1977), and Paley method (Paley, Bhave, Herzenberg, & Bowen, 
2000). The predicated final limb length discrepancy varies vastly between these 
methods (Monier, Aronsson, & Sun, 2015) and thus there is not one method that is 
more accurate than another. Therefore, determining the most effective timing to start 
treatment is difficult and can lead to possible over- or under-compensation for the 
observed unequal limb length. When the correction is not successful, either because of 
surgical failure or miscalculated predictions of final limb length discrepancy, surgical 
interventions have to be repeated (Stevens, 2016) and therefore increase the risk of 
post-surgical complications.  
While surgical intervention is typically recommended only for discrepancies of 2 
cm or more (Gross, 1978; Gurney 2002; Knutson, 2005), some studies have shown that 
discrepancies of 0.5-1 cm (0.6-1.2% limb length difference based on young adult height) 
may impact everyday walking (White, Gilchrist, & Wilk, 2004) leading to problems into 
adulthood including knee osteoarthritis (Harvey et al., 2010; Resende et al., 2016). 
Conservative methods of correction are typically recommended for those with these 
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minor limb length inequalities such as shoe lifts or prosthetics (Campbell et al., 2018; 
Hasler & Kreig, 2012; Wilson & Thompson, 1939). While inexpensive and less invasive, 
these methods do not permanently change the length of the bone. An alternative non-
invasive method for permanently lengthening limbs would therefore be ideal. A study by 
Zhang et al. (2010) showed that applying intermittent 0.5 N lateral loads to the knee 
joints of mice (~8-weeks old) increased femoral (2.3%) and tibial length (3.7%). This 
increase in limb length is noteworthy because treatment occurred during slower rates of 
longitudinal bone growth when mice were close to reaching skeletal maturity. Long-term 
effects of these studies have also not yet been done. Serrat et al. (2015) demonstrated 
that using once daily targeted limb heating (40°C for 40mins/day) to unilaterally increase 
femoral (1.3%) and tibial (1.5%) length of growing mice (3-5 weeks of age) is another 
non-invasive alternative to treating limb length discrepancies. At skeletal maturity (12 
weeks of age), femoral (1.0%) and tibial (1.0%) lengths remained significantly increased 
on the heat-treated sides (Serrat et al., 2015).  
 
1.2 REGULATION OF GROWTH PLATE DURING POSTNATAL LINEAR GROWTH  
1.2.1  Endocrine Regulation of Linear Growth  
The process of postnatal longitudinal growth is tightly controlled by 1) endocrine 
actions by molecules, such as hormones, distributed in the blood that act on target cells 
of the growth plate, and 2) paracrine/autocrine actions by locally produced factors 
expressed in epiphyseal chondrocytes or surrounding perichondrium. Mutations in 
genes encoding any of these regulators result in dysfunctional chondrocytes, abnormal 
longitudinal growth, and skeletal dysplasia including short-limbed dwarfism. By 
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endocrine action, systemic factors shown to regulate longitudinal growth include growth 
hormone (GH), insulin-like growth factor 1 (IGF1), thyroid hormone, estrogen, androgen, 
glucocorticoids, and vitamin D (Börjesson et al., 2010; van der Eerden, Karperien, & 
Wit, 2003; Lui, Nilsson, & Baron, 2014; Ohlsson et al., 1993; Simpson, Asling, & Evans, 
1950; Tryfonidou et al., 2010; Wang, Shao, & Ballock, 2010). For example, while 
circulating thyroid hormone has been shown to increase longitudinal bone growth 
indirectly by increasing systemic GH secretion (Ohlsson et al., 1993), it also has been 
shown to directly interact with the epiphyseal chondrocytes and initiate terminal 
differentiation (Ohlsson, Nilsson, Isaksson, Bentham, & Lindahl, 1992a; Stevens et al., 
2000).  
 
1.2.2  Autocrine/Paracrine Regulation of Linear Growth  
In regards to autocrine/paracrine regulation within growth plate cartilage, locally 
acting factors reported include Indian hedgehog (Ihh), parathyroid hormone-related 
protein (PTHrP), fibroblast growth factors (FGFs) (including FGF1, -2, -9 and -18), bone 
morphogenic proteins (BMPs) (including BMP2-7), vascular endothelial growth factor 
(VEGF), IGF1, and Wnt (van der Eerden et al., 2003; Karimian, Chagin, & Sävendahl, 
2012; Kronenberg, 2003; Lui et al., 2014; Maeda, Schipani, Densmore, & Lanske, 2010; 
Tryfonidou et al., 2010; Wang et al., 2010). Different regional zones of growth plate 
chondrocytes are regulated by particular factors. For instance, regulation of 
prehypertrophic chondrocytes (chondrocytes at maturation that no longer proliferate) in 
the region between the proliferative zone and hypertrophic zone, have been 
characterized by the expression of signaling molecules responsible for the successful 
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and timely transition from proliferative to hypertrophic chondrocytes. These include FGF 
receptors (Lazarus, Hedge, Andrade, Nilsson, & Baron, 2007; Su, Jin, & Chen, 2014), 
BMPs (Garrison, Yue, Hanson, Baron, & Lui, 2017; Nilsson et al., 2007), and Ihh/PTHrP 
receptors (Vortkamp et al., 1996).  
Often, it has been shown that longitudinal bone growth is controlled by the 
collaboration of both endocrine and paracrine/autocrine actions when systemic factors 
interact with locally expressed factors of the growth plate cartilage to promote 
chondrocyte proliferation and hypertrophy. Among these interactions, estrogen 
(endocrine) has been shown to regulate expression of IGF1 (autocrine/paracrine) in 
growth plate chondrocytes (Börjesson et al., 2010). Thus, in addition to the independent 
influences of systemic and local factors on the growth plate, there are important 
interactions between regulators to maintain growth. While the impact of some factors 
(such as IGF1) act predominantly over others, there is no evidence supporting that one 
is mutually exclusive from the rest in regulating longitudinal bone growth. There is still 
much to be understood regarding the molecular mechanisms involved in linear growth 
and further research will lead to a greater depth of comprehension.  
 
 
1.3 GROWTH HORMONE AND INSULIN-LIKE GROWTH FACTOR REGULATE 
LINEAR GROWTH 
  
1.3.1  Evolution of the Somatomedin Hypothesis 
GH and IGFs have an integral role in maintaining normal growth and 
development. The original understanding of the means by which GH and IGFs regulate 
growth was set into motion after experiments conducted in 1957 by Salmon and 
Daughaday (Salmon & Daughaday, 1957). In the early 1970s, the same group in 
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addition to other investigators referred to their findings as the somatomedin hypothesis, 
which described pituitary-gland derived GH to act upon the liver to secrete an 
intermediate hormone stimulating somatic growth (Daugaday et al., 1972). The 
intermediates were termed insulin-like growth factor 1 (IGF1) and insulin-like growth 
factor 2 (IGF2) (also referred to as somatomedin C and A) later in the decade 
(Rinderknecht & Humbel, 1978a,b). Both factors are important for growth and 





Table 1. Mouse Models with Disrupted IGF1 Regulation 
Model Phenotype Citation 
Igf1 null mice (global 
IGF1 disruption) 
95% mice died prenatally; 
undetectable levels of IGF1 in 
serum and tissues; significant 
decrease in tibial length 
(70%); abnormal chondrocyte 
proliferation and differentiation 
Baker et al., 1993 
Bikle et al., 2001 
Powell-Braxton et al., 1993 
Wang et al., 2006 
Igf2 null mice (global 
IGF2 disruption) 
Mice are viable; reduced body 
growth (60%) at birth; normal 
postnatal growth 
DeChiara, Efstratiadis, & 
Robertson, 1990 
Yakar et al., 1999 
LID mice (systemic 
disruption of liver-
derived IGF1) 
75% reduction in serum IGF1; 
no significant change in body 
length; no significant change 
in tibial length; slight decrease 
in femoral length (6%)  
Sjögren et al., 1999 
Yakar et al., 1999 




65% reduction in serum IGF1; 
no significant change in body 
length; slight decrease in 
femoral length (7.5%) 
Ueki et al., 2000 
LID+ALSKO mice 
(systemic disruption of 
liver-derived IGF1 and 
ternary complexes 
(IGF1/ALS/IGFBP-3)) 
85-90% reduction in serum 
IGF1; significant reduction in 
body length (30%); significant 
decrease in femoral length 
(20%) 
Yakar et al., 2002 
(Col2a1)-driven Cre 
mice (local disruption 
of chondrocyte-derived 
IGF1) 
40% reduction in chondrocyte 
IGF1; Significant decrease in 
postnatal body length; no 
morphological differences in 
proliferative and hypertrophic 
regions 
Govoni et al., 2007a 
CartIgf1r-/- mice (local 
disruption of cartilage-
specific IGF1R) 
Mice died shortly after birth Wang et al., 2011 
 
TamCartIgf1r-/- mice 
(local disruption of 
cartilage-specific 
IGF1R induced by 
tamoxifen injections) 
Significant decrease in body 
length (40%); disorganized 
growth plates associated with 
reduced chondrocyte 
proliferation and differentiation 
Tahimic, Wang, & Bikle, 2013 
Wang et al., 2011 
Wu, Yang, & De Luca, 2015 





The introduction of the dual effector theory in 1985 disputed the original 
somatomedin hypothesis and proposed an additional IGF1-independent role of GH 
(Green, Morikawa, & Nixon, 1985). This revision came with reports of local IGF1 
production in nonhepatic tissues, including bone (Tahimic et al., 2013) demonstrating 
that IGF1 acts as both an endocrine and autocrine/paracrine factor. In the growth plate, 
investigators found that GH directly stimulated cell differentiation in the RZ of precursor 
cells, while local IGF1 production mediated clonal expansion of the resulting PZ 
chondrocytes (Isaksson, Jansson, & Gause, 1982, Isaksson, Eden, & Jansson, 1985; 
Ohlsson et al., 1992a; Ohlsson, Nilsson, Isaksson, & Lindahl, 1992b; Ohlsson, 
Bengtsson, Isaksson, Andreassen, & Slootweg 1998; Schlechter, Russell, Greenberg, 
Spencer, & Nicoll, 1986). Recent research also supports the direct contribution of GH 
acting on the growth plate independent of IGF1 (Dobie et al., 2015; Wu et al., 2015). 
The evolution of the somatomedin hypothesis incorporates an adaptation of previous 
theories to describe a more complex interplay between GH and IGF1, including 
negative feedback mechanisms where IGF1 inhibits further GH production (Moody et 
al., 2014). The interaction between IGF1 and GH is commonly referred to as the 





Figure 3. GH/IGF1 Axis in Postnatal Limb Elongation 
Flow diagram illustrates the complex interplay between GH and IGF1 in promoting 
longitudinal bone growth. In addition to stimulating IGF1 production in the liver as 
originally proposed in the somatomedin hypothesis, GH also stimulates longitudinal 
growth (1) by promoting local production of IGF1 in growth plate chondrocytes and (2) 
independent of IGF1 as explained by the dual effector theory. IGF1 also has 
autocrine/paracrine effects independent of GH promoting longitudinal growth locally in 
growth plate chondrocytes. The red arrow demonstrates the negative feedback 
mechanism of IGF1 inhibiting further GH synthesis and release. Tibia illustration 



















1.3.2 IGF Induced Signaling Pathway 
IGF binding protein-3 (IGFBP-3) is the major carrier of IGFs. In serum, majority of 
IGFs (~75%) exist in a ternary complex of one molecule each of IGF1, IGFBP-3, and 
the acid labile subunit (ALS) (Holman & Baxter, 1996; Yakar et al., 2002). The ternary 
complex prolongs the half-life of serum IGFs and regulates transport from the circulation 
to the target tissue (Baxter, 2000; Holman & Baxter, 1996; Le Roith, Bondy, Yakar, Liu, 
& Butler, 2001). Similar to IGF1, IGF2 binds to IGFBPs (Baxter, 2000; Le Roith et al., 
2001). Upon release at the surface of the target tissue, both IGFs are capable of binding 
to the receptor tyrosine kinase type 1 IGF receptor (IGF1R) (Le Roith et al., 2001) 
expressed in all regions of the growth plate (Parker et al., 2007; E. Wang, J. Wang, 
Chin, Zhou, & Bondy, 1995). The activation of the IGF1R leads to a signaling cascade 
involving the phosphatidylinositide 3-kinase (P13K) and mitogen-activated protein 
kinase (MAPK) pathways ultimately leading to cell survival and proliferation, which 
contributes to longitudinal growth rate (Fig. 4). IGF2 is classically described to be 
essential only during prenatal growth (DeChiara et al., 1990; Lund et al., 1986; Yakar et 
al., 1999), whereas IGF1 is expressed at low levels during embryonic development and 
is important for postnatal growth (Baker et al., 1993; Liu, Baker, Perkins, Robertson, & 
Efstratiadias, 1993; Powell-Braxton et al., 1993). Evidence supports that IGF1 is more 
critical to postnatal longitudinal bone growth compared to IGF2 because the postnatal 
phenotype of the Igf1 null is more severe than the Igf2 null mice (see Table 1) (Baker et 





Figure 4. IGF1 Induced Intracellular Signaling Pathway  
Model demonstrates how IGF1 functions as a ligand and binds to its receptor (IGF1R) 
triggering two downstream signaling cascades including the phosphatidyl inositol-3 
kinase (P13K) and mitogen-activated protein kinase (MAPK) pathways and ultimately 
leading to cell survival and proliferation. Illustration based on Crudden, Girnita, A, and 
Girnita, L (2015). 
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1.3.3  GH and IGF1 Distinct and Overlapping Functions on Linear Growth 
One example of a mouse model that demonstrates the importance of the 
GH/IGF1 axis is the growth hormone receptor knockout (GHR-/-) mouse. The GHR-/- 
mouse is a model of human Laron Syndrome, a recessively inherited inactivating 
mutation(s) in the GHR. The disease is characterized by GH resistance, high serum 
GH, and low serum IGF1 (Laron, 2015a; List et al., 2011; Sims et al., 2000; Zhou et al., 
1997). While at birth these mice are similar in size to their wild-type littermates 
(suggesting prenatal growth not dependent on GH), the significant size difference 
becomes apparent during postnatal development (Zhou et al., 1997). GHR-/- mice have 
a 30-40% reduction in body size (List et al., 2011; Sims et al., 2000; Yakar & Isaksson, 
2016; Zhou et al., 1997) as well as a 65% reduction in tibial growth rate (Davies et al., 
2007; Wang, Zhou, Cheng, Kopchick, & Bondy, 2004) and decreased chondrocyte 
proliferation and hypertrophy (List et al., 2011). Studies by Lupu et al. (2001) 
determined that GH and IGF1 have distinct, yet overlapping, functions during 
mammalian linear growth. When comparing mutant mouse models of Igf1 mutant mice, 
GHR-/- (lacking GH action), and double-mutants (Ghr/Igf1), it was determined that the 
observed growth retardation of the double Ghr/Igf1 nullizygotes was more severe than 
that of either single mutant model (Lupu et al., 2001). With advancements in the field of 
endocrinology, investigators continue to refine the original somatomedin hypothesis and 






1.3.4  GH and IGF1 Treatment of Hormonal Deficiencies 
 As described, normal longitudinal bone growth requires functional hormonal 
regulation. Hormonal disorders involving the deficient or excessive production of the 
important hormones of growth (GH, IGF1, thyroid hormones, glucocorticoids, and sex 
steroids), can lead to abnormally short or tall stature. Short stature characterized by 
stunted linear growth may result from GH deficiency (Lupu et al., 2001; Ohlsson et al., 
1998; Tritos & Klibanski, 2016), IGF1 deficiency (Liu et al., 1993; Mohan et al., 2003; 
Powell-Braxton et al., 1993; Wang, Zhou, & Bondy, 1999; Wang et al., 2006; Yakar & 
Isaksson, 2016), hypothyroidism (Bassett & Williams, 2016), or hypercortisolism (Bello 
& Garrett, 1999; Silvestrini et al., 2000). Thyroid hormone (T3) deficiency in children is 
associated with growth retardation (Rivkees, Bode, & Crawford, 1988) and studies in 
mice using knockout models have shown that linear growth is impaired in thyroid 
hormone deficient mice (Basset et al., 2008; Friedrichsen et al., 2003) when levels are 
normal but the thyroid receptor (TRα1 and TRβ) is mutated (Göthe et al., 1999; 
Kindblom et al., 2005).  
One of the main problems associated with short stature in children is the 
development of behavioral and emotional problems (van der Eerden et al., 2003; 
Gordon, Crouthamel, Post, & Richman, 1982; Sandberg, 2000). The most common 
treatment option for children with stunted linear growth involves frequent subcutaneous 
injections of recombinant human GH until adult height is reached (Ohlsson et al., 1998; 
Pfäffle, 2015; Wit & Oostdijk, 2015). In addition to treatment of short stature as a result 
of hormonal disorders, GH has also been used to treat short stature resulting from 
chromosomal disorders and genetic syndromes including Turner syndrome (Pfäffle, 
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2015; Ranke, 1995a, Tritos & Klibanski, 2016; Wit & Oostdijk, 2015), Achondroplasia 
(Harada et al., 2017), Prader-Willi syndrome (Moix, Gimébez-Palop, & Caixàs, 2018; 
Pfäffle, 2015), and Noonan syndrome (Noonan & Kappelgaard, 2015; Pfäffle, 2015). 
Other therapies including oxandrolone (man-made steroid similar to testosterone), 
estrogens, gonadotropin-releasing hormone (GnRH) and IGF1 have also been used to 
increase linear bone growth (Wit & Oostdijk, 2015). While GH therapy is more 
commonly used in clinical settings, IGF1 has also been shown to effectively reverse 
skeletal growth discrepancies (Azcona et al., 1999; Backeljauw, Kuntze, Frane, 
Calikoglu, & Chernausek, 2013; Chernausek et al., 2007; Laron & Klinger, 2000; Laron, 
2001; Laron & Kauli, 2015b; Lupu et al., 2001; Midyett et al., 2010; Ranke et al., 1995b, 
1999; Sims et al., 2000). However, there are more adverse effects associated with IGF1 
treatment including hypoglycemia (abnormally low levels of glucose in the bloodstream) 
(Clemmons, 2004; Guevara-Aguirre et al., 1997; Laron & Klinger, 2000; Lindsey & 
Mohan, 2016; Ross, Lee, Gut, & Germak, 2015). In patients that already show 
symptoms of hypoglycemia, such as those with Laron’s Syndrome (GH insensitive), 
IGF1 therapy can intensify these symptoms and can lead to loss of consciousness or 
seizures (Chernausek et al., 2007; Cohen et al., 2014; Kovacs et al., 1999). Other risks 
with IGF1 treatment include headaches, intracranial hypertension, growth of the 
nasopharyngeal lymphoid tissues, hearing loss, and injection site lipohypertrophy 
(Backeljauw et al., 2013; Chernausek et al., 2007; Midyett et al., 2010; Ranke et al., 
1995b). Therefore, it would be favorable to develop a successful drug treatment 




1.4 IGF1 AS A PRIMARY MEDIATOR OF LONGITUDINAL BONE GROWTH 
1.4.1  Function of Locally Expressed IGF1 
Numerous studies have supported the importance of both GH and IGF1 in 
mediating linear bone growth; however, IGF1 appears to be the most critical regulator of 
postnatal growth. In mutant animal models where GH action is impaired (Laron, 2015a; 
List et al., 2011; Lupu et al., 2001; Sims et al., 2000; Wang et al., 2004; Zhou et al., 
1997), animals thrived despite being significantly smaller than the wild-type 
counterparts. In contrast, in mutant animals where local IGF1 action is impaired, most 
animals died shortly after birth and those that did survive had severe growth defects 
(Tahimic et al., 2013; Wang et al., 2011; Wu et al., 2015) supporting the importance of 
local chondrocyte-produced IGF1. The observed growth defects suggest that while a 
degree of circulating IGF1 is necessary (Yakar et al., 2002), local action of IGF1 may be 
more critical for longitudinal bone growth than serum IGF1 (see Table 1).  
The role of local IGF1 in the proliferation of chondrocytes in mice and rats has 
been debated. Investigators have detected the expression of IGF1 in the PZ of the 
epiphyseal growth plate measured by in situ hybridization (Lazowski et al., 1994; Lupu 
et al., 2001; Nilsson, Carlsson, Isgaard, Isaksson, & Rymo, 1990; Ohlsson et al., 
1992a). However, these results were not in agreement with the findings of two different 
groups from the early to mid-1990s that were both unable to detect IGF1 mRNA in 
proliferating chondrocytes by in situ hybridization methods, and instead found IGF2 
mRNA (Shinar, Endo, Halperin, Rodan, & Weinreb, 1993; Wang et al., 1995). Additional 
investigators also identified the expression of IGF2 in the PZ (Parker et al., 2007; 
Reinecke, Schmid, Heyberger-Meyer, Hunziker, & Zapf, 2000). In all cases, it was 
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consistently reported that the level of IGF2 expression in the PZ decreased with age. 
Overall IGF1 expression levels increase after birth, including those in proliferating 
chondrocytes (Parker et al., 2007). The absence of IGF1 mRNA in proliferating 
chondrocytes by Shinar et al. (1993) and Wang et al. (1995) was reported using rodents 
during the earliest stages of postnatal development. Therefore, it is possible that these 
rodents had not yet reached the postnatal age by which an increase in IGF1 expression 
in the PZ can be detected, such as that reported by Parker et al. (2007). 
The significance of IGF2 in early postnatal chondrocyte development, secondary 
to IGF1, has begun to emerge. IGF2 is not included in the GH-IGF1 axis (Humbel, 
1990; Pierce, Dickey, Felli, Swanson, & Dickhoff, 2010) but recent studies are now 
investigating the role of IGF2 in postnatal bone growth after a group discovered that 
human postnatal growth restriction was associated with nonsense IGF2 mutations 
(Begemann et al., 2015). Uchimura et al. (2017) have shown significant reductions in 
bone length in IGF2-null mice at postnatal periods prior to weaning (1-3 weeks of age) 
and their histological analysis suggests IGF2 has a role in regulating chondrocyte 
development by controlling the progression from proliferation to hypertrophy. The 
mechanism and extent by which IGF2 regulates longitudinal bone growth through 
cartilage development remains unclear and its evaluation will be important in future 
experiments.  
Regardless of its local versus systemic roles, IGF1 is undisputedly a significant 
factor in epiphyseal cartilage development. Local regulation of IGF1 has been studied in 
other regions of the growth plate aside from the PZ. Cell kinetic studies using 
hypophysectomized rats (pituitary gland removed reducing systemic levels of GH and 
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IGF1) determined that IGF1 regulated all phases of chondrocyte differentiation in the 
growth plate including the RZ of chondrocyte precursors (Hunziker, Wagner, & Zapf, 
1994a). IGF1 expression has also been observed in the HZ of epiphyseal growth plates 
(Lazowski et al., 1994; Nilsson et al., 1990) and local regulation by IGF1 has been 
shown to augment chondrocyte hypertrophy (Abbaspour et al., 2008; Mushtaq, Bijman, 
Ahmed, & Farquharson, 2004; J. Wang et al., 1999; Y. Wang et al., 2006). An observed 
35% reduction in HZ height was reported in an IGF1 null mouse model (Wang et al., 
1999). IGF1 has also been shown to induce collagen X production (made in the HZ) 
(Repudi, Patra, & Sen, 2013; Wang et al., 1999). When local expression of IGF1 was 
blocked by the binding of Wnt induced secreted protein 3 (WISP3), a protein involved in 
cell differentiation, IGF1-induced collagen X expression was reduced (Repudi et al., 
2013).  
 
1.4.2  IGF1 Antagonists 
Mouse models designed to control the expression of IGF1 through genetic 
manipulation are a useful method for studying IGF1 regulation. Another approach for 
studying IGF1 action and its role in regulating linear bone growth is by blocking IGF1 
action. The major target of an IGF1 antagonist is the IGF1R, which serves as the 
gateway for IGF1 action (see Fig. 3). When activation of the IGF1R is inhibited, the 
growth promoting effects of IGF1 are blocked (Fig. 4). Multiple types of antagonists of 
IGF1 have been studied including small-molecule tyrosine kinase inhibitors (TKIs) and 
competitive antagonists such as monoclonal antibodies directed against the IGF1R or 
the use of IGF1 peptide analogs (Table 2). Since hormones and growth factors, 
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including IGF1, function to promote growth by inducing cell proliferation and survival, 
hormone antagonists are often investigated as means for treating abnormal cell growth 
such as carcinogenesis. However, many of these antagonists face scrutiny because of 
the reports of failure in clinical trials (Guha, 2013). Therefore, investigators are 
continuing to seek a better understanding of these antagonists using animal models 
(Moody et al., 2014) and continue to research alternatives for IGF1 antagonists to 
improve targeted therapies (Guha, 2013).  
Apart from clinical studies using IGF1 antagonists as anti-cancer drugs, testing 
antagonists for their ability to block IGF1 action in various tissues, including bone, 
should be done. Since many of these drugs are administered systemically, the smaller 
sized antagonists (<0.9 kDa) are more soluble and better for transport out of the 
vasculature and into the tissue (Hadacek & Bachmann, 2015; Macielag, 2012). As 
highlighted in Table 2, IGF1 peptide analogs are effective because of their specificity, 
small molecular size (0.6-1.2 kDa) and low toxicity (Haylor et al., 2000; Huang, Golden, 
Tarjan, Madison, & Stern, 2000; Kleinridders, 2016; Pietrzkowski, Wernicke, Porcu, 
Jameson, & Baserga, 1992; Smith et al., 1999). Multiple IGF1 peptide analogs have 
been used to inhibit cellular proliferation including JB1, JB2 and JB3 (Pietrzkowski et al., 
1992). Presently, JB1 is the analog commercially available to researchers that 
competitively binds to IGF1R and blocks downstream IGF1 activity (Brock et al., 2011; 
Huang et al., 2000; Kleinridders, 2016; Todd, Fraley, Peck, Schwartz, & Etgen, 2007; 
Wen et al., 2012) (Fig. 5). As with many antagonists, resistance is possible. Haylor et al. 
(2000) reported a bell-shaped curve with the dose response of JB3 and its successful 
inhibition of kidney growth in rats. In addition to determining an effective range of 
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treatment, challenges still arise in eliciting a tissue specific response without affecting 
other systems dependent on IGF1 for normal growth. Therefore, further investigation 






Table 2. Summary of IGF1 Antagonists in Inhibiting Overall Growth 
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Figure 5. JB1 Blocks IGF1R Signaling  
Model demonstrates how IGF1 peptide analog, JB1, competitively binds to the IGF1R. 
JB1 thus inhibits IGF1 binding preventing IGF1R activation and ultimately blocking 
kinase signaling that would otherwise lead to cell survival and proliferation (repressed 
downstream effects indicated by the red “X”). Illustration based on Crudden et al. 
(2015). 
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1.5 REGULATION OF LINEAR GROWTH BY TEMPERATURE 
1.5.1  Temperature Regulates Linear Growth in Nature 
For over 50 years, several environmental factors have been shown to influence 
bone growth and development. As reviewed by Schell, Gallo, & Ravenscroft (2009), 
environmental factors include nutrition, altitude, climate and temperature. Temperature 
has classically been described to influence extremity length as described by Allen’s rule 
that warm-blooded animals living in cold climates display decreased length of 
extremities and appendages (Allen, 1877). Temperature regulated limb length is thought 
to be an adaptation to the cold climate by reducing the body mass to surface area ratio 
(Newman, 1953).   
 
1.5.2  Temperature Regulates Linear Growth in Laboratory Setting 
Allen’s rule is often still applied to a variety of different species in present day 
studies. In humans, Allen’s rule was demonstrated in a study suggesting that shorter 
limbs (including those of Neanderthals, a group of archaic humans) are advantageous 
for survival in cold climates by reducing the metabolic cost of maintaining body 
temperature (Tilkens, Wall-Scheffler, Weaver, & Steudel-Numbers, 2007). In reptiles, 
studies have shown that increased incubation temperature (32°C) of embryonic 
crocodiles led to increased tibial length (Pollard et al., 2017). Serrat (2014b) thoroughly 
reviewed the impact of temperature on extremity growth in various species. For 
instance, mice from 3.5-12 weeks of age housed at warm ambient temperature (27°C) 
displayed longer limbs than cold-reared mice (7°C) (Serrat, Williams, & Farnum, 2010). 
Overall results of Allen’s rule replicated in laboratory settings (mainly in rodents) appear 
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to be most profound when experimentation occurs during the active period of postnatal 
growth. Al-Hilli and Wright (1983) studied effects of warm ambient temperature (33°C) 
on tail growth in young mice (3 weeks of age) and showed heat enhanced tail growth 
occurred during the first 3-4 weeks of exposure. Serrat (2013) reanalyzed this 
temperature sensitive period of postnatal growth in young mice (3 weeks of age) and 
found that the “critical phase” of temperature sensitive growth occurs between 3-5 
weeks of age, followed by a later “maintenance phase,” whereby limb length differences 
are simply maintained.  
 
1.5.3  Unilateral Heating Model Enhances Bone Lengthening 
Serrat et al. (2015) later showed that targeted unilateral limb heating (40°C) in 
growing mice (3-5 weeks of age) increased limb length on heat-treated sides. However, 
the mechanism of action is unclear. It can be difficult to narrow down a single 
mechanism responsible for temperature-altered physiology, as there are numerous 
possibilities, both direct and indirect, and include altered cellular gene expression, 
vascularization, transport of nutrients and growth factors (Serrat, 2014b), and systemic 
hormone concentrations. It is likely that multiple mechanisms are involved in 
temperature-enhanced limb growth. Since the cartilaginous growth plate drives linear 
bone growth and the observed temperature induced changes in limb length occur 
concurrently with periods of elevated growth plate activity (3-5 weeks of age in the 





1.5.4  Potential Function of IGF1 in Heat-Enhanced Linear Growth 
As previously discussed, IGF1 is the main regulator of linear growth since normal 
skeletal development does not occur without functional IGF1 activity (see Table 1) (Liu 
et al., 1993; Mohan et al., 2003; Powell-Braxton et al., 1993; Wang et al., 2006). In 
addition to liver-derived serum IGF1 (endocrine), it has also been suggested by rodent 
studies that locally expressed IGF1 (autocrine/paracrine) regulates cellular mechanisms 
of longitudinal bone growth in the growth plate (Isaksson et al., 1982, 1985; Isaksson, 
Ohlsson, Nilsson, Isgaard, & Lindahl, 1991; Ohlsson et al. 1992a, 1992b, 1998; 
Schlechter et al., 1986). Therefore, a working hypothesis for heat-enhanced linear 
growth is that temperature increases activity of IGF1, which increases rates of 
chondrocyte proliferation and hypertrophy to subsequently enhance limb growth. Heat-
enhanced linear growth may occur by: (1) indirectly increasing IGF1 access to the 
growth plate with temperature-enhanced blood flow (endocrine actions), (2) directly 
increasing IGF1 activity within the growth plate (autocrine/paracrine actions) with 
temperature-enhanced expression of regulators, or (3) a combination of both.  
While supporting evidence of temperature-enhanced blood flow and vascular 
transport are discussed in later sections, literature also supports that IGF1 expression 
increases with higher temperature. A recent study showed that during early 
development in a population of eels (endoskeleton is entirely made of bone), those 
reared in warmer temperatures (22°C) compared to colder temperatures (16°C), were 
significantly longer in length and had increased gene expression of IGF1 (Politis et al., 
2017). Other studies comparing the effect of thermal manipulation on IGF1 expression 
in skeletal muscles of growing broiler chicks showed increased expression associated 
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with increased temperature (Al-Zghoul et al., 2016; Halevy, Krispin, Leshem, McMurtry, 
& Yahav, 2001). In addition to the suggested relationship between temperature and 
IGF1 expression in developing tissues, temperature has also been shown to weaken 
the affinity of IGF1 binding to ALS in its ternary complex (ALS-IGF1-IGFBP3) 
accounting for increased free IGF1 in the circulation (Holman & Baxter, 1996). Further 
research is required to determine if temperature impacts IGF1 action in bone and 
cartilage tissue in mammals during development.   
 
1.6 ROLE OF VASCULATURE IN PROMOTING LONGITUDINAL BONE GROWTH 
 
1.6.1  Vascular Supply of the Growth Plate 
In addition to local and systemic factors that regulate the well-controlled process 
of endochondral ossification, vascular systems are also crucial because they transport 
regulators that are essential for longitudinal bone growth. Therefore, it is important to 
understand the blood supply of growth plate cartilage. Although bone is a highly 
vascularized tissue, signaling molecules involved in bone elongation must overcome a 
challenge that is unique to the growth plate. Cartilage does not have a penetrating blood 
supply. Systemic factors essential for bone elongation are delivered from surrounding 
blood vessels (Brodin, 1955; Maes, 2013; Trueta, 1968). These vascular routes include: 
1) epiphyseal vessels, 2) metaphyseal vessels, and 3) perichondral vessels (Brookes & 
Revell, 1998; Brighton, 1978; Spira & Farin, 1967; Wirth et al., 2002). Perichondral 
vessels arise from a ring vessel found in the encircling fibrochondrosseous structure in 
the perichondrium known as the groove of Ranvier (Brookes & Revell, 1998; Walzer et 
al., 2014). The epiphyseal vessels have been reported to provide the means for normal 
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chondrocyte proliferation, while chondrocyte hypertrophy is dependent on the 
metaphyseal vessels (Trueta & Amato, 1960; Zoetis et al., 2003). Studies have shown 
that the epiphyseal vasculature is essential for normal growth plate cartilage 
development (Maes et al. 2004; Maes, 2013; Trueta, 1968; Williams, Zipfel, Tinsley, & 
Farnum, 2007). While the viability of chondrocytes may be dependent on epiphyseal 
vasculature as opposed to metaphyseal vasculature (Trueta, 1968), metaphyseal 
vessels are essential for providing osteogenic factors that replace cartilage with bone 
during the process of endochondral ossification.  
 Studies have recently emerged using novel techniques to investigate the not fully 
elucidated mechanism of molecular transport into the growth plate through the 
surrounding vasculature. Multiphoton microscopy (MPM) as described by Zipfel, 
Williams, & Webb (2003) is an attractive, noninvasive method of in vivo fluorescent 
imaging in living anesthetized animals. Investigators have used MPM imaging as a 
means of tracking systemic fluorescent tracers through the vasculature into the growth 
plate (Farnum, Lenox, Zipfel, Horton, & Williams, 2006; Serrat, Williams, & Farnum, 
2009; Serrat et al., 2010; Serrat, Efaw, & Williams 2014a; Williams et al., 2007). For 
biological significance, the size of the fluorescent tracers was selected based on the 
range of endogenous molecules that diffuse into the growth plate. The comprehension 
of how signaling molecules enter the growth plate through the surrounding vasculature 
is helpful in understanding regulation of growth plate chondrocytes. For example, very 
small amounts of molecules larger than 40kDa enter the growth plate (Serrat et al., 
2014a), but molecules less than 10kDa were found to enter the growth plate through all 
three vascular routes (Farnum et al., 2006). Larger sized molecules (10kDa and 
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greater) appear to enter the growth plate from the surrounding perichondral vessels 
(Williams et al., 2007). Transport of molecules into the growth plate is relevant to 
understanding how larger signaling molecules such as FGFs (FGF2, 18kDA; FGF18, 
23kDa), PTHrP (9-23kDa), and BMPs (BMP-2, 26kDa) expressed in the perichondrium 
regulate growth plate chondrogenesis (Kronenberg, 2003).  
 
1.6.2  Transport of Systemic IGF1 into the Growth Plate 
IGF1 is the major circulating hormone of growth. At a molecular weight of 
7.6kDa, IGF1 falls within the range of molecules that readily enter the growth plate 
through the surrounding vasculature (less than 10kDa). Therefore, it is beneficial to 
study IGF1 transport and improve our understanding of its role in regulating growth 
plate chondrocytes. In an attempt to develop the means to facilitate this expansion in 
knowledge, Serrat and Ion (2017) developed a methodology for fluorescently labeling 
IGF1 in order to track its transport into the growth plate using MPM. They showed that 
biologically active IGF-488 (IGF1 conjugated with Alexa Fluor 488) entered the growth 
plate and localized to chondrocytes (Serrat & Ion, 2017). In addition to the general 
comprehension of growth plate chondrocyte regulation, vascular transport studies also 
are important in the development of therapies for growth plate disorders. IGF1 is used 
as a drug to treat impaired growth in growth hormone insensitive children, i.e Laron 
Syndrome patients (Azcona et al., 1999; Backeljauw et al., 2013; Chernausek et al., 
2007; Laron & Klinger, 2000; Laron, 2001, 2015a; Laron & Kauli, 2015b; Lupu et al., 
2001; Midyett et al., 2010; Ranke, 1995a; Ranke et al., 1995b, 1999; Sims et al., 2000). 
It is therefore essential to understand how IGF1 can be modulated to improve effective 
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treatment. Modulation may include methods for increasing IGF1 activity within the 
growth plate, or better targeting its delivery to the growth plate.  
Environmental factors, such as temperature, can affect vascular systems in bone 
and affect their growth (Reviewed by Serrat (2014b)). In vivo imaging studies using 
MPM have shown that warm temperature increases molecular uptake into the growth 
plate (Serrat et al., 2009, 2010, 2014a). Temperature enhanced solute delivery is size-
dependent as the transport of smaller molecules (less than 10kDa) is increased by over 
150%, while larger molecules (40kDa and larger) are increased by less than 50% 
(Serrat et al., 2014a).  
 
1.6.3 Chondrocyte Expression of Angiogenic Factors  
Angiogenesis (development of new blood vessels) is essential for normal linear 
bone growth. During endochondral ossification, hypertrophic chondrocytes secrete 
angiogenic factors that initiate vascular invasion and recruit bone absorbing and forming 
cells to replace mineralized cartilage with bone. The key regulator of angiogenesis 
during both prenatal and postnatal growth and development is vascular endothelial 
growth factor (VEGF). Survival is dependent on functional VEGF during both embryonic 
(Carmeliet et al., 1996; Ferrara et al., 1996) and early postnatal life (Gerber et al., 
1999a). Different VEGF isoforms exist but only VEGF-A is expressed in growth plate 
cartilage and therefore is the most important for regulating longitudinal bone growth 
(Emons et al., 2010). There are also additional splice isoforms of VEGF-A that vary 
between species. Hypertrophic chondrocytes in both human and murine growth plates 
secrete VEGF (Filipowska, Tomaszewski, Niedźwiedzki Ł, Walocha, Niedźwiedzki T, 
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2017; Gerber et al., 1999b; Horner et al., 1999; Hunziker, 1994b; Maes et al., 2004; van 
der Eerden et al., 2003; Zelzer & Olsen, 2005) to promote vascular invasion from the 
metaphyseal bone throughout postnatal limb elongation. In human growth plates, the 
most common splice isoforms are VEGF121, VEGF165 and VEGF189 (Emons et al., 2010; 
Maes et al., 2004). The analogous isoforms in mice are VEGF120, VEGF164 and VEGF188 
(Maes et al., 2002, 2004). Interestingly, Maes et al. (2004) discovered that different 
processes of vascularization require specific isoforms of VEGF-A and that the combined 
action of VEGF120 and VEGF188  is required for both epiphyseal and metaphyseal 
vascularization. Other local factors expressed by hypertrophic chondrocytes that 
promote angiogenesis include FGFs (Baron et al., 1994; Hung, Yu, Lavine, & Ornitz, 
2007; Liu, Lavine, Hung, & Ornitz, 2007) and matrix metalloproteinase 9 (MMP-9) 
(Engsig et al., 2000; Gerber et al., 1999b; Maes et al., 2002; van der Eerden et al., 
2003; Vu et al., 1998). Systemic factors including estrogen (Emons et al., 2010) and 
IGF1 (Ahmed & Farquharson, 2010; Álvarez-García et al., 2010) have also been shown 
to induce vascular invasion by stimulation of VEGF in growth plate chondrocytes.  
Normal longitudinal bone growth is dependent on VEGF expression in growth 
plate chondrocytes. Inhibition of VEGF in young mice (24 days old) suppressed blood 
vessel invasion, lengthened the hypertrophic zone and reduced bone growth, all of 
which was corrected after anti-VEGF treatment ended (Gerber et al., 1999b). These 
results are clinically relevant to actively growing children that may require therapeutic 
intervention using angiogenesis inhibitors to prevent unwanted formation of new blood 
vessels such as in pediatric cancers. A monoclonal antibody against VEGF, 
bevacizumab (Avastin®; Genentech, Inc), has been used in adults as a FDA approved 
 
 41 
anti-cancer agent (Ferrara, 2004) and is considered a promising treatment option for 
children (Barone & Rubin, 2013; Han et al., 2016). It is especially important to improve 
chemotherapy in pediatric patients since children are undergoing an essential stage of 
bone development requiring growth factors, including IGF1 and VEGF, for bone 
elongation. Therefore, as with IGF1 antagonists, the development of non-invasive 
methods for targeting drugs directly to a tissue is beneficial for preserving linear growth 
in children. 
 
1.7 SCOPE OF CURRENT WORK 
 The goal of the current studies in this dissertation is to build upon an established 
method of targeted limb heating as a potential non-invasive alternative to enhance bone 
lengthening. This study tests the overall hypothesis that exposure to warm 
temperature augments the actions of IGF1 in the growth plate and permanently 
increases length of the extremities. The central aims of this study are 1) to determine 
if IGF1 enhances bone elongation in heat-treated extremities and 2) determine the long-
term extent of left-right limb length asymmetries and potential vasculature modifications 
resulting from unilateral heat-treatment.  
The application of the model for targeted limb heating (unilateral heating model) 
and its functional impact is described in Chapter 2. This chapter sets the foundation for 
following experiments using the unilateral heating model as a means to test the overall 
hypothesis. As discussed above, the epiphyseal growth plate is the primary site of 
longitudinal bone growth, and regulated by IGF1 (Börjesson et al., 2010; Lui et al., 
2014; Ohlsson et al., 1993; Tryfonidou et al., 2010; van der Eerden, 2003; Wang et al., 
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2010). Chapter 3 tests the hypothesis that there will be a unilateral increase in bone 
length associated with increased chondrocyte proliferation and hypertrophic zone 
expansion in the growth plate with heat-treatment. Observation of morphological 
changes in the growth plate is a means to assess heat-enhanced bone elongation. In 
Chapter 4, a study administering a low dose of IGF1 (2.5 mg/kg, once daily) coupled 
with targeted limb heating tests the hypothesis that IGF1 administered with heat-
treatment will further enhance limb length than with heat alone. To further test the 
overall hypothesis of this thesis, Chapter 5 describes the outcome of linear growth with 
heat-treatment when IGF1 activity is blocked. The hypothesis is that with diminished 
IGF1 activity, heat-enhanced limb length is attenuated. The goal shared by both 
Chapter 4 and 5 is to demonstrate that unilateral exposure to warm temperature 
augments actions of IGF1 in the growth plate to enhance bone length.    
The long-term impact of targeted limb heating after the end of treatment is 
elucidated in Chapter 6. This study tests the hypothesis that differential limb length will 
be maintained throughout skeletal development after treatments have ended. The goal 
of this chapter was also to demonstrate that persistent limb length differences will be 
prominent in mice administered IGF1 following heat-treatment. The final chapter of this 
thesis (Chapter 7) describes a pilot study measuring limb surface temperature following 
heating and tests the hypothesis that skin temperature of heat-treated limbs will remain 
elevated for an extended time following treatment. This chapter prefaces future studies 
into possible mechanisms of the targeted heating-model as it suggests a heat-induced 
increase in blood flow that accelerates bone lengthening. Together, current studies 
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within the chapters of this thesis will use the unilateral heating model to test the overall 




CHAPTER II: FUNCTIONAL IMPACT OF TARGETED LIMB HEATING IN MICE 
2.1 INTRODUCTION 
Both congenital and acquired bone elongation disorders arise during early stages 
of development. Without childhood medical intervention, problems associated with 
these disorders can persist into adulthood and often are accompanied by painful health 
conditions. Limb length discrepancy (LLD) of the lower limbs is characterized by the 
asymmetric length of the lower extremities and can result from trauma or disease 
(Morscher, 1977; Shapiro, 1982; Wilson & Thompson, 1939). Untreated LLD can lead to 
chronic and painful musculoskeletal disabilities (Campbell et al., 2018; Gurney, 2002). 
While the options for intervention vary based on the severity of the discrepancy, 
research has addressed possible treatment options that typically involve more 
permanent, invasive procedures (Gurney, 2002; Hasler & Krieg, 2012; Niedzielski, 
Flont, Domżalski, Lipczyk, & Malecki, 2016; Pendleton et al., 2013; Sabharwal et al., 
2015; Stevens, 2016). Traditionally, intervention is recommended for what has been 
considered an important functional discrepancy of 2 cm or more (Gross, 1978; Gurney 
2002; Knutson, 2005). However, studies within the last two decades have shown that a 
left-right asymmetry in limb length of less than 2 cm (0.5-1 cm) is functionally significant 
(Harvey et al., 2010; Resende et al., 2016; White et al., 2004). Smaller left-right 
asymmetries involve more conservative methods for correction such as shoe lifts or 
prosthetics (Campbell et al., 2018; Golightly et al., 2007a; Hasler & Krieg, 2012; Wilson 
& Thompson, 1939), but these methods do not permanently change the length of the 
bone. It is important to explore alternative, noninvasive methods for correcting LLD, 
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including even small discrepancies, during critical stages of postnatal longitudinal bone 
growth.  
A promising noninvasive alternative involves using targeted heat (40°C) to 
increase bone length on one side of the body (Serrat et al., 2015). After two weeks of 
localized unilateral heating, Serrat et al. (2015) demonstrated increases in tibial 
elongation rate (>12%), femoral length (1.3%) and tibial length (1.5%). The ultimate goal 
of these studies is to use heat-based therapy to correct a range of bone growth 
impairments such as LLD in children. However, one fundamental question is whether 
these heat-induced limb length differences are functionally significant.    
One functional outcome of LLD includes gait disturbances (Aiona et al., 2015; 
Kaufman et al., 1996; Khamis & Carmeli, 2017; Mahmood et al., 2010; Song et al., 
1997) resulting from a pelvic tilt toward the shorter side (Kerr, Grant, & MacBain, 1943; 
Rush & Steiner, 1946). Therefore, this study aimed to determine if the small 
discrepancies after one week of daily intermittent targeted limb-heating result in 
changes in weight bearing. Longitudinal x-ray imaging and weight bearing distribution 
analyses were used to test the hypothesis that heat-induced limb length asymmetry 
has a functional impact on weight bearing in mouse hindlimbs.  
 
2.2 MATERIAL AND METHODS 
2.2.1 Animals and Experimental Design 
 All procedures were approved by the Institutional Animal Care and Use 
Committee of Marshall University (Protocol 558). Female C57BL/6 (N=12) mice were 
obtained from Hilltop Lab Animals, Inc. (Scottdale, PA, USA) at 21 days weaning age. 
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Previous studies have shown that heat-enhanced bone elongation occurs in both male 
and female mice with unilateral heat-treatment (Serrat et al., 2015). These studies 
focused only on female mice since there were no reported differences between the 
sexes and because other related studies in our laboratory required females. Mice were 
singly housed at 21°C in standard plastic caging, exposed to a 12 hour light/dark cycle 
and provided with food and water ad libitum.  
Mice post-weaning were treated with 40 minutes of daily unilateral heat (40°C) 
for 7 days beginning when mice were 3-weeks old following methods described by 
Serrat et al. (2015). This period of postnatal growth was chosen because it has 
previously been shown as a period of rapid, temperature sensitive growth (Serrat, 
2013). Relative to human development, this pre-pubertal age range is comparable to 
the period between toddler age and elementary school (as shown in Fig. 2). Mice were 
anesthetized under 1.5% isoflurane and positioned right lateral recumbent on a 40°C 
gel heating pad each day (Fig. 6). Heat-treatment was deliberately scheduled to begin 
at the same time each day at the beginning of the light cycle (~7 a.m.) when growth 
plate height and growth rate are maximal (Noonan et al., 2004; Stevenson, Hunziker, 
Hermann, & Schenk, 1990). For each day of treatment, placement of each individual 
mouse was rotated along the anesthesia manifold to account for any positioning effects 
(the end positions for example are closer to the edge of the gel heating pad and 
closer/further from the source of isoflurane). Limbs on the heat-treated side were fitted 
in custom made insulating booties to warrant uniform heat distribution. Foam separators 
were placed between the limbs as a thermal shield preventing heat transfer to the non-
heated limb (30°C). Ear and hindlimb temperatures were taken throughout heating and 
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core temperature and respirations were recorded as means of physiological monitoring. 






Figure 6. Diagram of the Unilateral Heating Method 
Labeled photograph shows the unilateral heating method during the 40 minutes of 
treatment (40°C). Temperature of heating pad topped with custom gel packs (colored 
yellow) is manually controlled by a thermostat (not shown in image) and maintained at 
40°C. Mice are positioned right lateral recumbent along the anesthesia manifold and 
anesthetized with 1.5% isoflurane. Isoflurane flows through the plastic tubing controlled 
for each individual mouse. Limbs on the heat-treated side are fitted in custom made 
insulating booties. Foam separators are placed between the limbs (temporarily removed 
from position 4 to reveal the insulating booties underneath).  
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2.2.2 Tibial Radiographs 
 Radiographs were collected from mice (N=6) at the start (3 weeks of age) and 
end (4 weeks of age) of the limb-heating experiments using an IVIS Lumina XRMS live 
animal imaging system (Perkin Elmer, Waltham, MA, USA). Mice were anesthetized 
individually under 1.5% isoflurane and positioned in ventral recumbency on a heated 
platform. Each mouse was secured to the platform with adhesive tape with its hindlimbs 
extended and taped down following published methods to ensure reproducible limb 
positioning and a true projection of the tibia (Fig. 7) (Hughes & Tanner, 1970). High-
resolution x-ray images were taken following methods described in the literature 
(McManus & Grill, 2011) using modified settings (animal energy, 35 Kv 100μA, filtered 
x-rays) at 5 cm X 5 cm field of view with f/stop set at 4 and subject height at 1.5 cm. The 
mouse was then returned to its individual cage and observed during anesthesia 














Figure 7. Radiographs Collected Before and After Unilateral Heat-Treatment  
Digital radiographs (29 X 45mm area) of the same mouse taken with an IVIS Lumina 
XRMS live animal imaging system before (3-weeks of age) and after (4-weeks of age) 
heating. Individual mouse represents one of the experimental group (N=6) used to 






2.2.3 Hindlimb Weight Bearing 
 Starting and ending weight-bearing data were collected from mice (N=12) 
following x-ray procedures (~2 hours after anesthesia recovery). Weight bearing was 
measured using an incapacitance meter (Stoelting Company, Wood Dale, IL, USA), a 
device for measuring weight distribution of the two hindlimbs of a small rodent or bird. 
The incapacitance meter records hindlimb weight bearing of each side of the mouse. 
The mouse is placed in an angled plexiglass chamber positioned in a rearing posture so 
that each hindlimb is placed over a separate force plate. Prior to collection, mice were 
acclimated (2-5 minutes) to the chamber following published methods (TenBroek, 
Yunker, Nies, & Bendele, 2016). Measurements were collected during 3-second 
intervals and mean weight distribution was calculated during that period, thus 
accounting for possible shifts in weight from one side to another during testing. A total of 
3-5 recordings were taken per mouse at each time point and mean weight distribution 
from each hindlimb was used in data analyses. Methodology adapted from Racine et al. 
(2018).  
 
2.2.4 Tissue Collection 
 All experimental mice (N=12) were euthanized for tissue collection 1 day after the 
last day of heat-treatment when final x-ray and weight bearing analyses were performed 
at the 4 weeks of postnatal age endpoint. Long bones (femora) from each side were 
dissected, cleaned, dried, and scanned on a flatbed scanner. It has previously been 
found that the intact femur can be dissected and cleaned most consistently for reliable 
bone length data. Proximal tibiae from each hindlimb were dissected, cleaned and 
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bisected. One unfixed half was arranged on a glass slide and cover-slipped with 
glycerol in PBS prepared for tibial elongation rate analysis. Methodology adapted from 
Racine et al. (2018).  
 
2.2.5 Tibial Elongation Rate Analysis and Long Bone Measurements 
 A single intraperitoneal injection of oxytetracycline (OTC) (7.5 mg/kg, Norbrook 
200 mg/mL) was administered to mice at the experimental start, 8 days prior to 
euthanization and tissue collection. OTC is a calcium chelator that integrates into 
mineralizing tissue and leaves a band of fluorescence that can be visualized using a UV 
filter. Fluorescence was visualized in unfixed slab sections of tibiae using Ocular Image 
Acquision Software (version 1.05.211) under 2.5X magnification with a Leica DM2500 
epifluorescence microscope (Leica Microsystems, Wetzlar, Germany) coupled with a 
QImaging Retiga R6 6.0 megapixel monochrome camera (Surrey, BC, Canada) and 
using a UV filter. Tibial elongation rate (μM/day) was quantified by measuring the 
distance between the metaphyseal chondro-osseous junction, where calcification 
begins, and the proximal edge of the OTC band in metaphyseal bone, where the 
fluorescent label is visualized after the 8-day period of growth.  
 Images of scanned femora were calibrated in ImageJ (version 1.48, National 
Institutes of Health, USA) using a metric ruler and measurements were taken by 
drawing a line between proximal and distal landmarks on the articular ends. Femoral 
length was measured as the distance between the proximal-most point on the greater 
trochanter and the distal-most point on the medial condyle. These methods of 
quantifying tibial elongation rate and limb length have been described as reliable 
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techniques in past experiments (Lee et al., 2016; Rolian, 2008; Serrat et al., 2015; 
Wilsman et al., 2008).   
 Tibial length was measured from digital x-rays at the start and end of the study 
(Fig. 7). Radiographs were calibrated in ImageJ using a razor blade for scale. The tibia 
was selected for analysis because its landmarks could be most consistently identified in 
both left and right hindlimbs of the same animal over time. Tibial length was measured 
as the distance from the middle of the proximal articular surface to the distal-most 
projection of the medial malleolus. Methodology adapted from Racine et al. (2018).  
 
2.2.6 Statistical Analysis and Sample Size 
 Statistical analyses were performed using SPSS 25.0 software (IBM Corporation, 
Armonk, NY) with p<0.05 as accepted significance. Non-treated and heat-treated side 
comparisons for femoral length, tibial length, and tibial elongation rate were made using 
one-tailed paired t-tests. Linear regression, with asymmetry in tibial elongation rate as 
the regressor and weight bearing as the dependent variable, was used to assess the 
relationship between weight bearing of hindlimbs and tibial elongation rate. Data were 
reported as mean ± standard deviation (SD) in tabular format and as mean ± standard 
error (SE) in graphical format. Study included a total of N=12 mice to account for 
potential loss of samples and missing cases were excluded from statistical analysis on 
an analysis-by-analysis basis. Sample sizes for measurements that are documented as 
less than the size of the experimental sample set was a result of either sample loss due 
to damage during dissection, poor acclimation to the incapacitance meter, and/or 





2.3.1 Unilateral Heating Parameters 
 After 7 days of unilateral heating, mice gained an average of 5 g between the 
start and the end of the study, consistent with the weight gain of age-matched non-
treated control mice (Serrat et al., 2015). The core temperature averaged 36°C during 
heat-treatment, which is analogous to the core temperature of a healthy C57BL/6 
mouse (Gordon, 2012, 2017). While anesthetized the average surface temperature of 
non-treated hindlimbs was 30°C and the heat-treated hindlimbs were 40°C. The 
average time to anesthesia recovery after limb heating was 1 minute.  
 
2.3.2 Bone Length and Tibial Elongation Rate 
 At the beginning of the study, prior to unilateral heating, there were no significant 
left-right differences in tibial length (paired t=0.65, p=0.55) measured on x-rays (Fig. 7, 
Table 3). At the experimental end when mice were 4 weeks of age following 7 days of 
targeted limb heating, tibial length (paired t=11.5, p<0.001) measured on x-rays 
increased by 0.9% on heat-treated sides (Fig. 7, Table 3) and femoral length (paired 
t=7.7, p<0.001) measured from the digital scans increased by 1.4% on the heat-treated 
side (Fig. 8A). Tibial elongation rate measured by OTC labeling averaged 
160±14μM/day on the non-treated side and 170±13μM/day on the heat-treated side with 





Figure 8. Extremities are Lengthened on the Heat-Treated Side  
(A) Error bar plot comparing femoral length of non-treated and heat-treated limbs, show 
femoral length increased on the heat-treated side by 1.4% after 7 days of heating. (B) 
Tibial elongation rate increased on the heat-treated side by 6.5%. Mean ± 1 standard 
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Table 3. Comparison of Hindlimb Weight Bearing and Tibial Length Measured by 
X-Rays.  
 
Values are mean (standard deviation). Sample size (N) is number of left-right pairs. 
Significantly larger on heat-treated side by one-tailed paired t-test: *p< 0.05; **p<0.01; 









Tibial Length (mm) 
    measured from x-rays Before  12.93 (0.27) 12.94 (0.26)ns 0.1 6 
After 14.19 (0.14) 14.32 (0.12)*** 0.9 5 
Hindlimb Weight Bearing (g) 
    measured using incapacitance meter Before  3.36 (0.38) 3.23 (0.25)ns -2.9 7 
After 5.44 (0.58) 6.51 (0.80)*** 19.6 8 
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2.3.3 Hindlimb Weight Bearing 
 As with starting tibial length, there were no significant left-right differences in 
hindlimb weight bearing (paired t=0.94, p=0.38) at the start of the study (Table 3). 
Although not statistically significant, hindlimb bearing was about 3% greater on the 
intended non-treated side prior to unilateral heating. After 7 days of targeted limb 
heating, hindlimb weight bearing (paired t=11.9, p<0.001) was nearly 20% greater on 
the heat-treated side (Table 3). There was also a significant positive linear relationship 
between the increase in weight bearing and increase in tibial elongation rate (R2=0.82, 





Figure 9. Increase in Weight Bearing and Tibial Elongation Rate are Correlated 
After 7 Days of Unilateral Heat-Treatment 
Scatter plot of individual mice shows a significant positive linear relationship between 
the increase in weight bearing and increase in tibial elongation rate after 7 days of 



































 The goal of this study was to determine if the heat-induced differences in limb 
length are functionally significant as assessed by changes in hindlimb weight bearing. 
Our data support the hypothesis that heat-induced limb length asymmetry has a 
functional impact on weight bearing in mouse hindlimbs.  
After 7 days of targeted limb heating, there was a nearly 1% increase in tibial 
length on the heat-treated side determined by measurements from x-ray images of live 
anesthetized mice (Table 3). This increase in tibial length is comparable to the 1.4% 
increase in femoral length measured by postmortem femoral scans (Fig. 8). While the 
femoral length increase was slightly greater, this may be due to a larger sample size, or 
because the dried femoral landmarks were more distinct than those of the tibia in the 
radiographs. The femur was not measured in radiographs because its proximal and 
distal ends were more prone to distortion. Endpoint tibial length measured from whole 
tibia postmortem was also not accomplished since tibiae were reserved for tibial 
elongation rate analyses.  
The heat-enhanced bone length and tibial elongation rate measured after 7 days 
of heating was associated with a nearly 20% increase in hindlimb weight bearing on the 
heat-treated side (Table 3). This increase in hindlimb weight bearing positively 
correlates to tibial elongation rate indicating that gait asymmetry increases along with 
bone elongation (Fig. 9). The positive correlation between hindlimb weight bearing and 
tibial elongation rate is consistent with similar findings in human studies (Kaufman et al., 
1996; Khamis & Carmeli, 2017). One limitation to this study was the difficulty to obtain 
longitudinal weight bearing data (before and after measurements from the same mouse) 
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using the incapacitance meter since data could only be used when the mice were calm, 
immobile, and properly positioned within the plexiglass chamber. Using a dynamic gait 
analysis would be beneficial because it would enable the collection of data in 
unrestrained mice in their natural posture. An additional study to further support the 
functional significance of heat-induced limb length asymmetry may include a balance 
beam test with mice. Assessment of motor coordination and balance response to heat-
treatment would be relevant since poor balance is associated with human limb length 
discrepancies (Azizan et al., 2018; Bonnet, Cherraf, Szaffarczyk, & Rougier, 2014).  
Radiography and weight bearing analyses were useful methods for acquiring 
before and after bone length and hindlimb weight bearing measurements from the same 
mouse. Measurements collected at the start of the experiment are useful for evaluating 
the functional importance of targeted limb heating because they demonstrate the natural 
differences in both bone length and weight bearing prior to experimental manipulation. 
In humans, many individuals have a degree of normal left-right asymmetry in the 
lengths of their lower limbs (Green & Anderson, 1955; Knutson, 2005). Serrat et al. 
(2015) showed that there was no inherent side asymmetry in non-treated control 
animals. The current study further supported that left-right asymmetry is heat-induced 
and not a natural variation by comparing the before and after measurements of both 
tibial length and weight bearing.  
 
2.5 CONCLUSION 
 In conclusion, even small discrepancies in limb length (nearly 1% to 1.4%) have 
a functional impact on hindlimb weight distribution (nearly 20%) in young mice. These 
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results suggest that heat-based therapies should continue to be pursued as a non-
invasive alternative to surgical correction of limb length discrepancy. Chapter 6 tests the 
hypothesis that heat-induced limb length asymmetry is maintained to skeletal maturity 
(12 weeks of age). However, future studies will determine if left-right limb length 
asymmetry in skeletally mature mice has a functional impact on weight bearing. This 
would be translatable to the orthopedic problems described to accompany LLD and gait 
disturbances in adulthood. The functional significance of the heat-induced difference in 
limb length sets the foundation to further experimentation using the unilateral heating 





CHAPTER III: CHONDROCYTE PROLIFERATION AND HYPERTROPHY IN TIBIAL 
GROWTH PLATES INCREASES AFTER 7 DAYS OF TARGETED LIMB HEATING 
 
3.1 INTRODUCTION 
 During longitudinal bone growth via endochondral ossification, cartilaginous 
growth plates undergo a process of proliferation, expansion and apoptosis. Bone growth 
rate is largely dependent on the dynamics of cartilage growth. It is therefore likely that 
heat enhanced bone elongation involves modifications to growth plate cartilage. Others 
have determined the main contributing factors to longitudinal growth include: the 
amount of columnar cells in the proliferative zone of the growth plate, the rate of 
proliferation, and the size of expanded cells in the hypertrophic zone (Cooper et al., 
2013; Farnum, 2007; Hunziker et al., 1987; Hunziker & Schenk, 1989; Hunziker, 1994b; 
Kember, 1993; Rolian, 2008; Walker & Kember, 1972; Wilsman et al., 1996a, 1996b, 
2008).  
 The growth period from 3-5 weeks of age in mice post weaning is the most rapid, 
temperature sensitive period of longitudinal bone growth (Al-Hilli & Wright, 1983; 
Callewaert et al., 2010; Li et al., 2017; Serrat, King, & Lovejoy, 2008). Temperature as a 
therapeutic intervention therefore should be most effective during this stage of early 
postnatal linear growth in mice. Treatment with 40°C unilateral heat for 40 minutes/day 
over a period of 14 days in mice starting at 3 weeks of age resulted in extremity 
lengthening and enhanced tibial elongation rate in both male and female mice (Serrat et 
al., 2015). This phase of growth is an ideal period to focus therapeutics for optimum 
limb lengthening results.  
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The objective of this study was to determine how localized heating impacts bone 
growth at the site of the cartilage growth plate after one and two weeks of limb heating.  
The one week duration of heating was selected in addition to two weeks since the mice 
have the largest gain in body mass from 3-4 weeks of age as shown by growth curves 
provided by Hilltop Lab Animals, Inc (“Growth Chart C57BL/6,” 2018) and The Jackson 
Laboratory (“Body Weight Information for C57BL/6J,” 2018). This study tested the 
hypothesis that increased bone length in heat-treated limbs will be associated 
with increased chondrocyte proliferation and hypertrophic zone expansion 
compared to the non-treated contralateral limbs.  
   
3.2 MATERIAL AND METHODS 
 
3.2.1 Animals and Experimental Design 
 All procedures were approved by the Institutional Animal Care and Use 
Committee of Marshall University (Protocol 558). Female C57BL/6 (N=24) mice were 
obtained from Hilltop Lab Animals, Inc. (Scottdale, PA, USA) at 21 (N=18) or 28 (N=6) 
days weaning age. Mice were singly housed at 20°C in standard plastic caging, 
exposed to a 12 hour light/dark cycle and provided with food and water ad libitum. 
 As indicated by the unilateral heating methods schematic (Fig. 10) mice post-
weaning were treated with daily unilateral heat (40°C). Unilateral heat-treatment for 7 
days began when mice were 3 weeks (N=6) and 4 weeks old (N=6), and treatment for 
14 days started when mice were 3 weeks old (N=6). The procedural room temperature 
remained at 19°C while mice were anesthetized under 1.5% isoflurane and positioned 
right lateral recumbent on a 40°C heating pad each day for 40 minutes.  
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Mice were weighed and given subcutaneous injections of a saline solution (3:1, 
1xPBS:dH2O) at a volume of 0.01mL/g daily at the beginning of the light cycle. Mice 
were injected with saline because they serve as a control group to compare with their 
weight-matched littermates injected with drug treatments discussed in Chapters 4 and 
5. Previous studies in our laboratory have shown that there are no significant 
differences in heat-treatment outcome variables between non-injected and saline-







Figure 10. Unilateral Heating Schematic  
Mice were injected subcutaneously (SQ) with saline one hour prior to treatment of 40°C 
unilateral heat for 40 minutes daily for: (1) 7 days from 3-4 weeks of age, (2) 7 days 
from 4-5 weeks of age or (3) 14 days from 3-5 weeks of age. Euthanasia and tissue 
collection occurred 1 day after the last day of heat-treatment. Mouse illustration based 
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SALINE 
Harvest Harvest 
5 weeks 4 weeks 3 weeks 
Age 
Day of Trial 
40°C unilateral heat 40 min/day 
from 3-4 weeks of age 
from 4-5 weeks of age 
from 3-5 weeks of age 




3.2.2 Tissue Collection 
 All experimental mice (N=24) were euthanized for tissue collection 1 day after the 
last day of heat-treatment. Mice that were subjected to unilateral heating from 3-4 
weeks of postnatal age (N=6) were euthanized at the 4 weeks of age endpoint and 
those treated from 3-5 weeks of postnatal age (N=18) were euthanized at the 5 weeks 
of age endpoint (Fig. 10). It is important to note that although tissues were collected 
from mice treated for 7 days from 4-5 weeks of age, only weight gain comparisons are 
made from these mice in this study since mice from 3-4 weeks of age grew more rapidly 
in comparison. Therefore, mice treated for 7 days from 3-4 weeks of age were 
preferable for analysis.   
Long bones (femora and humeri) from each side were dissected, cleaned, dried, 
and scanned on a flatbed scanner. Proximal tibiae from each hindlimb were dissected, 
cleaned and bisected. One unfixed half was arranged on a glass slide and cover-slipped 
with glycerol in PBS prepared for tibial elongation rate analysis. The other tibial half was 
fixed in 10% neutral buffered formalin for 24 hours, decalcified in 19% EDTA (pH 7.4) 
for 1 week, rinsed in PBS, dehydrated in a series of ethanol, cleared in xylene, and 
embedded in paraffin. Sagittal sections 6μM thick were cut with a microtome (Leica 
RM2125) and mounted on Diamond™ White Glass slides (Globe Scientific) for 
histological analysis.  
 
3.2.3 Tibial Elongation Rate Analysis and Long Bone Measurements 
 A single intraperitoneal injection of oxytetracycline (OTC) (7.5 mg/kg, Norbrook 
200 mg/mL) was administered to mice 7 days prior to euthanization and tissue 
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collection. Fluorescence was visualized in unfixed slab sections of tibiae using the UV 
filter on a fluorescence stereoscope. Measurements collected from scans of femora, 
and quantification of tibial elongation rate, were done as described in Chapter 2 
(Material and Methods 2.2.5). Images of scanned humeri were also calibrated and 
measured in ImageJ, but humeral length was measured as the distance between the 
proximal- and distal-most articular ends.   
 
3.2.4 Growth Plate Morphometry 
 Serial sections of proximal tibiae were deparaffinized in xylene, rehydrated in a 
graded series of ethanol, and incubated in Weigert’s hematoxylin for 6 minutes prior to 
Safranin-O (0.1%, Sigma)/ fast green (0.01%, Fisher) staining. Stained sections were 
dehydrated in graded series of ethanol and xylenes and cover slipped with DPX 
(Sigma). Sections were then imaged using Ocular Image Acquisition Software (version 
1.05.211) under 20X magnification with a Leica DM2500 optical microscope (Leica 
Microsystems, Wetzlar, Germany) fitted with a QImaging Retiga R6 color camera 
(QImaging Corporation).  
 The heights of individual growth plate zones (reserve, proliferative and 
hypertrophic) were measured from calibrated images in ImageJ. Measurements were 
taken at five different points across the width of the growth plate and the mean was 
calculated to represent the height for each zone. Total growth plate height was 
determined by the sum of the individual zones. Each individual zone was then 
normalized to the total growth plate height to allow comparisons among ages. It is 
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important to note that tibiae from mice (N=6) treated for two weeks (N=12) were not 
used for histological analysis due to sample loss during tissue processing. 
 
3.2.5 Immunohistochemistry 
 Serial sections of proximal tibiae from mice treated from 3-4 weeks of age were 
stained using a rabbit polyclonal antibody against PCNA (Santa Cruz, sc-7907) at a 
dilution of 1:200 (Table 4). Serial sections of proximal tibiae from mice treated 3-5 
weeks of age were stained using a monoclonal rabbit antibody against PCNA (Cell 
Signalling, #13110) at a dilution of 1:200 after the previously used antibody against 
PCNA was discontinued. In both cases, antigen unmasking was accomplished by 
incubating slides at 40°C with a pre-warmed sodium citrate buffer (pH 3.5) for 30 
minutes followed by a rinse cycle and another incubation at 40°C in a 1:100 dilution of 
chondroitinase ABC (Sigma, C2905) for 10 minutes. Endogenous peroxidase activity 
was quenched with 3% hydrogen peroxide (H2O2) at room temperature (21°C) for 10 
minutes followed by a 1-hour incubation in normal blocking serum. Incubation with the 
primary antibody occurred in the humidified chamber at room temperature overnight. 
The avidin-biotin complex (ABC) horseradish peroxidase method was then used to 
detect positive immunostaining either with the ImmunoCruz rabbit ABC staining system 
(Santa Cruz Biotechnology, sc-2018) or the VECTASTAIN Elite ABC-HRP kit (Vector, 
Rabbit IgG, PK-6101). Both methods used DAB as the chromagen (Vector, SK-4100) 
and all were counterstained with 0.1% methyl green (Sigma), dehydrated and cover 
slipped with DPX before allowing to dry overnight prior to imaging.  
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 Stained sections were imaged using the Leica DM2500 optical microscope as 
previously described above. Chondrocytes within the proliferative zone of the proximal 
tibial growth plate visualized as dark brown nuclei were manually counted as positively 
stained cells for PCNA. Chondrocytes were counted in a 130μM wide sample area (two 
per section). This size was chosen because it consistently contained an area of the 
growth plate encompassing all zones of chondrocytes to allow comparisons among 
samples. The percent of positively stained cells was quantified by dividing the number 










Length of  
Heat-Treatment 
1° Ab / 2° Ab Detection Kit Company Catalog No. Dilution 
7 days 
(3-4 weeks of age) 
PCNA Santa Cruz sc-7907 1:200 
IGF1R Santa Cruz sc-712 1:200 
Phospho-IGF1R abcam ab39396 1:100 
ImmunoCruz ABC Santa Cruz sc-2018 as instructed 
14 days 
(3-5 weeks of age) 
PCNA Cell Signalling #13110 1:200 
IGF1R abcam ab131476 1:100 
Phospho-IGF1R abcam ab39398 1:100 
Vectastain Elite ABC Vector Laboratories PK-6101 as instructed 
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3.2.6 Statistical Analysis and Sample Size 
 Statistical analyses were performed using SPSS 25.0 software (IBM Corporation, 
Armonk, NY) with p<0.05 as accepted significance. Non-treated and heat-treated side 
comparisons for humeral length, femoral length, tibial elongation rate, growth plate zone 
heights and percent cells positive for PCNA expression were made using one-tailed 
paired t-tests. Multiple comparisons made between durations of heat-treatment were 
made using a one-way ANOVA with the Tukey post hoc test. Data were reported as 
mean ± standard deviation (SD) in tabular format and as mean ± standard error (SE) in 
graphical format.  
Sample sizes for measurements that are documented as less than the size of the 
experimental sample set was a result of either sample loss during dissection or sample 
processing. Since left-right comparisons are made, if one side is damaged during 
dissection, sample preparation, tissue processing, sectioning or staining, the entire left-
right pair is lost. Samples and missing cases were excluded from statistical analysis on 
an analysis-by-analysis basis. 
 
3.3 RESULTS 
3.3.1 Unilateral Heating Parameters 
 Mice treated for 7 days from 3-4 weeks of age gained 4.7±0.7g, and mice treated 
for 7 days from 4-5 weeks of age gained 1.6±1.0g in mass (Fig. 11). Thus, the largest 
growth spurt of experimental mice occurred from 3-4 weeks of age. This growth spurt is 
as shown by Hilltop Lab Animals, Inc (“Growth Chart C57BL/6,” 2018) and The Jackson 
Laboratory (“Body Weight Information for C57BL/6J,” 2018). Change in mass 
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significantly differed between each experimental group as determined by multiple 
comparison analysis using one-way ANOVA and Tukey post hoc test (F(2,21)=53.3, 
p<0.01). Therefore, the mice treated for 7 days from 3-4 weeks of age were selected for 
analysis instead of the slower growing mice from 4-5 weeks of age.  
Mice treated for 14 days from 3-5 weeks of age gained 6.0±0.9g in mass (Fig. 
11). This total gain is nearly equivalent to the sum of the mass gained after 7 days of 
heating from mice 3-4 weeks and 4-5 weeks of age. The core temperature averaged 
36°C during all extents of unilateral heating, consistent with the other limb heating 
studies in the previous chapter and those to follow. While anesthetized the average 
surface temperature of non-treated hindlimbs was 30°C and the heat-treated hindlimbs 





Figure 11. Majority of Body Mass Gained During 14 Days of Unilateral Heat-
Treatment Occurs During the First 7 Days   
Scatter plots show the change in mass of individual mice treated for (1) 7 days from 3-4 
weeks of age (open circles), (2) 7 days from 4-5 weeks of age (gray circles) and (3) 14 
days from 3-5 weeks of age (dark gray circles). Significance (p<0.05) in the mean 
change in mass between heat-treatment durations is denoted as: a, 3-4 weeks and 4-5 
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3.3.2 Bone Length and Tibial Elongation Rate 
 At experimental end, mice treated for 14 days from 3-5 weeks of age had an 
increase in femoral length (paired t=10.1, p<0.001) of 1.1% on the heat-treated side 
(Fig. 12A; Table 5). Humeral length did not differ (paired t=1.0, p=0.34) (Table 5). Mice 
treated for 7 days from 3-4 weeks of age, femoral length (paired t=4.4, p<0.01) 
increased by 1.7% (Fig. 12A, Table 5). Humeral length did not differ (paired t=0.74, 
p=0.50) (Table 5). Multiple comparisons by one-way ANOVA with Tukey post hoc tests 
showed no significant differences in heat-enhanced femoral length between durations of 
treatment (F(1,14)=2.7, ns, p=0.12). 
Mice treated for 14 days had a tibial elongation rate of 110±11μM/day on the 
non-treated side and 121±11μM/day on the heat-treated side with an increase on the 
heat-treated side (paired t=7.8, p<0.001) of nearly 11% (Fig. 12B; Table 5). Mice treated 
for 7 days of treatment had a tibial elongation rate of 157±11μM/day on the non-treated 
side and 169±13μM/day on the heated side with an increase on the heat-treated side 
(paired t=4.6, p<0.01) of nearly 8% (Fig. 12B; Table 5). Multiple comparison analysis by 
one-way ANOVA determined no significant differences in heat-enhanced tibial 




Table 5. Comparison of Non-Treated and Heat-Treated Sides of Saline-Injected 
Experimental Mice Bone Parameters. 
 
Values are mean (standard deviation). Length of heat-treatment is in days (age of mice 
during treatment). Sample size (N) is number of left-right pairs. Significantly larger on 
heat-treated side by one-tailed paired t-test: **p<0.01; ***p<0.001; ns, not significant. 
Significant differences in percent increase between durations of heat-treatment by one-
















Humeral Length (mm) 
7 days 
(3-4 weeks) 
9.27 (0.14) 9.23 (0.20)ns -0.4 6 
14 days 
(3-5 weeks) 
10.14 (0.11) 10.15 (0.13)ns 0.1ns 9 
Femoral Length (mm) 
7 days 
(3-4 weeks) 
10.44 (0.19) 10.62 (0.26)** 1.7 6 
14 days 
(3-5 weeks) 
12.86 (0.18) 13.00 (0.17)*** 1.1ns 9 




156.88 (11.24) 168.94 (12.85)** 7.7 5 
14 days 
(3-5 weeks) 




Figure 12. Extremities are Lengthened on the Heat-Treated Side  
(A) Error bar plots show percent change in heat-treated limb compared to non-treated 
limb. Femoral length increased on the heat-treated side by 1.7% and 1.1% for mice 
treated for 7 days (3-4 weeks of age) and 14 days (3-5 weeks of age) respectively. (B) 
Tibial elongation rate increased on the heat-treated side by 7.7% and 10.8% after 7 
days of heating and 14 days of heating respectively. Mean ± 1 standard error plotted. 
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3.3.3 Growth Plate Morphometry 
 Normalized proliferative zone (PZ) height was reduced by 9.0% on the heat-
treated sides of mice treated for 7 days from 3-4 weeks of age (paired t=10.2, p<0.001), 
and 7.3% on the heat-treated sides of mice treated for 14 days from 3-5 weeks of age 
(paired t=3.5, p<0.05) (Fig. 13A, C; Table 6). The normalized hypertrophic zone (HZ) 
height increased by 8.6% on the heat-treated sides of mice treated for 7 days (paired 
t=9.0, p<0.001) and 8.8% on the heat-treated sides of mice treated for 14 days (paired 
t=4.2, p<0.05) (Fig. 13B, C; Table 6). There were no significant changes in reserve zone 
height (zone of quiescent chondrocytes) at any duration of heat-treatment (paired t=0.0 
and 0.6; p=1.00 and 0.59 respective to as reported above). Multiple comparison 
analysis by one-way ANOVA determined no significant differences in heat-enhanced PZ 
height (F(2,14)=0.84, ns, p=0.46) and HZ height (F(2,14)=0.94, ns, p=0.42) between 







Table 6. Comparison of Growth Plate Morphometry between Non-Treated and 
Heat-Treated Sides of Saline-Injected Experimental Mice. 
 
Values are mean (standard deviation). Length of heat-treatment is in days (age of mice 
during treatment). Sample size (N) is number of left-right pairs. Significantly larger on 
heat-treated side by one-tailed paired t-test: *p< 0.05; **p<0.01; ***p<0.001; ns, non-
significant. Significant differences in percent increase between durations of heat-

















0.104 (0.015) 0.104 (0.011)ns 0.9 5 
14 days 
(3-5 weeks) 
0.118 (0.008) 0.114 (0.015)ns -0.4ns 5 




0.450 (0.023) 0.412 (0.019)** -9.0 5 
14 days 
(3-5 weeks) 
0.466 (0.039) 0.430 (0.027)* -7.3ns 5 




0.448 (0.026) 0.484 (0.025)** 8.6 5 
14 days 
(3-5 weeks) 




Figure 13. When Normalized to Total Proximal Tibial Growth Plate Height, PZ is 
Reduced on the Heat-Treated Side and HZ is Enlarged  
(A) Error bar plot shows percent change in heat-treated limb compared to non-treated 
limb. Normalized proliferative zone (PZ) height is reduced on the heat-treated side by 
9.0% in mice treated for 7 days from 3-4 weeks of age and 7.3% in mice treated for 14 
days from 3-5 weeks of age. (B) Normalized hypertrophic zone (HZ) height is enlarged 
by 8.6% in mice treated for 7 days from 3-4 weeks of age and 8.8% in mice treated for 
14 days from 3-5 weeks of age. (C) Non-treated and heat-treated tibial growth plates 
from the same mouse treated from 3-4 weeks of age, stained with Safranin-O/fast green 
to distinguish cartilage (red) from bone (green/blue). Arrows indicate the different zones 
within the growth plate. The vertical yellow line denotes the PZ while the green line 
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3.3.4 PCNA Expression 
 PCNA expression in chondrocytes of the PZ was increased on the heat-treated 
side of mice treated for both 7 days (3-4 weeks of age) and 14 days (3-5 weeks of age) 
(Fig. 14). Expression of PCNA increased by 8.6% on the heat-treated side of mice 
treated for 7 days from 3-4 weeks of age (paired t=2.7, p<0.05) and 16.7% on the heat-
treated side when mice were treated for 7 days from 3-5 weeks of age (paired t=2.9, 
p<0.05)(Fig. 14A). Multiple comparisons by one-way ANOVA determined no significant 





Figure 14. Expression of PCNA, Marker for Cell Proliferation, Increased with Heat-
Treatment in the PZ of the Proximal Tibial Growth Plate  
(A) Error bar plot shows percent of chondrocytes positive for PCNA expression on non-
treated (open circles) and heat-treated (gray circles) sides. PCNA expression increased 
by 8.6% on the heat-treated sides of mice treated for 7 days from 3-4 weeks of age and 
increased by 16.7% on the heat-treated sides of mice treated for 14 days from 3-5 
weeks of age. (B) Immunoreactivity of PCNA in non-treated and heat-treated proximal 
tibial growth plates from the same mouse treated from 3-4 weeks of age. Positive 
staining, shown by dark brown nuclei, within the PZ of the growth plate (region between 
the double arrows) increases on the heat-treated side by >10%. Mean ± 1 standard 
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3.4 DISCUSSION  
 
The goal of this study was to determine how unilateral heating enhances 
longitudinal bone growth at the cellular level. Femoral length (1.7%) and tibial 
elongation rate (7.7%) increased on the heat-treated sides of mice treated for 7 days 
from 3-4 weeks of age (Fig. 12, Table 5). Chondrocyte proliferation (8.6%) and size of 
the hypertrophic zone (8.6%) also increased in these mice (Fig. 13B, 12; Table 6). After 
14 days of treatment, femoral length (1.1%) and tibial elongation rate (10.8%) increased 
on the heat-treated sides of mice treated 3-5 weeks of age (Fig. 12, Table 5). 
Chondrocyte proliferation (16.7%) and size of the hypertrophic zone (8.8%) also 
increased in these mice (Fig. 13B, 12; Table 6).  
The data supported the hypothesis that there will be a unilateral increase in bone 
length associated with increased chondrocyte proliferation and hypertrophic zone 
expansion in the growth plate with heat-treatment. Humeral length did not differ 
between non-treated and heat-treated sides (Table 5), consistent with previous studies 
from our laboratory. The likely explanation is the similarity of humeral skin temperature 
to body core temperature accounting for a marginal temperature differential during 
treatment (Serrat et al., 2015). Results from Chapter 2 (mice were treated from 3-4 
weeks of age) suggest that one week of unilateral heat-treatment can effectively 
increase bone length (Fig. 8, Table 3). In this study, two separate age groups (3-4 
weeks and 4-5 weeks of age) were chosen for one week of unilateral heat-treatment.  
Mice from 3-4 weeks of age gained more mass after 7 days of treatment than the mice 
treated from 4-5 weeks (Fig. 11). The growth spurt that occurred when mice were 
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treated from 3-4 weeks of age supported the rationale for choosing that age group for 
data analysis.  
Although the impact of temperature on postnatal longitudinal bone growth has 
been documented (Serrat, 2014b), there had been a gap in our understanding of the 
kinetics of the growth plate cartilage with heating. This study demonstrated that 
longitudinal bone growth is accompanied by increased proliferation and hypertrophic 
zone expansion. Increased proliferation may be due to either an increase in 
chondrocyte number (not measured in this study), or rate of proliferation (Kember, 1993; 
Rolian, 2008). Here we measured proliferation as (PCNA) expression within the 
proliferative zone of the growth plate. PCNA immunohistochemistry was chosen over 
other methods for analyzing cell proliferation such as bromodeoxyuridine (BrdU), 
because PCNA is a less invasive technique and both methods have shown similar 
results (Wildemann et al., 2003).  
PCNA expression increased on the heat-treated sides at all durations of heat-
treatment, but trends indicate that proliferation was increased to a larger extent with two 
weeks of treatment (Fig. 14). While PCNA expression was exclusively measured in the 
proliferative zone of the growth plate, there was observed positive staining in the 
hypertrophic zone as well. Other studies have also reported positive staining of PCNA in 
the hypertrophic zone of rabbit growth plates (Enishi et al., 2014) and suggest 
hypertrophic chondrocytes (more commonly described to undergo programmed cell 
death) survive, proliferate and transdifferentiate into bone forming cells (Bahney et al., 
2014; Enishi et al., 2014; Hu et al., 2017; Zhou et al., 2014).  
 
 84 
In addition to hypertrophic zone height, the height of the reserve and proliferative 
zones were also analyzed (Table 6). Reserve zone height was unaffected as expected 
since chondrocytes in this zone are quiescent and do not participate in bone growth. 
Minor differences in total height of the growth plate were seen on heat-treated sides 
(data not shown), which is similar to what was observed in a study comparing control- 
(21°C) and warm-housed (27°C) mice (Serrat, 2014b).  
Interestingly, the height of the proliferative zone decreased on heat-treated sides 
after 7 days (9.0%) and 14 days (7.3%) of unilateral heating (Fig 13A; Table 6). A cause 
for the reduced proliferative zone height after heat-treatment may be explained by the 
mechanical properties of proliferating chondrocytes. Periods of rapid bone growth are 
often accompanied by increased matrix synthesis exerting pressure on the 
chondrocytes causing them to flatten (Prein et al., 2016; Walker & Kember, 1972). 
Compressed columns of chondrocytes may also be a consequence of the expanding 
hypertrophic zone. Therefore, a shortened proliferative zone height does not necessarily 
reflect decreased proliferation, but a more compressed region of cells. However, to 
show the cells are compressed would involve comparing numbers of chondrocytes in 
the proliferative zone between growth plates of non-treated and heat-treated limbs (not 
done in this study). Another possibility for a shortened proliferative zone height may be 
due to heat-induced changes to Indian hedgehog (Ihh)/parathyroid hormone-related 
protein (PTHrP) negative feedback mechanisms that control the transition from 
proliferative, to hypertrophic chondrocytes. Downregulation of Ihh/PTHrP (maintains 
chondrocyte proliferation, and delays chondrocyte hypertrophy) would promote cell 
differentiation and leads to faster turnover to hypertrophic chondrocytes (van der 
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Eerden et al., 2003; Kronenberg, 2003; Wang et al., 2011). As an example, IGF1 has an 
important role in downregulating PTHrP to promote chondrocyte differentiation (Wang et 
al., 2011).  
Limitations of this study include the sample size for heat-treatment. While power 
analysis indicates 6 animals to be a sufficient effect size, it can be difficult to attain this 
number because of the laborious nature of the experiments. Our studies focus on left-
right differences after unilateral heat-treatment, and thus consistent collection of 
samples from both sides of the animal is necessary. If one side is damaged during 
dissection, sample preparation, tissue processing, sectioning or staining, the entire left-
right pair is lost. Left-right comparisons also limit the ability to collect the same samples 
for a variety of analyses. For example, since both left and right femora are needed to 
make left-right length comparisons, they cannot also be used for histological analysis. 
The rationale for selecting the proximal tibia for growth rate and histological analysis is 
because the proximal tibia contributes most to tibial lengthening compared to the distal 
end (as discussed in Chapter 1, Section 1.1.2) (J. Bisgard & M. Bisgard, 1935; Farnum, 
2007; Kember, 1972; Pritchett, 1992; Raimann et al., 2017; Rolian, 2008; Serrat et al., 
2007; Wilsman et al., 1996a, 1996b, 2008). The growth plate of the proximal tibia also 
has been shown to have a higher rate of cell division and hypertrophy compared to sites 
of other long bones including that of the distal femur (Rolian, 2008).  
 
3.5 CONCLUSION 
In conclusion, evidence supports the hypothesis that there will be a unilateral 
increase in bone length associated with increased chondrocyte proliferation and 
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hypertrophic zone expansion in the growth plate with heat-treatment. The hypothesis 
was supported by results from mice treated for 7 days (3-4 weeks of age) and 14 days 
(3-5 weeks of age). This study demonstrated that investigating morphological changes 
in the growth plate is a means to assess heat-enhanced bone elongation.  Future 
studies will determine how targeted limb heating affects the activity of insulin-like growth 
factor I (IGF1), the major growth factor that regulates longitudinal bone growth. 
Improving and understanding the methods for using targeted limb heating to enhance 
bone elongation is important for developing a noninvasive alternative for treatment of 





CHAPTER IV: SUBCUTANEOUS INJECTIONS OF LOW DOSE IGF1 IN 
CONJUNCTION WITH TARGETED LIMB HEATING CAN AUGMENT HEAT-
ENHANCED BONE GROWTH 
 
4.1 INTRODUCTION 
The GH/IGF1 axis has been extensively studied and is often described as the 
major control system of postnatal growth and development (Le Roith et al., 2001; 
Woodall, Breier, O’Sullivan, & Gluckman, 1991) particularly of skeletal growth (Isgaard, 
Nilsson, Lindahl, Jansson, & Isaksson, 1986; Hunziker et al., 1994a; Lindsey & Mohan, 
2016; Lupu et al., 2001; Mohan et al., 2003; Oberbauer & Peng, 1995; Yakar & 
Isaksson, 2016; Wu et al., 2015). This anabolic axis involves the dependent and 
independent relationship between GH and IGF1 and their associated factors in 
regulating linear growth in both an endocrine and paracrine/autocrine manner. Severe 
growth retardation observed in double Ghr/Igf1 mutant mice supports that both GH and 
IGF1 are essential for linear growth (Lupu et al., 2001). However, IGF1 is a critical part 
of this axis because there is greater linear growth defects without the action of IGF1 
(Baker et al., 1993; Bikle et al., 2001; Liu et al., 1993; Mohan et al., 2003; Powell-
Braxton et al., 1993; Wang et al., 2006) compared to when GH action is impaired 
(Kasukawa, Baylink, Guo, & Mohan, 2003; Mohan et al., 2003). It has been reported 
that 83% of postnatal growth is dependent on the GH/IGF1 system and 69% of that 
dependent on IGF1 (Ciarmatori, Kiepe, Haarmann, Huegel, & Tönshoff, 2007). While 
studies have shown that postnatal growth can occur absent circulating levels of IGF1 
(Fan et al., 2009; Sjögren et al., 1999; Ueki et al., 2000; Yakar et al., 1999, 2002; Yakar 
& Isaksson, 2016), disruptions in local IGF1 impair longitudinal bone growth  (Govoni et 
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al., 2007a,b; Sheng, Zhou, Bonewald, Baylink, & Lau, 2013; Wang et al., 2011; Yakar, 
Courthland, & Clemmons, 2010; Yakar & Isaksson, 2016).  
Administration of GH and IGF1 has been used for treatment of stunted linear 
growth. GH therapy is more commonly used in clinical settings to treat short stature 
(Ohlsson et al., 1998; Pfäffle, 2015; Wit & Oostdijk, 2015) such as those resulting from 
GH deficiency or other chromosomal and genetic syndromes (Harada et al., 2017; Moix 
et al., 2018; Noonan & Kappelgaard, 2015; Pfäffle, 2015; Ranke, 1995a, Tritos & 
Klibanski, 2016; Wit & Oostdijk, 2015). IGF1 is not as commonly used because of the 
adverse effects associated with increased serum IGF1 (such as hypoglycemia) during 
treatment (Clemmons, 2004; Guevara-Aguirre et al., 1997; Laron & Klinger, 2000; 
Lindsey & Mohan, 2016; Ross et al., 2015). However, long-term treatment with IGF1 
has been shown to effectively reverse skeletal growth discrepancies (Azcona et al., 
1999; Backeljauw et al., 2013; Chernausek et al., 2007; Laron & Klinger, 2000; Laron, 
2001; Laron & Kauli, 2015b; Lupu et al., 2001; Midyett et al., 2010; Ranke et al., 1995b, 
1999; Sims et al., 2000).  
It is clear that IGF1 has an essential role in longitudinal growth. Without the 
action of IGF1, if survived past birth, there is a reported 70% reduction in body size and 
40% reduction in linear bone growth (Liu et al., 1993; Mohan et al., 2003; Powell-
Braxton et al., 1993; J. Wang et al., 1999; Y. Wang et al., 2006; Yakar & Isaksson, 
2016). Studies have used IGF1 to enhance linear growth in various animal models. It 
has been shown that IGF1 administered through local administration directly into the 
growth plate has significantly increased bone length (Isgaard et al., 1986). Since 
targeted heat can increase vascular supply to the growth plate (Chapter 1, Section 
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1.6.2), the goal of this study was to use unilateral limb heating as a method to target a 
low dose of IGF1 administered subcutaneously once daily to the growth plate on the 
heat-treated side. This study tests the hypothesis that IGF1 administration with 
heat-treatment will further enhance limb length than with heat alone. Published 
studies are still ongoing to optimize IGF1 therapy in children without complications 
(Hansen-Pupp et al., 2017). Using limb heating to target once daily, low doses of IGF1 
only to sites of longitudinal bone growth would improve current IGF-based therapies for 
children by enhancing limb elongation without the negative side effects.   
 
4.2 MATERIAL AND METHODS 
4.2.1 Animals and Experimental Design 
 All procedures were approved by the Institutional Animal Care and Use 
Committee of Marshall University (Protocol 558). Female C57BL/6 (N=32) mice were 
obtained from Hilltop Lab Animals, Inc. (Scottdale, PA, USA) at 21 (N=12) and 28 
(N=24) days weaning age. Mice were singly housed at 21°C in standard plastic caging, 
exposed to a 12 hour light/dark cycle and provided with food and water ad libitum. 
 As described in the previous chapters and as indicated by the unilateral heating 
methods schematic (Fig. 15), mice were subjected to same procedural conditions. Mice 
were treated for 7 days from 3-4 weeks of age and for 14 days 3-5 weeks of age. Mice 
were weighed each day and given subcutaneous injections of IGF1 (2.5mg/kg; 
Peptrotech). IGF1 injections were administered daily at the start of the light cycle one 
hour prior to heat-treatment for 7 days (N=6) and 14 days (N=12). IGF1 has been 
administered subcutaneously anywhere from once daily, to continuously, in other animal 
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studies at a dosage range of 2-6 mg/kg (Ding, List, Bower, & Kopchick, 2011; Lynch, 
Cuffe, Plant, & Gregorevic, 2001; Sims et al., 2000; Woodall et al., 1991). Therefore, the 
selected dose of 2.5 mg/kg administered once daily is considered low in comparison. 
While IGF1-injected twice a day may be more effective at promoting overall growth, this 
study aimed to target a small dose of IGF1 unilaterally using warm temperature without 
subsequent systemic effects. The timing of injections was also deliberate because peak 
IGF1 in circulation is approximately one hour after subcutaneous injections (Woodall et 
al., 1991) and study intended to time the peak of IGF1 with heat-treatment. Left-right 
comparisons in IGF1-injected mice were made to the saline-injected control mice 
treated for 7 days from 3-4 weeks of age (N=6) and 14 days from 3-5 weeks of age 






Figure 15. Unilateral Heating Schematic  
Mice were injected subcutaneously (SQ) with IGF1 (2.5mg/kg) one hour prior to 
treatment of 40°C unilateral heat for 40 minutes daily for 7 days from 3-4 weeks of age 
or 14 days from 3-5 weeks of age. Euthanasia and tissue collection occurred 1 day after 
the last day of heat-treatment. Mouse illustration based on “mouse clip art black and 
white” from clipartstockphotos.com. 
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4.2.2 Tissue Collection and Sample Analysis 
 Long bones (femora and humeri) were collected and measured as described in 
Chapter 3 (Sections 3.2.2 and 3.2.3). Proximal tibial halves from each hindlimb were 
collected (Section 3.2.2) for tibial elongation rate analysis (Section 3.2.3) and growth 
plate morphometry (Sections 3.2.4) following methods described in Chapter 3.  
 
4.2.3 Immunohistochemistry 
 Serial sections of proximal tibiae from mice subjected to 7 days (N=12, 6 per 
saline control and IGF1) and 14 days (N=12, 6 per saline control and IGF1) of unilateral 
heating were stained using rabbit polyclonal antibodies against PCNA following 
methods as described in Chapter 3 (Section 3.2.5). Rabbit polyclonal antibodies against 
IGF1R and phospho-IGF1R (phospho-Y1161) were also used to assess IGF1 activity in 
the PZ of growth plates following the same methods. Analysis focused on the 
proliferative zone (PZ) specifically as the site of actively proliferating chondrocytes to 
determine the heat-enhanced effect in conjunction with IGF1 administration.  
 
4.2.4 Statistical Analysis and Sample Size 
 Statistical analyses were performed using SPSS 25.0 software (IBM 
Corporation, Armonk, NY) with p<0.05 as accepted significance. Non-treated and heat-
treated side comparisons for humeral length, femoral length, tibial elongation rate, 
growth plate zone heights, and percent cells positive for protein expression were made 
using one-tailed paired t-tests. Multiple comparisons made between saline controls and 
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IGF1-injected mice were made using a one-way ANOVA. Data were reported as mean 
± standard deviation (SD) in tabular format and as mean ± standard error (SE) in 
graphical format.  
Sample sizes for measurements that are documented as less than the size of the 
experimental sample set was a result of either sample loss during dissection or sample 
processing. Since left-right comparisons are made, if one side is damaged during 
dissection, sample preparation, tissue processing, sectioning or staining, the entire left-
right pair is lost. Samples and missing cases were excluded from statistical analysis on 
an analysis-by-analysis basis. 
 
4.3 RESULTS 
4.3.1 Unilateral Heating Parameters 
 IGF1-injected mice treated for 7 days from 3-4 weeks of age gained 5.1±0.5g 
while saline control mice (established in Chapter 3) gained 4.7±0.7g (Fig. 16A). IGF1-
injected mice treated for 14 days from 3-5 weeks of age gained 6.4±0.8g while saline 
control mice (also established in Chapter 3) gained 6.0±0.9g (Fig. 16B). There was no 
significant difference in the amount of mass gained between saline and IGF1-injected 
mice after 7 days (F(1,11)=1.4, ns, p=0.27) or 14 days (F(1,23)=0.9, ns, p=0.35) of limb 
heating. The core temperature averaged 36°C during all extents of unilateral heating. 
During the duration mice were anesthetized, the average surface temperature of non-
treated hindlimbs was 30°C and the heat-treated hindlimbs were 40°C, consistent with 
parameters during the daily limb heating reported in previous chapters. At the end of 
each daily heat-treatment (40mins), the average time for saline control mice to recover 
 
 94 
from anesthesia after 7 days and 14 days of heating was 1.6±0.33mins and 
1.5±0.37mins respectively. The average time for IGF1-injected mice to recover from 
anesthesia was 3.3±0.79mins and 3.0±0.80mins, which was significantly longer than the 
saline controls after both 7 days (F(1,11)=22.35, p<0.001) and 14 days (F(1,23)=31.5, 





Figure 16. Overall Change in Mass was not Impacted by IGF1 Injections at Either 
Length of Heat-Treatment 
(A) Scatter plots show the change in mass of individual mice after 7 days of heat-
treatment from 3-4 weeks of age. Saline control mice (open circles) gained an average 
of 4.7g and IGF1-injected mice (gray circles) gained an average of 5.1g. (B) Scatter 
plots show the change in mass of individual mice after 14 days of heat-treatment from 
3-5 weeks of age. Saline control mice gained 6.0g and IGF1-injected mice gained 6.4g. 
Significance (p<0.05) is the mean change in mass between injections. One-way ANOVA 
indicated no significant difference in overall gain in mass between saline control and 
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4.3.2 Length of Long Bones and Tibial Elongation Rate 
 Femoral length of IGF1-injected mice treated for 7 days increased on the heat-
treated sides by 1.7% (paired t=3.8, p<0.05) (Fig. 17A(a), Table 7). Femoral length of 
IGF1-injected mice treated for 14 days increased by 1.9% (paired t=7.6, p<0.001) on 
the heat-treated sides (Fig. 17B(a); Table 7). Compared to saline controls (Chapter 3; 
Fig. 12A, Table 5), the heat-induced increase in femoral length of IGF1-injected mice 
(1.7%) treated for 7 days was equivalent to that of the controls. However, femoral length 
of IGF1-injected mice (1.9%) treated for 14 days was significantly greater (F(1,20)=6.3, 
p<0.05) than that of the saline controls (1.1%) as determined by one-way ANOVA.  
Humeral length did not differ between non-treated and heat-treated sides in 
saline control mice as shown in Chapter 3 (Table 5). Humeral length of IGF1-injected 
mice treated for 7 days also did not differ (paired t=1.4, ns, p=0.23). However, there was 
a slight 0.7% increase in humeral length on the heat-treated side of IGF1-injected mice 
treated for 14 days (paired t=3.6, p<0.05), which was significantly greater (F(1,20)=6.5, 
p<0.05) than saline mice as determined by one-way ANOVA. 
Tibial elongation rate of IGF1-injected mice treated for 7 days increased on the 
heat-treated side by 7.3% (paired t=2.9, p<0.05) (Fig. 17A(b), Table 7). Tibial elongation 
rate of IGF1-injected mice treated for 14 days increased by 18.7% (paired t=7.2, 
p<0.001) on the heat-treated side (Fig. 17B(b), Table 7). Compared to saline controls 
(Chapter 3; Fig. 12B, Table 5), the heat-induced increase in tibial elongation rate of 
IGF1-injected mice (7.3%) treated for 7 days was not greater than the controls (7.7%) 
as determined by one-way ANOVA (F(1,9)=0.02, ns, p=0.89). However, tibial elongation 
rate of IGF1-injected mice (18.7%) treated for 14 days was significantly greater 
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(F(1,18)=5.3, p<0.05) than that of the saline controls (10.8%) as determined by one-way 
ANOVA. Together, left-right comparisons of femoral and humeral length, as well as 
tibial elongation rate, indicate that injections of low dose IGF1 further enhances heat 




Table 7. Comparison of Non-Treated and Heat-Treated Sides of IGF1-Injected 
Experimental Mice Bone Parameters.  
 
Values are mean (standard deviation). Sample size (N) is number of left-right pairs. 













Humeral Length (mm) 
7 days 
(3-4 weeks) 
9.31 (0.23) 9.27 (0.19)ns -0.4 6 
14 days 
(3-5 weeks) 
10.29 (0.15) 10.36 (0.16)*** 0.7 12 
Femoral Length (mm) 
7 days 
(3-4 weeks) 
10.51 (0.20) 10.68 (0.28)* 1.7 6 
14 days 
(3-5 weeks) 
12.86 (0.18) 13.10 (0.22)*** 1.9 12 




157.51 (6.16) 168.85 (8.93)* 7.3 5 
14 days 
(3-5 weeks) 





Figure 17. Extremities are Lengthened on the Heat-Treated Sides when Injected 
with Saline and IGF1 
(A) Error bar plots compare saline- and IGF1-injected mice treated for 7 days (3-4 
weeks of age) and shows percent change in heat-treated limb compared to non-treated 
limb. (a) Femoral length increased by 1.7% on the heat-treated sides of both saline and 
IGF1-injected mice (b) Tibial elongation rate increased by 7.7% and 7.3% on the heat-
treated sides of saline and IGF1-injected mice. (B) Error bar plots compare saline- and 
IGF1-injected mice treated for 14 days (3-5 weeks of age). (a) Femoral length increased 
by 1.1% and 1.9% on the heat-treated side of saline and IGF1-injected mice. (b) Tibial 
elongation rate increased by 10.8% and 18.7% on the heat-treated side of saline and 
IGF1-injected mice. Mean ± 1 standard error plotted. *p< 0.05; **p<0.01; ***p<0.001, 
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4.3.3 Growth Plate Morphometry 
 The height of the PZ normalized to total growth plate height was significantly 
reduced by 9.0% on the heat-treated sides of saline control mice (Chapter 3; Fig. 13A, 
C; Table 6) and by 5.9% on the heat-treated sides of IGF1-injected mice (paired t=2.6, 
ns, p=0.059) treated for 7 days (Fig. 18A(a), Table 8). The height of the PZ was reduced 
by 7.3% on the heat-treated sides of saline mice (Chapter 3; Fig. 13A, C; Table 6) and 
by 7.8% on heat-treated sides of IGF1-injected mice (paired t=3.7, p<0.05) treated for 
14 days (Fig. 18B(a), Table 8).  
The height of the hypertrophic zone (HZ) normalized to the total growth plate 
height was significantly enlarged by 8.6% on the heat-treated sides of saline control 
mice (Chapter 3; Fig. 13B, C; Table 6) and by 5.3% on the heat-treated sides of IGF1-
injected mice (paired t=5.1, p<0.01) treated for 7 days (Fig. 18A(b), Table 8). The 
expansion in the HZ height observed in IGF1-injected mice (5.3%) was significantly less 
than that of the controls (8.6%) as determined by one-way ANOVA (F(1,9)=7.8, p<0.05). 
The height of the HZ expanded by 8.8% on the heat-treated sides of saline mice 
(Chapter 3; Fig. 13B, C; Table 6) and by 9.4% of IGF1-injected mice (paired t=4.4, 
p<0.05) treated for 14 days (Fig. 18B(b), Table 8). Overall, PZ and HZ height was 
comparable between saline and IGF1-injected mice. However, the left-right differences 





Table 8. Comparison of Growth Plate Morphometry Between Non-Treated and 
Heat-Treated Sides of IGF1-Injected Experimental Mice. 
 
Values are mean (standard deviation). Sample size (N) is number of left-right pairs. 
Significantly larger on heat-treated side by one-tailed paired t-test: *p< 0.05; **p<0.01; 
***p<0.001; ns, non-significant. 
 













0.104 (0.019) 0.106 (0.011)ns 5.7 5 
14 days 
(3-5 weeks) 
0.138 (0.011) 0.134 (0.011)ns -1.0 5 




0.450 (0.029) 0.422 (0.028)ns -5.9 5 
14 days 
(3-5 weeks) 
0.460 (0.010) 0.426 (0.023)* -7.8 5 





0.448 (0.023) 0.474 (0.031)** 5.3 5 
14 days 
(3-5 weeks) 




Figure 18. Proximal Tibial Growth Plate Morphometry After Administration of Low 
Dose IGF1 with Targeted Heating  
(A) Error bar plots compare growth plate (GP) morphometry of mice treated for 7 days 
and shows percent change in heat-treated limb compared to non-treated limb. (a) 
Proliferative zone (PZ) height decreased by 9.0% and 5.9% on heat-treated sides of 
saline control and IGF1-injected mice respectively. (b) Hypertrophic zone (HZ) height 
increased by 8.6% and 5.3% in saline and IGF1-injected mice. (B) Error bar plots 
compare GP morphometry of mice after 14 days of treatment. (a) PZ height decreased 
by 7.3% and 7.8% in saline and IGF1-injected mice (b) HZ height increased by 8.8% 
and 9.4% in saline and IGF1-injected mice. Mean ± 1 standard error plotted. *p< 0.05; 
**p<0.01; ***p<0.001, significance in left-right comparisons; #p<0.05 comparing % 
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4.3.4 PCNA Expression 
In saline control mice treated for 7 days, the percent of chondrocytes positive for 
PCNA in the PZ was 85.1± 6.9% on the non-treated sides, and 91.9±2.0% on the heat-
treated sides for an 8.6% increase in expression (Chapter 3; Fig. 14). Chondrocytes in 
the PZ of IGF1-injected mice were positive for a lesser 79.3±4.6% on non-treated sides 
and 83.3±4.4% on the heat-treated sides for a 5.0% increase in PCNA expression 
(paired t=3.5, p<0.05) on the heat-treated side (Fig. 19A). In saline mice treated for 14 
days, chondrocytes were positive for PCNA in 77.6±11.5% and 89.3±4.5% on the non-
treated and heat-treated sides respectively for an increase of 16.7% (Chapter 3; Fig. 
14). Chondrocytes in the PZ of IGF1-injected mice were positive for 84.9±4.5% and 
93.2±3.9% PCNA on the non-treated and heat-treated sides respectively for an increase 
of 9.9% (paired t=5.1, p<0.01) on the heat-treated side (Fig. 19B). There were no 
significant differences in the heat-induced increase in PCNA expression between saline 
and IGF1-injected mice treated for 7 day days (F(1,10)=0.7, ns, p=0.43) and 14 days 








Figure 19. Expression of PCNA in the PZ of Proximal Tibial Growth Plates After 
Administration of Low Dose IGF1 with Targeted Heating  
(A) PCNA expression in mice treated for 7 days (a) Error bar plots show percent of 
chondrocytes positive for PCNA expression on non-treated (open circles) and heat-
treated (gray circles) sides. PCNA expression increased by 8.6% and 5.0% on the heat-
treated sides of saline and IGF1-injected mice respectively. (b) Left-right comparison of 
proximal tibial growth plates from an IGF1-injected mouse immunostained for PCNA. A 
larger quantity of PCNA staining was counted on heat-treated sides. Positive staining is 
shown by dark brown nuclei within the PZ of the growth plate (region between the 
double arrows). (B) PCNA expression in mice treated for 14 days (a) Error bar plot 
shows a 16.7% and 9.9% increase in saline and IGF1-injected mice. (b) Left-right 
comparison of proximal tibial growth plate from an IGF1-injected mouse immunostained 











































































































































































4.3.5 IGF1R and pIGF1R Expression in Proliferating Chondrocytes 
IGF1R expression in the PZ of mice treated for 7 days increased by 14.5% 
(paired t=3.2, p<0.05) and 7.7% (paired t=2.39, ns, p=0.076) on the heat-treated sides 
of saline control and IGF1-injected mice respectively (Fig. 20A(a), Table 9). This 
increase of IGF1R expression on the heat-treated sides of IGF1-injected mice was 2-
fold less compared to the saline mice (F(2,15)=26.6, p<0.001). Activation of the IGF1R, 
assessed by pIGF1R expression in the PZ, increased by 7.7% (paired t=5.3, p<0.01) 
and 28.2% (paired t=3.5, p<0.05) on the heat-treated sides of saline and IGF1-injected 
mice respectively (Fig. 20A(b), Table 9). This increase of pIGF1R expression on the 
heat-treated sides of IGF1-injected mice was over 3-fold more compared to the saline 
(F(2,15)=16.8, p<0.001). Therefore, even though IGF1-injected mice had less of a heat-
induced increase in IGF1R expression, there was a greater increase in activation of 
these receptors compared to saline controls.  
IGF1R expression in the PZ of mice treated for 14 days increased by 37.6% 
(paired t=6.1, p<0.01) and 30.8% (paired t=3.5, p<0.05) on the heat-treated side of 
saline and IGF1-injected mice respectively (Fig. 20B(a), Table 9). Differences were 
comparable between saline and IGF1-injected mice (F(1,7)=0.16, ns, p=0.70). 
Expression of pIGF1R increased by 23.9% (paired t=5.2, p<0.01) and 25.4% (paired t= 
6.3, p<0.01) on the heat-treated sides of saline and IGF1-injected mice respectively 
(Fig. 20B(b), Table 9). Differences were comparable between the injection groups 




Table 9. Comparison of Non-Treated and Heat-Treated Expression of Markers for 
IGF1 Activation in Proliferative Zone of Tibial Growth Plates in Saline and IGF1-
Injected Mice. 
 
Values are mean (standard deviation). Sample size (N) is number of left-right pairs. 
Significantly larger on heat-treated side by one-tailed paired t-test: *p< 0.05; **p<0.01; 
ns, non-significant. Significant differences in percent increase between saline controls 
and IGF1-injected mice by one-way ANOVA: #p<0.05; ns, non-significant. 
 
Length of  
Heat-Treatment 












Saline 69.68 (6.36) 79.52 (7.61)* 14.5 5 
IGF1 72.10 (11.87) 75.70 (11.63)ns 7.7# 5 
pIGF1R expression 
Saline 84.85 (10.36) 90.97 (7.90)** 7.7 6 




Saline 37.98 (11.24) 51.03 (11.44)** 37.6 4 
IGF1 47.40 (22.22) 57.93 (17.43)* 30.8ns 4 
pIGF1R expression 
Saline 59.28 (9.40) 72.48 (4.84)* 23.9 4 




Figure 20. Heat-Induced Effect on IGF1 Activity in the PZ of the Tibial Growth 
Plate with IGF1 Administration  
(A) Expression in saline control and IGF1-injected mice with 7 days of unilateral heating. 
(a) Error bar plot shows percent change in heat-treated limb compared to non-treated 
limb. IGF1R expression increased by 14.5% and 7.7% in the PZ on the heat-treated 
side of saline and IGF1-injected mice. (b) pIGF1R expression in the PZ increased by 
7.7% and 28.2% of saline and IGF1-injected mice. (B) Expression in saline and IGF1-
injected mice with 14 days of heating. (a) IGF1R expression in the PZ increased by 
37.6% and 30.5% in saline and IGF1-injected mice. (b) pIGF1R expression in the PZ 
increased by 23.9% and 25.4% in saline and IGF1-injected mice. Mean ± 1 standard 
error plotted. *p< 0.05; **p<0.01; ns, significance in left-right comparisons; #p<0.05 









































































































































































Previous chapters have established that in a group of saline control mice, 
targeted limb heating can enhance longitudinal growth on the heat-treated sides after 
both 7 days (shown in Chapters 2 and 3) and 14 days of heating (Chapter 3). Heat-
enhanced limb elongation was shown with unilateral increases in femoral length, tibial 
elongation rate, chondrocyte proliferation and hypertrophic expansion in proximal tibial 
growth plates. The goal of this study was to determine if targeted limb heating in 
conjunction with the administration of a low dose of the growth-promoting drug IGF1 
would further enhance bone elongation without impacting overall physiology. Results of 
the current study show that there was an additional heat-enhanced increase in femoral 
length and tibial elongation rate in IGF1-injected mice. There was also a greater rate of 
proliferation and hypertrophic zone expansion on heat-treated sides compared to saline 
controls. Data supported the hypothesis that IGF1 administration with heat-treatment 
will further enhance limb length than with heat alone.  
Both saline and IGF1-injected mice had similar recorded core temperatures and 
surface limb temperatures. While mice have been shown to demonstrate weight gain 
with increased serum levels of IGF1 (D’Ercole,1993; Mathews et al., 1988; Woodall et 
al., 1991; Yakar & Isaksson, 2016), overall gain in mass did not differ between saline 
and IGF1-injected mice (Fig. 16). Livers collected and weighed from both saline and 
IGF1-injected mice (data not shown) also were comparable between saline and IGF1-
injected mice treated for 7 days (p=0.49) and 14 days (p=0.68). Similar liver mass 
between saline and IGF1-injected mice was not unexpected, as the stimulatory effect of 
GH on the liver has been shown to be independent of IGF1 (Blutke et al., 2014). 
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Comparable weights between treatment groups further supported the rationale to use a 
low dose of IGF1.  
An interesting observation during the unilateral heating regimen was the 
differential anesthesia recovery time between the saline controls and IGF1 mice. The 
mice injected with IGF1 took on average twice as long to wake up from the anesthesia 
than the saline controls which was observed throughout the duration of both the 7 days 
and 14 days of heating. Anesthesia recovery is a concern for patients with pituitary 
disease (Menon, Murphy, & Lindley, 2011) including those with acromegaly (excess 
GH, normal to high IGF1). Acromegaly presents a variety of challenges for general 
anesthesia including prolonged awakening associated with obstructed airways (Chung 
& Mokhlesi, 2014) common in these patients (Menon et al., 2011). While recovery time 
with IGF1 has not been previously reported in the literature, other drugs including 
caffeine (Fong et al., 2017; Wang, Fong, Mason, Fox, & Xie, 2014) have been shown to 
accelerate recovery from anesthesia by facilitating neurotransmitter release. Since IGF1 
has been shown to cross the blood-brain barrier (Pan & Kastin, 2000; Yan et al., 2011), 
it is likely prolonged anesthesia recovery as an outcome of IGF1 administration could be 
explained by IGF1 regulation in the brain. Since other tissues, including the brain, were 
not examined in this study the cause of extended recover time with IGF1 remains 
unknown. However, this finding aided to support if IGF1 administration was successful 
throughout the duration of heat-treatment.  
While not intended to be an indicator of effective IGF1 treatment, comparing 
wake up times was a useful method throughout experimentation. These observations 
were not supported by other means of confirming successful IGF1 administration, such 
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as measuring levels of IGF1 or glucose in the blood following injections. Assays for 
serum IGF1 require a considerable volume of blood that could not be collected daily 
since mice are very small in size and to collect a sufficient volume of blood would 
require animal sacrifice. A smaller volume of blood is needed to measure serum 
glucose and lower levels of glucose would be indicative of increased serum IGF1 
(Clemmons, 2004). However, to obtain even a small amount of blood from experimental 
mice would cause a degree of stress to the animals, potentially interfering with the 
results of heat-treatment. Since low levels of glucose, or hypoglycemia, is associated 
with increased levels of IGF1, mice were monitored during the first couple days of 
treatment. While uncommon, there were cases when mice required glucose injections 
(15% glucose solution, 0.01mL per gram body weight) when demonstrating adverse 
signs of IGF1 administration following heat-treatment (nonappearance of anesthesia 
recovery and labored breathing). Hypoglycemia was another physiological response 
indicative to increased levels of IGF1. 
Outcome variables showed that with 7 days of unilateral heating, there was 
almost a 2% increase in femoral length in both saline control and IGF1-injected mice 
(Fig. 17A(a), Table 7). After 14 days of heating, femoral length increased by just over 
1% on the heat-treated sides of saline controls but femora were almost 2% longer on 
the heat-treated sides of IGF1-injected mice (Fig. 17B(a), Table 7). Tibial elongation 
rate after 7 days of heating was also comparable between saline control and IGF1 mice 
with a heat-induced increase of over 7% (Fig. 17A(b), Table 7). After 14 days of heating 
the increase in tibial elongation rate on the heat-treated side was almost 19% with IGF1 
administration, 2.5-fold greater than the over 7% increase observed in saline controls 
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(Fig. 17B(b), Table 7). While both femoral length and tibial elongation rate significantly 
increased with targeted limb heating, further enhancement with IGF1 was only apparent 
with 14 days of heating.  
In Chapter 3, longitudinal growth was assessed on the cellular level by amount of 
proliferation and hypertrophy in proximal tibial growth plates. Increased femoral length 
and tibial elongation rate were accompanied by increased PCNA expression in 
proliferating chondrocytes and expanded heights of the hypertrophic zone. In this study, 
when mice were administered IGF1, there was a significant 5.0% and 9.9% increase in 
PCNA expression on the heat-treated sides after 7 days and 14 days of heating 
respectively (Fig. 19). These increased levels of expression were not significantly 
greater than that of saline controls. However, trends in overall PCNA expression 
suggest an increased rate in proliferation when IGF1-injected mice were treated for 14 
days. Longitudinal bone growth gradually slows with age and can be associated with a 
decline in proliferation and hypertrophic zone height (Forcinito et al., 2011; Lui et al., 
2011; Nilsson & Baron, 2004; Nilsson et al. 2014; Walker & Kember, 1972). While 
comparisons were not made between treatment durations in this study, marginal 
differences can be seen. Overall PCNA expression in the PZ decreased in saline mice 
treated for 14 days from 3-5 weeks of age (older) compared to expression in mice 
treated for 7 days from 3-4 weeks of age (younger) (Fig. 19). However, overall PCNA 
expression increased in IGF1-injected mice treated for 14 days compared to 7 days 
which indicates that although the left-right comparisons in PCNA expression levels were 
similar between saline and IGF1-injected mice at both durations, there was a higher rate 
of proliferation when IGF1-injected mice were treated for 14 days. However, since 
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observations are made from trends in overall PCNA expression (not between non-
treated and heat-treated sides), further analysis is required to determine if the increased 
rates in proliferation in IGF1-injected mice are results of targeted limb heating.  
Hypertrophic zone expansion was significantly increased by 5% and 9% on the 
heat-treated sides of IGF1-injected mice after 7 days and 14 days of unilateral heat-
treatment respectively (Fig. 18A(b), B(b); Table 8). Again, while there was still a heat-
induced increase in expansion, the increase was not beyond that of saline controls. The 
increase in hypertrophic height in IGF1-injected mice was a significant 3% less than the 
saline mice after 7 days of heating, and comparable after 14 days of heating. Similar to 
the trends observed when comparing heat-treatment duration of expression of PCNA, 
IGF1-injected mice after 14 days of treatment displayed a greater difference in height of 
the hypertrophic zone compared to those treated for 7 days (Fig. 18).  
Multiple explanations are possible to rationalize why extremity lengthening is 
similar between saline control and IGF1-injected mice with 7 days of heating, yet IGF1 
further increases lengthening with 14 of heating. All possibilities require further 
investigation before determining the contributing factor(s). In normal physiological 
conditions, IGF1 levels decline after birth then increase during the early rapid stages of 
postnatal growth (Daughaday, Parker, Borowsky, Trivedi, & Kapadia, 1982; Gluckman & 
Butler, 1983; Hansen-Pupp et al., 2011), eventually dropping throughout childhood until 
adolescence. If levels of IGF1 are elevated during the rapid 3-4 week period of growth, 
than additional IGF1 in the system may not further heat-enhanced growth.  
IGF-binding proteins (IGFBPs) regulate the bioavailability of IGF1 in the serum. 
Studies have shown that mouse models created to lower IGF1s affinity for IGFBPs have 
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increased bioavailability of IGF1 to tissues resulting in increased body length (Elis et al., 
2011). If the low dose of injected IGF1 is bound to IGFBPs, there may not be a enough 
IGF1 available to the growth plates of long bones to further enhance limb elongation 
with heat-treatment. In addition, temperature has been shown to weaken the affinity of 
IGF1 binding to ALS in its ternary complex (ALS-IGF1-IGFBP3) accounting for 
increased free IGF1 in the circulation (Holman & Baxter, 1996). A longer duration of 
heat-treatment may be necessary to increase IGF1 bioavailability. Using a similar 
mouse model allowing us to investigate the effects of IGF1 independent of IGFBPs 
would be effective to determining if the binding proteins are the limiting factor.  
Past studies have also shown that the genetic background of the mouse model 
may contribute to variation in skeletal growth observed with increased serum IGF1 
(Yakar & Isaksson, 2016). It is possible that increased serum IGF1 has minimal effects 
on enhancing linear growth in C57BL/6 mice from 3-4 weeks of age as another possible 
explanation of the similarity observed between saline control and IGF1-injected mice 
with 7 days of heating. An extensive study would need to be conducted to quantify 
linear growth with increased serum IGF1 in various mouse models.   
IGF1 activity was assessed by measuring expression of IGF1R and pIGF1R in 
the growth plate. IGF1R expression in the PZ on heat-treated sides of IGF1-injected 
mice treated for 7 days (7.7%) was not significant and was significantly less than the 
heat-induced increase in IGF1R expression in saline mice (14.5%). As rationalized 
above, if IGF1 serum levels are further elevated from 3-4 weeks of age, there may be a 
higher degree of receptor internalization (Chow, Condorelli, & Smith, 1998; Girnita, 
Worrall, Takahashi, Seregard, & Girnita, 2014) as a result of an increased amount of 
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IGF1 binding and activating the available receptors. Despite the similarity of IGF1R 
expression in non-treated and heat-treated sides with IGF1 administration, there was a 
significant increase in pIGF1R expression (28.2%) on the heat-treated sides, which was 
20% greater than what was measured in saline controls (7.7%)(Fig. 20A, Table 9). Both 
saline and IGF1-injected mice treated for 14 days had a significant increase in IGF1R 
and pIGF1R expression on heat-treated sides but there was no difference between the 
injection groups (Fig. 20B, Table 9). Therefore, it is possible that the outcome of 
increased IGF1 signaling from 3-4 weeks of age is observed by the increased bone 
elongation measured in heat-treated limbs from mice treated from 3-5 weeks of age. 
Overall, results suggest that IGF1 activity was augmented with heat-treatment, and with 
additional IGF1 administered in conjunction with unilateral limb heating IGF1 activity is 
further increased when mice were treated for 7 days. Increased IGF1 activity after 7 
days of treatment also indicates that despite the IGF1-driven increase shown in femoral 
length and tibial elongation rate of mice treated for 14 days (Fig. 17B, Table 7), there 
was a higher degree of IGF1 signaling detected in the PZ of mice treated for 7 days 
(Fig. 20A, Table 9). Further investigation is required to better understand the 
complicated IGF1 signaling cascade involved in growth plate chondrocytes in response 
to additional IGF1 with targeted limb heating. 
One shortcoming of this study is examining IGF1 activity within the limited scope 
of growth plate chondrocytes. Studies have shown that with an increase in IGF1 activity 
in osteoblasts via the Col1a1(3.6) promoter, there was increased femoral length 
(Brennan-Speranza, Rizzoli, Kream, Rosen, & Ammann, 2011; Jiang et al., 2006). 
While not examined in this study, IGF1 receptors are expressed in osteoblasts 
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responsible for bone formation in the process of bone remodeling. With prolonged heat-
treatment, IGF1 may increase osteoblast activity to enhance longitudinal bone growth 
independent of activity within the growth plate. Since osteoblasts also contribute to 
radial growth, examining bone density would indicate if heat-treatment augments IGF1 
activity in osteoblasts with IGF1 injections.  
 
4.5 CONCLUSION 
In conclusion, IGF1 activity is augmented with heat-treatment and low dose 
IGF1-administration in conjunction with targeted limb heating can further enhance bone 
elongation. IGF1-injected mice treated for 14 days had an additional heat-enhanced 
increase in femoral length and tibial elongation rate compared to saline control mice 
(heat alone). There was also more proliferation and an increased hypertrophic zone 
height on heat-treated sides with IGF1 administration following 14 days of heating 
despite the comparable left-right differential to saline mice. A heat-enhanced increase in 
IGF1 activity was shown during both 7 days and 14 days of heating but was more 
pronounced from mice heated for 7 days during the rapid period of growth. Further 
studies are needed to better understand IGF1 signaling at the level of growth plate 
cartilage when IGF1 administration is coupled to targeting limb heating. Chapter 5 will 




CHAPTER V: IGF1 IS ESSENTIAL FOR HEAT-ENHANCED BONE ELONGATION 
5.1 INTRODUCTION 
 As discussed in Chapter 1, there are a vast number of possible mechanisms, 
both indirect and direct, by which localized heat enhances longitudinal growth. Although 
multiple prospects create various avenues of study, this study focuses on a possible 
direct effect of temperature on local regulation at the cellular level in the growth plate of 
long bones. The process of chondrocyte proliferation and hypertrophy in the growth 
plate is regulated by various contributing factors, none of which are mutually exclusive. 
Many have reviewed local regulation of the growth plate during postnatal longitudinal 
growth (Kronenberg, 2003; Lui et al., 2014; Mackie et al., 2008; van der Eerden et al., 
2003). Each functional zone of chondrocytes has a degree of local regulation by 
numerous factors that play a role in maintaining efficient endochondral ossification. For 
instance, Indian hedgehog (Ihh), parathyroid hormone-related protein (PTHrP), bone 
morphogenic proteins (BMPs), fibroblast growth factors (FGFs), and insulin-like growth 
factor-1 (IGF1) among others are expressed throughout distinctive regions of the growth 
plate and interact to regulate the rate of proliferation and hypertrophy. When these 
factors are inhibited, disturbances of longitudinal bone growth occur leading to 
conditions such as short stature (Grunwald & De Luca, 2015; Lee et al., 2016; LuValle & 
Beier, 2000; Maeda et al., 2010; Wang et al., 2004; Woods, Camacho-Hubner, Savage, 
& Clark, 1996).  
IGF1 produced by epiphyseal chondrocytes has been reported to regulate all 
regions of growth plate cartilage (Tahimic et al., 2013; Ulici et al., 2008; J. Wang et al., 
1999; Y. Wang et al., 2006) despite the conflicting findings on its role in chondrocyte 
 
 117 
proliferation (Govoni et al., 2007a; Parker et al., 2007; Reinecke et al., 2000; Shinar et 
al., 1993; Wang et al., 1995). Increased chondrocyte proliferation and hypertrophy have 
also been shown following direct treatment with IGF1 as a resulting growth response 
(Abbaspour et al., 2008; Mushtaq et al., 2004). IGF1 activity in the growth plate whether 
locally or systemically derived, has a significant role in regulating longitudinal bone 
growth.  
IGF1 is a putative target of study in the process of heat-enhanced limb 
elongation because of its essential role in longitudinal bone growth. Potential methods 
for studying the action of IGF1 in the growth plate include (1) the administration of IGF1 
blocking drugs such as IGF1 peptide analogues that specifically inhibit the downstream 
action of the IGF1 receptor (IGF1R) (Pietrzkowski et al., 1992; Smith et al., 1999) and 
(2) knockout mouse models with the absent or low levels of IGF1 (Yakar et al., 2010; 
Yakar & Isaksson, 2016). This study uses both. Experiments here utilize a small peptide 
analog of IGF1 known as JB1 that competitively binds to the receptor and blocks 
downstream IGF1 activity (Chapter 1, Fig. 5) (Brock et al., 2011; Huang et al., 2000; 
Kleinridders, 2016; Todd et al., 2007; Wen et al., 2012). This study also includes limited 
data using the growth hormone receptor knockout mouse (GHR-/-) recognized for 
having low levels of IGF1 and 30-40% reduction in body size (List et al., 2011; Sims et 
al., 2000; Yakar & Isaksson, 2016; Zhou et al., 1997). This chapter tests the 






5.2 MATERIAL AND METHODS 
 
5.2.1 Animals and Experimental Design 
 All procedures were approved by the Institutional Animal Care and Use 
Committee of Marshall University (Protocol 558). Female C57BL/6 (N=12) mice were 
obtained from Hilltop Lab Animals, Inc. (Scottdale, PA, USA) at 21 days weaning age. 
Mice were singly housed at 21°C in standard plastic caging, exposed to a 12 hour 
light/dark cycle and provided with food and water ad libitum. 
 As described in Chapter 2, and as indicated by the unilateral heating methods 
schematic (Fig. 21), mice were subjected to the same procedural conditions. Mice (N=6) 
were weighed each day and given subcutaneous injections of an IGF1 peptide analog 
(JB1, Sigma) that blocks downstream activity of IGF1. Injections of the IGF1 blocking 
drug JB1 (2.5 mg/kg) were administered daily at the start of the light cycle one hour 
prior to heat-treatment. The rationale for the dose and time period of JB1 administration 
was to be consistent with IGF1 drug treatment experiments described in Chapter 4. 
Dose was accepted following pilot trials that mimicked experimental conditions and 
tested the physiological response of the mice to the drug treatment. Saline-injected 
control (N=6) mice described in Chapter 3 served as the controls.  
 An additional group of female (N=5) growth hormone receptor (GHR) knockout 
(GHR-/-) mice on a C57BL/6 background was obtained from the Kopchick laboratory at 
Ohio University (Athens, OH, USA) at 21 days weaning age. GHR-/- mice model 
hereditary dwarfism in humans known as Laron Syndrome characterized by short 
stature, low serum IGF1, and GH resistance (Laron, 2015a; Laron & Kauli, 2015b; List 
et al., 2011; Sims et al., 2000; Zhou et al., 1997). These mice were housed under 
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similar conditions previously described. GHR-/- mice were not drug injected and were 
treated with unilateral heat (40°C for 40 mins/day) for 14 days. Although GHR-/- mice 
were not injected with saline, previous studies have shown that there are no significant 





Figure 21. Unilateral Heating Schematic 
Mice were injected subcutaneously (SQ) with IGF1 blocking drug (JB1, 2.5 mg/kg) one 
hour prior to treatment of 40°C unilateral heat for 40 minutes daily from 3-4 weeks of 
age. Euthanasia and tissue collection occurred 1 day after the last day of heat-
treatment. Mouse illustration based on “mouse clip art black and white” from 
clipartstockphotos.com. 
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5.2.2 Tissue Collection and Sample Analysis 
 Long bones (femora and humeri) were collected and measured as described in 
Chapter 3 (Sections 3.2.2 and 3.2.3). Proximal tibial halves from each hindlimb were 
collected (Section 3.2.2) for tibial elongation rate analysis (Section 3.2.3) and growth 
plate morphometry (Sections 3.2.4) following methods described in Chapter 3.  
 
5.2.3 Immunohistochemistry 
 Serial sections of proximal tibiae from mice subjected to 7 days (N=12, 6 per 
saline control and JB1) of unilateral heating were stained using rabbit polyclonal 
antibodies against IGF1R, phospho-IGF1R (phospho-Y1161) and PCNA (as described 
in Table 4) and rabbit polyclonal antibodies against pAkt, Thr308 (1:200, Santa Cruz, 
sc-16646) following methods as described in Chapter 3 (Section 3.2.5). Analysis 
focused on the proliferative zone (PZ) and the hypertrophic zone (HZ). PCNA was used 
as a marker for rate of proliferation (PZ only) and IGF1R, pIGF1R and pAkt were 
evaluated as markers of IGF1 activity (PZ and HZ). While an important part of the study, 
bisected tibiae were not collected from the GHR-/- mice following techniques necessary 
for immunohistochemistry analysis. Therefore, expression levels of PCNA, IGF1R, 
pIGF1R, and pAkt could, unfortunately, not be done in the GHR-/- model. 
 
5.2.4 Statistical Analysis 
 Statistical analyses were performed using SPSS 25.0 software (IBM Corporation, 
Armonk, NY) with p<0.05 as accepted significance and comparisons as described in 




5.3.1 Unilateral Heating Parameters 
 There was no significant difference in the amount of mass gained between 
controls and JB1-injected mice as determined by multiple comparison analysis using 
one-way ANOVA (F(1,11)=1.1, ns, p=0.311). JB1-injected mice treated for 7 days from 
3-4 weeks of age gained 4.3±0.5g while saline control mice (established in Chapter 3) 
gained 4.7±0.7g (Fig. 22). Therefore, the JB1-inject mice exhibited normal body growth. 
The core temperature averaged 36°C. While mice were anesthetized, the average 






Figure 22. Total Body Mass Gained in Mice Treated for 7 days from 3-4 weeks of 
Age did not Differ Between Saline Controls and JB1-Injected Mice  
Scatter plots show the change in mass of individual saline mice (open circles) and JB1 
mice (dark gray circles). One-way ANOVA revealed no significant differences in overall 






























5.3.2 Length of Long Bones and Tibial Elongation Rate 
 Femoral length was comparable on the non-treated sides of saline (10.44 mm) 
and JB-1 injected mice (10.46 mm) (Table 10). However, femoral length (paired t=0.3, 
ns, p=0.81) of JB1-injected mice did not differ between non-treated and heat-treated 
sides (Fig. 23A; Table 10) while saline mice had a significant 1.7% increase on heat-
treated sides (Chapter 3; Fig. 12A, Table 5). This heat-induced increase in femoral 
length was significantly greater (F(1,11)=6.2, p<0.05) than the JB1-injected mice. 
Humeral length was not different between sides for saline (Chapter 3; Table 5) or JB1-
injected mice (paired t=0.1, ns, p=0.91). 
 Tibial elongation rate was also comparable on the non-treated sides of saline 
mice (156.88 μM/day) and JB1-injected mice (153.31μM/day) (Table 10). However, 
tibial elongation rate of JB1-injected mice decreased by nearly 3% (paired t=1.9, ns, 
p=0.13) on the heat-treated side (Fig. 23B, Table 10), while saline mice had a significant 
increase of nearly 8% on the heat-treated side (Chapter 3; Fig. 12B, Table 5). This 
observed decrease was significantly less (F(1,9)=24.8, p<0.001) from the increase in 
tibial elongation rate in saline mice. The potential of limb heating to target JB1 to the 
heat-treated side was supported by data since unilateral differences in both femoral 
length and tibial elongation rate between saline and JB1-injected mice were seen on the 
heat-treated sides while the non-treated sides were similar between groups. Therefore, 
these results along with the observed normal body growth (Fig. 22) indicate that JB1 





Table 10. Comparison of Non-Treated and Heat-Treated Bone Parameters of 4-
Week Old Saline- and JB1-Injected Mice Following 7 Days of Heat-Treatment. 
 
Values are mean (standard deviation). JB1 emphasized as an IGF1 blocking drug in 
red. Sample size (N) is number of left-right pairs. Significantly larger on heat-treated 
side by one-tailed paired t-test: **p<0.01; ns, non-significant. Significant differences in 
percent increase between saline controls and JB1-injected mice by one-way ANOVA: 



















Humeral Length (mm) 
Saline 9.27 (0.14) 9.23 (0.20)ns -0.4 6 
JB1  9.09 (0.27) 9.10 (0.23)ns 0.1ns 6 
Femoral Length (mm) 
Saline 10.44 (0.19) 10.62 (0.26)** 1.7 6 
JB1 10.46 (0.27) 10.48 (0.33)ns 0.1# 6 
Tibial Elongation Rate (µM/day) 
 
Saline 156.88 (11.24) 168.94 (12.85)** 7.7 5 




Figure 23. Heat-Enhanced Growth Effects are Attenuated When IGF1 is Blocked  
(A) Error bar plots shows percent change in heat-treated limb compared to non-treated 
limb. Femoral length increased by 1.7% on the heat-treated side of saline control mice 
and no increase when IGF1 is blocked in mice injected with JB1. (B) Tibial elongation 
rate increased by 7.7% on the heat-treated side in saline mice and decreased by 2.6% 
in JB1-injected mice. (C) The PZ of proximal tibial growth plates in saline mice 
decreased by 9.0% on the heat-treated side but increased by 1.4% in JB1-injected 
mice. (D) The HZ of proximal tibial growth plates increased by 9.0% on the heat-treated 
side of saline mice but had a minimal increase of 0.4% in JB1 mice. Mean ± 1 standard 
error plotted. *p< 0.05; **p<0.01; ***p<0.001, significance in left-right comparisons; 
































































































































































A Femoral Length B Tibial Elongation Rate 
C D Proliferative Zone Height 
(Normalized to Total Height)  
Hypertrophic Zone Height 







5.3.3 Growth Plate Morphometry 
 The height of the PZ normalized to total growth plate height was significantly 
reduced by 9.0% on the heat-treated sides of saline mice (Chapter 3; Fig. 13A, C; Table 
6). JB1-injected mice displayed a 1.4% increase in PZ height (paired t=0.4, ns, p=0.68) 
on the heat-treated side (Fig. 23C). The height of the HZ normalized to the total growth 
plate height was significantly enlarged by 8.6% on the heat-treated sides of saline mice 
(Chapter 3; Fig. 12B, C; Table 6). JB1-injected mice had a minimal decrease of 0.4% in 
HZ height (paired t=0.0, ns, p=1.0) on the heat-treated side (Fig. 23D). The decrease in 
height of the PZ (F(1,10)=17.9, p<0.01) and HZ (F(1,10)=14.4, p<0.01) on heat-treated 
sides was significantly less when IGF1 is blocked than the increased heights reported in 
saline mice as determined by one-way ANOVA. Overall, blocking IGF1 activity in tibial 
growth plates attenuated the localized heat effect on growth plate morphometry. 
 
5.3.4 PCNA Expression 
PCNA expression (paired t=2.0, ns, p=0.12) decreased by 12.1% on the heat-
treated sides of JB1-injected mice (Fig. 24, Table 11). PCNA expression was 
significantly less (F(1,10)=10.6, p<0.01) than the 8.8% increase in expression on the 
heat-treated sides of saline control mice (Chapter 3; Fig. 14). Results indicate 
decreased proliferation in tibial growth plates with localized heating when IGF1 is 
blocked. However, while overall expression of PCNA was less in JB1-injected mice, 
chondrocytes still demonstrated a level of proliferation suggesting mechanisms 




Table 11. Comparison of Non-Treated and Heat-Treated Expression of PCNA in 
Proliferative Zone of Tibial Growth Plates in Saline and JB1-Injected Mice. 
 
Values are mean (standard deviation). JB1 emphasized as an IGF1 blocking drug in 
red. Sample size (N) is number of left-right pairs. Significantly larger on heat-treated 
side by one-tailed paired t-test: *p< 0.05; ns, non-significant. Significant differences in 
percent increase between saline controls and JB1-injected mice by one-way ANOVA: 
#p<0.05. 
  








Saline 85.10 (6.90) 91.93 (1.98)* 8.6 6 


















Figure 24. Expression of PCNA in the PZ of Proximal Tibial Growth Plates 















































Figure 24. (A) Error bar plots shows percent change in heat-treated limb compared to 
non-treated limb. PCNA expression increased by 8.6% on the heat-treated side of 
saline mice, and decreased by 12.1% in JB1-injected mice. (B) Comparison of heat-
treated proximal tibial growth plates from a saline and JB1-injected mouse 
immunostained for PCNA. A larger quantity of PCNA staining was counted in saline 
mice compared to JB1-injected mice. Positive staining is shown by dark brown nuclei 
within the proliferative zone of the growth plate (region between the double arrows). 
Mean ± 1 standard error plotted. *p< 0.05 significance in left-right comparisons; #p<0.05 




5.3.5 IGF1R, pIGF1R and pAkt Expression 
IGF1R expression in the PZ (paired t=5.0, p<0.01) of tibial growth plates 
decreased by 28.0% on the heat-treated side of JB1-injected mice. This decrease was 
significantly less (F(1,10)=39.4, p<0.001) than the 14.5% increase in IGF1R expression 
(paired t=3.2, p<0.05) on the heat-treated side of saline control mice (Fig. 25A, 26A(a); 
Table 12). Expression of activated IGF1R (pIGF1R) in the proliferative zone (paired 
t=3.2, p<0.05) of tibial growth plates decreased by 23.6% on the heat-treated side of 
JB1-injected mice. This decrease was significantly less (F(1,10)=24.0, p<0.001) than 
the 7.7% increase in pIGF1R expression (paired t=5.3, p<0.01) on the heat-treated side 
of saline mice (Fig. 25B, 26B(a); Table 12). The phosphatidylinositol-3 (PI-3) kinase 
pathway is one of several signaling pathways activated by IGF1-IGF1R interaction (the 
other is the mitogen-activated protein kinase (MAPK) pathway (Chapter 1, Fig. 4). 
Downstream activation of IGF1R was therefore investigated by measuring 
phosphorylated Akt (pAkt) expression as one of the key signaling molecules of the PI-3 
kinase pathway in the tibial growth plate (Choukair, Hϋgel, Sander, Uhlmann, & 
Tönshoff, 2014). Expression of pAkt decreased by 2.1% in the proliferative zone (paired 
t=0.2, ns, p=0.87) of tibial growth plates on the heat-treated side of JB1-injected mice. 
This decrease was significantly less (F(1,10)=6.4, p<0.05) than the 22.8% increase in 
pAkt expression (paired t=4.4, p<0.01) on the heat-treated side of saline control mice 
(Fig. 25C, Table 12). These data indicate that in the PZ, IGF1 activity is increased with 
heat-treatment (as reported in Chapter 4), and when IGF1 is blocked, there is a 
localized decrease in IGF1 activation.  
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IGF1R expression in the HZ (paired t=2.7, p<0.05) of tibial growth plates 
decreased by 19.2% on the heat-treated side of JB1-injected mice. This decrease was 
significantly less (F(1,10)=11.0, p<0.01) than the 10.4% increase in IGF1R expression 
(paired t=2.1, ns, p=0.11) on the heat-treated side of saline mice (Fig. 25A, 26A(b); 
Table 13). Expression of pIGF1R in the HZ (paired t=1.7, ns, p=0.17) of tibial growth 
plates decreased by 10.1% on the heat-treated side of JB1-injected mice. This 
decrease was significantly less (F(1,10)=9.0, p<0.05) than the 10.2% increase in 
pIGF1R expression (paired t=3.4, p<0.05) on the heat-treated side of saline mice (Fig. 
25B, 26B(b); Table 13). Expression of pAkt decreased by 22.4% in the HZ (paired t=4,1, 
p<0.05) of tibial growth plates on the heat-treated sides of JB1-injected mice. This 
decrease was significantly less (F(1,10)=8.0, p<0.05) than the 13.5% increase in pAkt 
expression on the heat-treated side of saline mice (paired t=1.7, ns, p=0.15) (Fig. 25C, 
Table 13). These data indicate that in the HZ, there is increased IGF1 activity because 












Table 12. Comparison of Non-Treated and Heat-Treated Expression of Markers for 
IGF1 Activation in Proliferative Zone of Tibial Growth Plates in Saline and JB1-
Injected Mice.  
 
Values are mean (standard deviation). JB1 emphasized as an IGF1 blocking drug in 
red. Sample size (N) is number of left-right pairs. Significantly larger on heat-treated 
side by one-tailed paired t-test: *p< 0.05; **p<0.01; ns, non-significant. Significant 
differences in percent increase between saline controls and JB1-injected mice by one-






























IGF1R expression  
Saline 69.68 (6.36) 79.52 (7.61)* 14.5 5 
JB1  68.83 (18.80) 50.25 (18.71)** -28.0# 6 
pIGF1R expression 
Saline 84.85 (10.36) 90.97 (7.90)** 7.7 6 
JB1 72.80 (15.38) 53.88 (4.75)* -23.6# 5 
pAkt expression 
Saline 55.21 (15.05) 66.23 (12.52)** 22.8 6 
JB1 37.62 (19.87) 38.14 (22.27)ns -2.1# 5 
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Table 13. Comparison of Non-Treated and Heat-Treated Expression of Markers for 
IGF1 Activation in Hypertrophic Zone of Tibial Growth Plates in Saline and JB1-
Injected Mice. 
 
Values are mean (standard deviation). JB1 emphasized as an IGF1 blocking drug in 
red. Sample size (N) is number of left-right pairs. Significantly larger on heat-treated 
side by one-tailed paired t-test: *p< 0.05; ns, non-significant. Significant differences in 





















IGF1R expression  
Saline 74.22 (9.94) 81.08 (2.95)ns 10.4 5 
JB1  74.95 (15.10) 59.57 (13.78)* -19.2# 6 
pIGF1R expression 
Saline 82.13 (7.39) 90.07 (4.23)* 10.2 6 
JB1 76.14 (12.74) 67.42 (10.13)ns -10.1# 5 
pAkt expression 
Saline 49.91 (14.15) 56.66 (17.93)ns 13.5 6 



















Figure 25. Expression of Markers of IGF1 Activation Decreases in Heat-Treated 
Proximal Tibial Growth Plates when IGF1 is Inhibited  
Comparison of heat-treated proximal tibial growth plates from a saline control and JB1-
injected mouse immunostained for (A) IGF1R (B) pIGF1R and (C) pAkt. A larger 
quantity of positive staining, shown by dark brown nuclei, was counted in saline mice 











Figure 26. Heat-Induced Effect on IGF1 Activity in the Tibial Growth Plate is 
Evident in the PZ and HZ 
(A) IGF1R expression in saline and JB1-injected mice. (a) Error bar plot shows percent 
change in heat-treated limb compared to non-treated limb. IGF1R expression in the PZ 
increased by 14.5% and decreased by 28% on heat-treated sides of saline and JB1-
injected mice. (b) IGF1R expression in the HZ increased by 10.4% and decreased by 
19.2% in saline and JB1-injected mice. (B) pIGF1R expression in saline and JB1-
injected mice. (a) pIGF1R expression in the PZ increased by 7.7% and decreased by 
23.6% in saline and JB1-injected mice. (b) pIGF1R expression in the HZ increased by 
10.2% and decreased by 10.1% in saline and JB1-injected mice. Mean ± 1 standard 
error plotted. *p< 0.05; **p<0.01, significance in left-right comparisons; #p<0.05 
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5.3.6 GHR-/- Growth Parameters 
 When levels of circulating IGF1 are low, femoral length (paired t=0.17, ns, 
p=0.88) and tibial elongation rate (paired t=0.3, ns, p=0.80) did not differ on the heat-
treated sides of 5 week old GHR-/- mice treated for 14 days (Fig. 27, Table 14). In wild-
type mice, femoral length and tibial elongation rate increased by 1.1% and 10.8% 
respectively as seen in Chapter 3 (Table 5). The heat-induced increase in femoral 
length (F(1,12)=29.2, p<0.001) and tibial elongation rate (F(1,12)=13.1, p<0.01) was 
significantly greater from the equivalent left-right pairs measured in GHR-/- mice. 

















Table 14. Comparison of Non-Treated and Heat-Treated Bone Parameters of 5-
Week Old Wild-Type and GHR-/- Mice. 
 
Values are mean (standard deviation). JB1 emphasized as an IGF1 blocking drug in 
red. Sample size (N) is number of left-right pairs. Significantly larger on heat-treated 
side by one-tailed paired t-test:  ***p<0.001; ns, non-significant. Significant differences 
in percent increase between saline controls and JB1-injected mice by one-way ANOVA: 































Humeral Length (mm) 
Wild-type 10.14 (0.11) 10.15 (0.13)ns 0.1 9 
GHR-/- 7.51 (0.04) 7.51 (0.04)ns 0.0ns 5 
Femoral Length (mm) 
Wild-type 12.86 (0.18) 13.00 (0.17)*** 1.1 9 
GHR-/- 9.32 (0.08) 9.32 (0.09)ns 0.0# 4 
Tibial Elongation Rate (µM/day) 
 
Wild-type 109.57 (11.18) 121.22 (10.70)*** 10.8 8 





Figure 27. Extremities of Growth-Hormone Receptor Knockout (GHR-/-) Mice are 
not Lengthened with Unilateral Heat-Treatment  
(A) Error bar plots shows percent change in heat-treated limb compared to non-treated 
limb. Femoral length increased by 1.1% on the heat-treated sides of wild-type mice 
treated for 14 days from 3-5 weeks of age. Femoral length did not change with 
treatment in GHR-/- mice. (B) Tibial elongation rate increased by 10.8% on the heat-
treated sides of wild-type mice, and GHR-/- mice had a minimal increase of 0.9% with 
heat-treatment. Mean ± 1 standard error plotted. ***p<0.001, significance in left-right 



















































































The goal of this study was to determine if the heat-enhanced bone elongation 
observed after targeted limb heating is IGF1 dependent. The heat-treatment effect on 
bone elongation is attenuated in growing mouse models exhibiting both locally blocked 
IGF1 and low IGF1. Femoral length and tibial elongation rate was shown to increase by 
over 1% and 7% respectively in heat-treated limbs of saline control mice after either 7 or 
14 days of unilateral heating. In JB1-injected (blocked IGF1) and GHR-/- (low levels of 
IGF1) mice, both femoral length and tibial elongation rate did not differ between the 
heat-treated and non-treated contralateral sides. Our data supported the hypothesis that 
with diminished IGF1 activity, heat-enhanced limb length is attenuated. 
Although we were not able to perform immunostaining on GHR-/- mice the 
results using our model and JB1 as an antagonist of IGF1 activity demonstrated that 
heat-enhanced chondrocyte proliferation and hypertrophy in proximal tibial growth 
plates was attenuated when IGF1 is blocked. Chondrocyte proliferation and hypertrophy 
are common indicators of longitudinal growth as discussed in Chapter 3. There is a 
positive relationship between rate of chondrocyte proliferation, size of chondrocyte 
enlargement, and linear bone growth rate (Cooper et al., 2013; Hunziker, 1994b; 
Kember, 1993; Rolian, 2008; Wilsman et al., 2008). According to the findings of this 
study, the proliferative and hypertrophic zones of growth plates on non-injected sides of 
saline control mice each made up 45% of the total growth plate height (the remaining 
10% being the reserve zone). On the heat-treated side, there was a shift in zonal height 
as the proliferative zone made up 41% of total growth plate height (Fig. 23C) while the 
hypertrophic zone of chondrocytes took up 48% of total height (Fig. 23D). This observed 
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shift in zones was absent in mice injected with the IGF1 blocking drug as the 
proliferative and hypertrophic zone height made up 42% and 47% of total height 
respectively on both non-treated and heat-treated sides. When evaluating proliferation 
in the growth plate, expression of PCNA increased by 8.6% on the heat-treated side of 
saline control mice but decreased by 12.1% when IGF1 was blocked (although not 
statistically significant) (Fig. 24, Table 11). Results demonstrated that an increased rate 
of proliferation with heat-treatment is dependent, in part, on IGF1 activity in the 
proliferative zone of the growth plate.  
To test for activation of IGF1 signaling, immunohistochemistry methods detected 
expression of specific markers for IGF1 activity in tibial growth plates including IGF1R, 
pIGF1R (activated receptor) and pAkt (downstream IGF1 activation). Measured 
expression levels of these markers (as done in Chapter 4) suggest in this study that the 
heat-enhanced increase in IGF1 activity is attenuated when IGF1 is blocked. On heat-
treated sides of the saline control mice, there was an increase in IGF1R, pIGF1R and 
pAkt expression while levels decreased when IGF1 was blocked in JB1-injected mice 
(Fig. 25, 26; Tables 12,13). Measured expression of signaling molecules as a result of 
IGF1 activated receptors including pIGF1R and downstream pAkt increased on the 
heat-treated sides of saline control mice by over 7%. Expression of pIGF1R and pAkt 
decreased by over 10% and 2% respectively on the heat-treated sides when the 
antagonist blocked IGF1 from binding to the receptor. This decrease in expression was 
observed in both the proliferative and hypertrophic zones of the growth plate as 
expected since IGF1 has been shown to increase cellular proliferation and 
differentiation both in vitro and in vivo (Abbaspour et al., 2008; Choukair et al., 2014; 
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Ciarmatori et al., 2007; Tahimic et al., 2013; Yakar & Isaksson, 2016). However, down 
regulation of pAkt was more substantial in the hypertrophic zone (22.4% decrease) 
compared to the proliferative zone (2.1% decrease). One plausible explanation for these 
results could be rationalized by findings from Ciarmatori et al. (2007) and Kiepe, 
Ciarmatori, Hoeflich, Wolf, & Tönshoff (2006) in growth plates of both cell lines and 
whole animals demonstrating that IGF1-driven proliferation is regulated by both the PI-3 
kinase and MAPK pathways, while the hypertrophic zone is regulated by only the PI-3 
kinase pathway (Ciarmatori et al., 2007; Kiepe et al., 2006). Regulation pathways could 
be compared in our model by analyzing expression levels of pAkt and important 
downstream signaling molecules from the MAPK pathway such as ERK. 
A surprising finding from this study was the significant decrease in IGF1R 
expression in both the proliferative zone (28% decrease) and the hypertrophic zone 
(19% decrease) from growth plates after treatment with the antagonist (Fig. 26A; Tables 
12,13). It was expected that with targeted limb heating IGF1R expression would either 
remain unchanged or increase in mice administered the IGF1 blocking drug since 
binding of IGF1 to its receptor enhances activation and initiates internalization and 
recycling of IGF1R (Chow et al., 1998; Yin, Guan, Liao, & Wei, 2009). Cell culture 
studies modeling the growth plate have shown that other antagonists of IGF1 signaling 
have reduced chondrocyte proliferation without impacting expression of IGF1R 
(Choukair et al., 2014). While literature does not support our findings, it is possible that 
the down regulation of IGF1R is a unique characteristic of IGF1 peptide analog JB1. 
The obscure ligand-independent mechanisms of IGF1R internalization may be a 
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potential mechanism of JB1-bound IGF1R down regulation (Morcavallo, Stefanello, 
Iozzo, Belfiore, & Morrione, 2014; Reilly, Mizukoshi, & Maher, 2004).  
Numerous studies have investigated the use of kinase inhibitors as a method for 
IGF1 inhibition in various tissues (Li et al., 2009; Pillai & Ramalingam, 2013; Refolo et 
al., 2017). However, blocking IGF1 activity by peptide analogs has been considered a 
more specific method for inhibiting cellular proliferation (Brock et al., 2011; Huang et al., 
2000; Kleinridders, 2016; Pietrzkowski et al., 1992; Todd et al., 2007; Smith et al., 1999; 
Wen et al., 2012). Besides their high specificity, IGF1 peptide analogues also have low 
molecular weights and low toxicity (Pietrzkowski et al., 1992). Monoclonal antibodies, 
such as αIR3, also have high specificity against IGF1R comparable to the peptide 
analogues, but are over 100-fold larger in size (Huang et al., 2000). Small molecular 
size is important for this study because the targeted growth plate is avascular and 
solute transport occurs by means of surrounding vasculature (Brodin, 1955). In vivo 
imaging studies have shown that molecules under 10kDa enter the growth plate from all 
directions of surrounding vasculature, while molecules over 40kDa cannot enter to a 
significant degree (Farnum et al., 2006). Aside from being commercially available, JB1 
was chosen for this study at only 1.2kDa and therefore falls well in the range of 
molecules capable of vascular transport into the cartilage growth plate. The small size 
of JB1 may also explain why heat-induced decrease in expression levels of IGF1 
signaling proteins were more prominent than the increase in expression seen in the 
heat-treated saline control mice. It is possible that the smaller size of JB1 (1.2kDa) 
allows for increased transport into the growth plate relative to IGF1 (7.6kDa). 
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The use of localized heat-treatment, as explained in Chapter 2, has been 
established as an effective method for enhancing limb elongation in growing mice 
(Serrat et al., 2015). Research into the mechanism of action is important in the hopes of 
translating our findings to develop a noninvasive alternative for treatment of bone 
elongation disorders in children. The ultimate goal would be to target localized heat to 
the site of the growth plate and increase limb elongation without impacting overall 
growth. In this study, there were no significant differences in change of body mass 
between saline controls and JB1-injected mice over the duration of heat-treatment and 
did not impact overall growth. The similarity observed between the non-treated sides of 
saline controls and JB1-injected mice is another indication that the effect of blocking 
IGF1 was limited to the heat-treated side.  
Limitations to this study include the small sample size of the GHR-/- mice. 
Unilateral heating experiments were carried out previous to establishing a consistent 
methodology as published (Serrat et al., 2015), and as described in the chapters of this 
dissertation. Also, since expression levels of PCNA, IGF1R, pIGF1R, and pAkt were not 
measured in the GHR-/- model, future studies will be essential to assay these important 
variables. Expanding upon the findings in the GHR-/- mouse model, future studies may 
be designed to understand the impact of heat-treatment on the GH-IGF1 axis at the 
level of the epiphyseal growth plate. While the current study focused on local IGF1 
activity in the growth plate, GH and related signaling molecules have yet to be studied in 
targeted limb heating experiments. GH has both direct and indirect control on the 
growth plate and has been shown to directly stimulate chondrogenesis and induce local 
IGF1 activity (Isaksson et al., 1982, 1985; Ohlsson, 1992b, 1998; Schlechter et al., 
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1986). In hope of translating the limb-heating model to treat children with bone 
lengthening disorders, including those with irregular GH-IGF1 regulation, it is important 
to determine if mild heat impacts GH in regulating longitudinal growth. Since the 
molecular size of GH (22 kDa) exceeds that of IGF1 (7.6 kDa) and the threshold of 
heat-enhanced vascular delivery (10 kDa) to the growth plate (Serrat et al., 2014a), the 
effects of heating would be expected to be at the level of local GH regulation. It is also 
expected that if targeted limb heating increases GH activity, it would not be independent 
of IGF1 since results from this study showed that when IGF1 activity was inhibited, and 
GH regulation was normal, the heat-enhanced growth effect was attenuated.  
 
5.5 CONCLUSION 
 In conclusion, with diminished IGF1 activity, heat-enhanced limb length is 
attenuated. Bone lengthening effects of temperature in hindlimbs of growing mice, such 
as increased femoral length and tibial elongation rate, were absent in GHR-/- mice (low 
levels of IGF1), and in JB1-injected mice (IGF1 was locally blocked). When IGF1 activity 
is blocked, the heat-induced increase in proliferation and height of hypertrophic zone is 
also attenuated. The variation between saline and JB1-injected mice in left-right 
differences of bone length, growth plate morphometry and IGF1 signaling despite both 
exhibiting normal body growth indicates that JB1 locally blocked IGF1 activity on heat-
treated sides. Together these results support the hypothesis that in the absence of IGF1 
activity, targeted limb heating cannot effectively increase bone elongation in growing 
mice. Chapter 6 will test whether heat-enhanced limb length can be maintained after 
treatment has ended into skeletal maturity.  
 
 146 
CHAPTER VI: DIFFERENTIAL LIMB LENGTH IS MAINTAINED THROUGHOUT 
SKELETAL DEVELOPMENT AFTER END OF TREATMENT 
 
6.1 INTRODUCTION 
 During the post-natal development, functional growth plate cartilage augments 
bone elongation with a rapid period of growth during early life then undergoes a gradual 
decline in growth velocity and eventually ceases during adolescence. This process has 
been termed as growth plate senescence (Lui et al., 2011). Although the murine growth 
plate does not completely close and form a bony union as it does in humans, both reach 
a period of growth culmination over a similar time frame and by comparable cellular 
kinetics (Dawson, 1925, 1935; Geiger et al., 2014; Walker & Kember, 1972). Once 
skeletal maturity is reached, the growth plate ceases to contribute to linear growth. In 
mice, skeletal maturity is reached by 12 weeks of age (Kilborn et al., 2002; Li et al., 
2017; Serrat et al., 2007; Stempel et al., 2011; Zoetis et al., 2003), while humans are 
considered skeletally mature at puberty between 13-18 years of age (Kelly & Diméglio, 
2008).  
Current treatment for bone elongation disorders including the invasive surgical 
procedures to correct limb length discrepancies, and the drug regimens for GH and 
IGF1 occur before skeletal maturity. Often, there is only a partially effective outcome 
after both surgical procedures (Gurney, 2002; Hasler & Krieg, 2012) and drug regimen 
therapy (Backeljauw et al., 2013; Laron, 2001; Ranke et al., 1995b; Wu et al., 2013). A 
goal of many therapies for bone elongation disorders is to maintain corrections past 
skeletal maturity to avoid resulting problems in adulthood. In children, while treatment is 
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most effective during early childhood when growth is most rapid (Kelly & Diméglio, 
2008), therapy continues until growth ceases at the end of puberty. 
The concept of using localized heat as a noninvasive alternative to surgical 
treatment for bone elongation disorders in children has thus far been supported by data 
demonstrating that targeted limb heating can effectively lengthen extremities during 
rapid periods of growth. However, in hopes of translating the results of this study into 
developing a noninvasive method for lengthening bones as a therapy for children, it is 
important to determine if the heat-enhanced bone elongation can be maintained 
throughout skeletal development. Studies have shown that femoral and tibial lengths 
remain almost 1% longer on the heat-treated sides of 12-week-old mice (Serrat et al., 
2015). The objective of this project was to understand the ability for unilaterally 
lengthened extremities to remain longer until skeletal maturity following both a 7 day 
and 14 day unilateral heating regimen in conjunction with low dose IGF1 administration. 
It is hypothesized that differential limb length will be maintained throughout 
skeletal development after treatments have ended. It is also expected based on 
findings from Chapter 4, that persistent limb length differences will be prominent in 
IGF1-injected mice. 
 
6.2 MATERIAL AND METHODS 
6.2.1 Animals and Experimental Design 
 All procedures were approved by the Institutional Animal Care and Use 
Committee of Marshall University (Protocol 558). Female C57BL/6 (N=31) mice were 
obtained from Hilltop Lab Animals, Inc. (Scottdale, PA, USA) at 21 and 28 days weaning 
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age. Mice were singly housed at 21°C in standard plastic caging, exposed to a 12 hour 
light/dark cycle and provided with food and water ad libitum. 
 As described in the previous chapters and as indicated by the unilateral heating 
methods schematic (Fig. 28), mice post-weaning were treated with daily unilateral heat 
(40°C) under the same procedural conditions. Mice were treated for 7 days from 3-4 
weeks of age and for 14 days from 3-5 weeks of age. Subcutaneous injections of either 
saline solution (3:1, 1xPBS:dH2O) at a volume of 0.01mL/g, or IGF1 (2.5mg/kg; 
Peptrotech), were administered to mice daily at the start of the light cycle one hour prior 
to heat-treatment for 7 days and 14 days (N=6 per group). These experimental groups 
have not yet been described in previous chapters as tissue collection occurred later in 
development. A group of non-heated, non-injected 3-week-old mice (N=7) were also 
kept under equivalent housing conditions as non-treated controls. Daily mass was 






Figure 28. Unilateral Heating Schematic  
Mice were injected subcutaneously (SQ) with either saline or IGF1 (2.5mg/kg) one hour 
prior to treatment of 40°C unilateral heat for 40 minutes daily for 7 days from 3-4 weeks 
of age and 14 days from 3-5 weeks of age. Euthanasia and tissue collection occurred at 
12 weeks of age when mice were skeletally mature. Mouse illustration based on “mouse 
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6.2.2 Tissue Collection and Long Bone Measurements 
 Long bones (femora and humeri) were collected and measured as described in 
Chapter 3 (Sections 3.2.2 and 3.2.3) but all experimental mice (N=31) were euthanized 
for tissue collection at 12-weeks of age at skeletal maturity. In this study tibiae were 
collected for long bone measurements since no histology was done. Non-treated 
controls (N=7) were also euthanized at the same endpoint to evaluate natural limb 
length differences at skeletal maturity.  
   
6.2.3 Statistical Analysis 
 Statistical analyses were performed using SPSS 25.0 software (IBM Corporation, 
Armonk, NY) with p<0.05 as accepted significance and comparisons as described in 
Chapter 4 (Section 4.2.4). 
 
6.3 RESULTS 
6.3.1 Unilateral Heating Parameters 
 At the start of 7 day unilateral heating, a group of 3-week-old female mice (N=17) 
were partitioned out into the corresponding non-treated controls (N=5) and heat-treated 
saline (N=6) and IGF1-injected mice (N=6). At the experimental start, all mice were 
comparable in mass (F(2,16)=2.7, ns, p<0.12), weighing an average of 9.0g (Fig. 29A, 
Table 15). At skeletal maturity, mice were also comparable in mass (F(2,18)=2.3, ns, 
p=0.14), weighing an average of 23.0g. The overall gain in mass was therefore 14.0g 
with no significant differences between non-treated controls, saline mice treated for 7 
days, or IGF1-injected mice treated for 7 days, as determined by multiple comparison 
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analysis using one-way ANOVA (Table 15). At the start of 14 days unilateral heating, 
another group of 3-week-old female mice (N=12) were separated into heat-treated 
saline (N=6) and IGF1-injected mice (N=6). At the experimental start, all mice were 
comparable in mass (F(1,11)=0.1, ns, p=0.83), weighing an average of 10.0g (Fig. 29A, 
Table 15). At skeletal maturity, mice were also similar in mass (F(1,11)=2.5, ns, 
p=0.14), weighing an average of 22.5g. Although IGF1-injected mice (23.1g) overall 
gained about 1.0g more than the saline controls (22.2g), this was not statistically 
significant (F(1,11)=2.0, ns, p=0.19). Therefore, with either 7 days or 14 days of limb 
heating, mass remained comparable between groups from the start at 3 weeks of age 
until skeletal maturity at 12 weeks of age (Table 15).  
The core temperature averaged 36°C during unilateral heating. While mice were 
anesthetized, the average surface temperature of non-treated hindlimbs was 30°C and 
the heat-treated hindlimbs were 40°C. These recorded temperatures were consistent 
with parameters during the daily limb heating reported in previous chapters. As reported 
in Chapter 4, the recovery time from anesthesia was longer in IGF1-injected mice 
compared to saline controls in this study. At the end of each daily heat-treatment 
(40mins), the average time for saline mice to recover from anesthesia after 7 days and 
14 days of heating was 1.4±0.23mins and 1.1±0.04mins respectively. The average time 
for IGF1-injected mice to recover from anesthesia was 2.6±0.50mins and 2.7±0.40mins, 
which was significantly longer than the saline controls after both 7 days (F(1,11)=33.2, 




Table 15. Comparison of Mass Between Heat-Treatment Groups at the Start of 
Treatment and at Skeletal Maturity 
 
Values are mean (standard deviation). Sample size (N) is number of mice weighed. 
  
Length of Heat-Treatment Injection Mass at Start (g) 
3-weeks old 
Mass at End (g) 
12-weeks old 
Change in Mass (g) N 
None 
None 8.6 (0.8) 22.7 (1.0) 14.0 (0.9) 5 
7 days 
Saline 9.3 (0.4) 23.6 (1.1) 14.3 (1.2) 6 
IGF1 9.2 (0.3) 22.4 (0.8) 13.2 (1.0) 6 
14 days 
Saline 10.1 (0.7) 22.2 (0.9) 12.2 (1.3) 6 




















Figure 29. Mass did not Differ Between Non-Treated Controls, Heat-Treated Saline 
Control Mice, and Heat-Treated IGF1-Injected Mice at Either Duration of Limb 
Heating  
(A) Error bar plots comparing starting (open circles) (at 3 weeks of age) and ending 
mass (gray circles) (at 12 weeks of age) of starting and ending mass from mice 
separated for 7 days of heating. (B) Comparison of starting and ending mass from mice 
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6.3.2 Length of Long Bones Following 7 days of Heating 
 In non-treated control mice (N=7) humeral (paired t=1.5, ns, p=0.19), femoral 
(paired t=0.2, ns, p=0.84) and tibial length (paired t=0.95, ns, p=0.41) did not differ 
between left-right non-heated sides at skeletal maturity when mice were 12 weeks old 
(Fig. 30). Following 7 days of limb heating, there was no difference in humeral length at 
skeletal maturity in saline (paired t=0.21, ns, p=0.84) and IGF1-injected mice (paired 
t=0.42, ns, p=0.69) (Table 16). Femoral length was increased by 0.5% (paired t=2.1, ns, 
p=0.09) and 1.0% (paired t=5.8, p<0.01) on the heat-treated sides of saline and IGF1-
injected mice respectively (Fig. 30A(a), Table 16). Tibial length was increased by 0.5% 
(paired t=3.7, p<0.05) and 0.4% (paired t=2.5, ns, p=0.06) on the heat-treated sides of 
saline and IGF1-injected mice respectively (Fig. 30A(b), Table 16). No significant 
differences in humeral (p=0.91), femoral (p=0.16) and tibial length (p=0.96) were 






Table 16. Comparison of Non-Treated and Heat-Treated Sides of Experimental 
Mice Bone Parameters Following 7 Days of Limb Heating. 
 
Values are mean (standard deviation). Sample size (N) is number of left-right pairs. 
Significantly larger on heat-treated side by one-tailed paired t-test: *p< 0.05; **p<0.01; 
ns, non-significant. Significant differences in percent increase between saline controls 






























Humeral Length (mm) 
Saline 11.89 (0.16) 11.89 (0.17)ns 0.0 6 
IGF1 11.84 (0.16) 11.82 (0.12)ns -0.1ns 6 
Femoral Length (mm) 
Saline 15.46 (0.30) 15.53 (0.25)ns 0.5 6 
IGF1 15.21 (0.18) 15.36 (0.18)** 1.0ns 6 
Tibial Length (mm) 
Saline 17.55 (0.37) 17.63(0.33)* 0.5 5 




Figure 30. Extremities Remained Longer on the Heat-Treated Sides at Skeletal 
Maturity when Limb Heating was Coupled with IGF1 Administration  
(A) Error bar plots show percent change in heat-treated limb compared to non-treated 
limb compare in saline and IGF1-injected mice treated for 7 days. (a) Femoral length 
was 0.5% and 1.0% longer on the heat-treated sides of saline and IGF1-injected mice 
(b) Tibial length was 0.5% and 0.4% longer on the heat-treated sides of saline and 
IGF1-injected mice. (B) Error bar plots compare % increase in bone length in saline and 
IGF1-injected mice treated for 14 days. (a) Femoral length was 0.6% and 1.0% longer 
on the heat-treated sides of saline and IGF1-injected mice (b) Tibial length was 0.1% 
and 0.8% longer on heat-treated sides of saline and IGF1-injected mice. Mean ± 1 
standard error plotted. *p< 0.05; **p<0.01; ***p<0.001, significance in left-right 
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6.3.3 Length of Long Bones Following 14 Days of Heating 
 Following 14 days of limb heating, there was no difference in humeral length at 
skeletal maturity in saline (paired t=0.95, ns, p=0.39) and IGF1-injected mice (paired 
t=0.06, ns, p=0.95) (Table 17). Femoral length was increased by 0.6% (paired t=2.3, ns, 
p=0.07) and 1.0% (paired t=6.7, p<0.001) on the heat-treated sides of saline and IGF1-
injected mice respectively (Fig. 30B(a), Table 17). The increase in femoral length on 
heat-treated sides was comparable (F(1,11)=2.0, ns, p=0.19) between saline and IGF1-
injected mice. Tibial length increased by 0.1% (paired t=0.74, ns, p=0.49) and 0.8% 
(paired t=7.3, p<0.001) on the heat-treated sides of saline and IGF1-injected mice 
respectively (Fig. 30B(b), Table 17). No significant differences in humeral (p=0.89) and 
femoral (p=0.28) lengths were determined between saline and IGF1-injected mice, but 
the increase in tibial length on heat-treated sides of IGF1-injected mice was greater 
than saline (p<0.01). Overall, results demonstrate that a degree of heat-enhanced bone 
length is maintained into skeletal maturity when limb heating is coupled with 




Table 17. Comparison of Non-Treated and Heat-Treated Sides of Experimental 
Mice Bone Parameters Following 14 days of Limb Heating. 
 
Values are mean (standard deviation). Sample size (N) is number of left-right pairs. 
Significantly larger on heat-treated side by one-tailed paired t-test: *p< 0.05; **p<0.01; 
***p<0.001; ns, non-significant. Significant differences in percent increase between 











Humeral Length (mm) 
Saline 11.73 (0.15) 11.74 (0.13)ns 0.1 6 
IGF1 11.90 (0.20) 11.90 (0.16)ns 0.0ns 6 
Femoral Length (mm) 
Saline 15.30 (0.08) 15.39 (0.15)ns 0.6 6 
IGF1 15.41 (0.14) 15.56 (0.14)*** 1.0ns 6 
Tibial Length (mm) 
Saline 17.42 (0.17) 17.44 (0.18)ns 0.1 6 




  In this study, differences in long bone length were examined in skeletally mature 
mice (12 weeks of age) to determine if the resulting heat-enhanced limb lengthening in 
young mice (3-4 and 3-5 weeks of age) reported in previous chapters is sustained until 
adulthood. IGF1 therapy has been shown to effectively increase skeletal growth and 
when administered in conjunction with 14 days of unilateral heating augments heat-
enhanced limb elongation (Chapter 4). Therefore, this study examined the long-term 
impact of IGF1 administration in conjunction with limb heating.  
As reported in Chapter 4, immediately following treatment end points, femoral 
lengths of saline mice treated for 7 days and 14 days were 1.7% and 1.1% longer on 
heat-treated sides respectively. Femoral length of IGF1-injected mice treated for 7 days 
and 14 days was 1.7% and 1.9% longer on heat-treated sides respectively. This study 
reports significant increases in femoral length of IGF1-injected mice after 7 days (1.0%) 
and 14 days (1.0%) of treatment, but less than significant increases in femoral length on 
heat-treated sides of saline mice after 7 days (0.5%) and 14 days (0.6%) of treatment 
(Fig. 30A(a), B(a); Tables 16, 17). Femoral length compared between sides of non-
treated mice was equivalent. Data supported the hypothesis that differential limb length 
was maintained throughout skeletal development after treatments have ended, and 
more so when heating was coupled with IGF1 administration.  
These results are not analogous to those reported by Serrat et al. (2015) in 
another study comparing persistent left-right increases in femoral length at skeletal 
maturity following 14 days of treatment. Serrat et al. (2015) reported a significant 1.0% 
increase in femoral length in non-injected 12-week-old mice treated for 14 days. 
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Discrepancy between studies may be explained by variations in methodology. It can be 
speculated whether or not an augmented limb length differential at skeletal maturity 
would have also been seen if that study were done in conjunction with IGF1 
administration. It was also reported by Serrat et al. (2015) that femoral length was 1.3% 
longer on heat-treated sides of mice treated for 14 days. Importantly, both studies show 
that despite the significant increase in femoral length maintained into adulthood, length 
differential was not sustained by the same extent at skeletal maturity as immediately 
following treatment. The diminished differential in limb length at skeletal maturity may be 
explained by similar mechanisms to those regulating the phenomenon of “catch-up” 
growth. Typically, catch-up growth is explained as recovery in linear growth from 
growth-inhibiting conditions (Lui et al., 2011; Reich et al., 2008). During catch-up 
growth, growth plates increase activity. Further investigation would be needed to 
determine if the heat-enhanced linear growth accelerates the onset of growth plate 
senescence and the non-treated side thus partially “catches-up” to the heat-treated 
side.  
Since the growth plate at skeletal maturity no longer contributes to longitudinal 
growth, tibial growth plates were not collected for growth rate and histological analysis 
as in previous studies described thus far. Therefore, the tibia served as an additional 
long bone for comparison of length. Tibial length was 0.5% and 0.1% on the heat-
treated sides of saline control mice after 7 days and 14 days of heating respectively 
(Fig. 30A(b), B(b); Tables 16, 17). The IGF1-injected mice had an increase of 0.4% and 
0.8% in tibial length on the heat-treated sides following 7 days and 14 days of heating 
respectively. Based on tibial length, the IGF1-injected mice maintained a more 
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substantial differential in length compared to saline controls, but only with 14 days of 
heating. Similar to what was observed in femoral length, the non-treated control left-
right tibial length was nearly equivalent. One limitation in this study is the possible 
discrepancy in tibiae measurements from inconsistent disarticulation and cleaning of 
bones from mice after the 7-day heat-treatment. Multiple personnel were responsible for 
the process of obtaining clean tibiae for measurement and collecting whole tibiae for 
long bone measurements was not as practiced and concise as those done for femora 
and humeri. However, the same individual consistently collected all tibiae from the 14-
day experiments.  
 
6.5 CONCLUSION 
In conclusion, heat-enhanced limb length is maintained throughout skeletal 
development after treatments have ended, and more so when heating was coupled with 
IGF1 administration. Since other studies have shown that heat-alone can maintain limb 
length differential, repeated studies are recommended to increase sample size and gain 
a better understanding of the potential of limb length differences to be maintained into 
adulthood. Nevertheless, in this study, IGF1 has a role in permanently sustaining heat-
enhanced bone growth. Future studies will investigate if heat-treatment elicits 
permanent changes to the growth plate allowing for maintenance of the limb length 
differential, such as permanent increases in vascular supply. It is important to determine 
the full potential of unilateral heat-treatment in maintaining limb length differential in 
order to translate these methods to treatment in children with bone growth disorders 
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CHAPTER VII: THERMAL IMAGING REVEALS TEMPERATURE RETENTION IN 
HINDLIMBS OF MICE AFTER TARGETED INTERMITTENT LIMB HEATING 
 
7.1 INTRODUCTION 
 The relationship between the vascular system (blood and vessels) and the 
epiphyseal growth plate is a complicated one. While bone is a highly vascularized 
tissue, growth plate cartilage is avascular and requires indirect vascular routes to supply 
nutrients and hormones that are essential for longitudinal bone growth (Brodin, 1955; 
Maes, 2013; Trueta, 1968). Temperature regulates vasculature (Serrat, 2014b). Heat 
increases blood flow in the limbs (Barcroft & Edholm, 1943; Chiesa, Trangmar, & 
González-Alonso, 2016) and exposure to warm temperature has also been shown to 
increase transport into the growth plate (Serrat et al., 2009, 2010, 2014a). Therefore, it 
is plausible that the heat-enhanced linear bone growth is enabled by changes in 
vasculature. 
Infrared thermal imaging is a technique that has been used to measure surface 
limb temperature in both clinical and veterinary applications (Inagaki, Ohno, Histome, 
Tanaka, & Takeshita, 1992; Jones, 1998; Soerensen & Pedersen, 2015; Turner, 2001) 
as well as in experimental settings (Dezechache, Wilke, Richi, Neumann, & 
Zuberbϋhler, 2017; McGreevy, Warren-Smith, Guisard, 2012; Tattersall & Milson, 2003; 
Tattersall, 2016). Tattersall and Milson (2003) captured infrared thermal images of 
golden-mantled ground squirrels to demonstrate a shift in blood flow to the periphery 
associated with cooling in hypoxic conditions. The advantage to using thermal imaging 
is methodology entails minimal stress to unanesthetized animals as a non-contact 
approach of acquiring skin temperature. Studies have shown that blood flow positively 
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correlates with skin temperature (Carter et al., 2014; Senay, Prokop, Cronau, & 
Hertzman, 1963; Song, Chelstrom, Levitt, Haumschild, 1989; Turner, 2001). Therefore, 
thermal imaging can be used to measure heat retention at the surface of the limb as an 
indicator of the extent of increased blood flow. If targeted limb heating results in an 
increase in blood flow as expected, it is hypothesized that skin temperature of heat-
treated limbs will remain elevated for an extended time following treatment.   
 
7.2 MATERIAL AND METHODS   
7.2.1 Infrared Thermal Imaging 
 As an extensive pilot study (IACUC approved) to determine the period of time in 
which limb temperature remains elevated on the heat-treated side after each daily 
regimen, female C57BL/6 (N=12) mice were obtained (Fig. 31). Experimental mice were 
treated with daily unilateral heat (40°C) under the same procedural conditions as 
described in previous chapters. Mice were treated for 7 days from 3-4 weeks of age 
(N=6) and 14 days from 3-5 weeks of age (N=6). No injections were administered. 
Infrared thermal images were captured at 320 X 240 resolution using a FLIR E8 infrared 
camera (sensitivity <0.06C in temperature range of -20 to 250°C). Images were 
captured 1 hour prior to limb heating and then 1, 4 and 8 hours post-heating. Imaging 
times were chosen based on a pilot study conducted prior to experiments that 
determined the optimal imaging settings. During the 7-day and 14-day heating regimen, 
5 separate days (over a total of 14 days of treatment) were chosen for imaging. 
Temperatures recorded over the 5 days (N=6 mice per day) were pooled at each time 
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point (N=5 recordings per time point) for a total of N=30 temperature recordings per 
time point.  
When each mouse was removed from the cage for imaging, the sleeping position 
was noted (if possible) to account for any positioning impact on surface temperature. 
Imaging intervals were chosen to avoid excessive imaging that negatively impacted 
daily gain in body mass. Mice were positioned consistently on a 4 inch cylindrical piece 
of polyethylene foam mounted to a mouse cage lid on a customized imaging cart. The 
camera was placed in a tailor-made stand at a 67.5° angle. Surface temperatures of the 
heat-treated (right) and non-treated (left) hindlimbs were obtained from calibrated 
images using the FLIR tools 2.1 software. Mean surface temperature was averaged 






Figure 31. Infrared Thermal Imaging Schematic 
Mice were treated with 40°C unilateral heat for 40 minutes daily for 7 days from 3-4 
weeks of age or 14 days from 3-5 weeks of age. Thermal images of hind limbs were 
captured using a FLIR E8 infrared thermal imaging camera (2008 © FLIR® Systems, 
Inc) 1 hour prior to, and 1 hour, 4 hours, and 8 hours post-heating. Euthanasia and 
tissue collection occurred 1 day after the last day of heat-treatment. Mouse illustration 
based on “mouse clip art black and white” from clipartstockphotos.com. 
  
3-week-old female mice treated daily 
for 7 days or 14 days with 40°C 
unilateral heat 40 min/day  
Hind limbs imaged using FLIR E8  
infrared thermal imaging camera 
Start of 12-hour light cycle End of 12-hour light cycle 
40°C unilateral heat for 40 mins 





-1 0 1 2 3 4 5 6 7 8 9 10 11 
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7.2.2 Statistical Analysis and Sample Size 
 Statistical analyses were performed using SPSS 25.0 software (IBM Corporation, 
Armonk, NY) with p<0.05 as accepted significance. Non-treated and heat-treated side 
comparisons for surface temperatures were done using one-tailed paired t-tests. The 
one-way ANOVA with a Tukey post hoc test was used to determine significant 
differences between multiple treatment days that infrared thermal images were captured 
throughout the duration of limb heating. Data were reported as mean ± standard 
deviation (SD) in tabular format and as mean ± standard error (SE) in graphical format. 
Sample sizes for measurements that are documented as less than the size of the 
experimental sample set were a result of failure to confidently obtain surface 
temperatures from thermal images such as when the limbs were properly positioned. 
 
7.3 RESULTS 
7.3.1 Temperature Retention in Hindlimbs Post-Heating 
Hindlimb surface temperature of female mice (N=6) was assessed using infrared 
thermal imaging recorded over 5 days throughout the duration of limb heating. Data 
were pooled at each time point (1hr prior to heating, and 1hr, 4hrs and 8hrs post-
heating) since no significant differences were observed between the multiple treatment 
days that infrared thermal images were captured (F(1,29)=0.20, ns, p=0.94). Surface 
limb temperature was 31.1±0.2°C on the non-treated side (left) and 30.8±0.2°C on the 
intended heat-treated side (right), 1hr prior to treatment (Fig. 32A). The 0.8% difference 
in temperature was not significant between contralateral sides (paired t=1.6, ns, 
p=0.13). Surface limb temperature was 30.3±0.9°C and 30.4±0.9°C on the non-treated 
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and heat-treated sides respectively, 1hr following treatment (Fig. 32A). The 0.4% 
difference in limb temperature was not significant between contralateral sides (paired 
t=0.7, ns, p=0.51). Surface limb temperature was 31.1±0.7°C and 31.5±0.8°C on the 
non-treated and heat-treated sides respectively, 4hrs following treatment (Fig. 32A, B). 
The 1.2% increase in limb temperature on the heat-treated side was significantly 
warmer than the non-treated side (paired t=2.3, p<0.05). Surface limb temperature was 
31.1±0.9°C and 30.9±0.7°C on the non-treated and heat-treated sides respectively, 8hrs 
following treatment (Fig. 32A). The 0.4% difference in limb temperature was not 
significant between contralateral sides (paired t=0.8, ns, p=0.40). Therefore, limb 
temperature remained elevated on the heated side up to 4 hours after treatment. 
If apparent at the onset of imaging, the sleeping position of the mouse was noted 
to compare if the hindlimb surface temperature reflected the huddled position of the 
mouse during sleep. Since mice have been shown to demonstrate a degree of 
handedness (Biddle, Coffaro, Ziehr, & Eales, 1993), if they also displayed sleep position 
preference (left versus right side sleeping) that may account for the measured limb 
temperature differentials. However, while some positions were not obvious, the 
positions that were observed did not relate to measured surface limb temperature of 








Figure 32. Thermal Imaging Shows Hindlimb Surface Temperature Remains 
Elevated up to 4 Hours Post-Heating  
(A) Error bar plot shows the difference in limb temperature between non-treated and 
heat-treated limbs at each time point (N=30, N=6 left-right limb temperatures pooled 
over N=5 days of heating). The heat-treated side was -0.8%, 0.4%, 1.2% and -0.4% 
warmer than the contralateral non-treated sides. (B) Captured infrared thermal images 4 
hours post-heating of non-treated (left) and heat-treated (right) hindlimbs. Image 
analyzed in FLIR tools using the iron color pallet to distinguish thermal profiles between 
23°C and 36°C. Warmer temperatures as seen by the lighter color profile, are observed 




-1 1 4 8
Hours After Heat-Treatment Start







































4 hours after heat-treatment 
A B 




 Warm temperature increases blood flow in limbs (Barcroft & Edholm, 1943; 
Chiesa et al., 2016) and measured skin temperature is positively correlated to blood 
flow (Carter et al., 2014; Senay et al., 1963; Song et al., 1989; Turner, 2001). Thermal 
imaging data revealed that temperature remained elevated (1.2% increase) on the 
heated side up to 4 hours post-heating. Therefore, data support the hypothesis that skin 
temperature of heat-treated limbs will remain elevated for an extended time following 
treatment. Results indicate that targeted limb heating caused an increase of blood flow 
in the limbs that is sustained up to 4 hrs after treatment ends. It is possible that this 
retention in limb temperature is due to a heat-enhanced increase in blood flow that 
facilitates bone lengthening.  
Temperatures were nearly equivalent (0.4% difference) 1 hr following treatment 
suggesting a systemic post-anesthesia thermoregulatory response. By 8 hrs post-
heating, limb temperatures were again similar (0.4% difference) reflecting increased 
activity as mice approached the dark cycle. Another possible explanation for these 
results are exemplified in a study by Song et al. (1989) measuring blood flow in heated 
human forearms (40°C for 60 mins). They found that blood flow momentarily declined 
before increasing for several minutes and then rapidly declining corresponding with 
changes in volume and speed of red blood cells (Song et al., 1989). Comparable, this 
study demonstrated a similar trend in changes in skin temperature but over a period of 
hours instead of minutes. This time differential may be due to whole limb warming 
versus only a localized portion of the limb, as well as a much smaller animal (mouse) 
compared to humans.  
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 One important question at the start of this pilot study was whether or not heat 
retention was additive with consecutive days of heat-treatment. After collection of 
temperatures at various time points during different treatment days, no differences were 
seen in the mean hindlimb temperature at each time point. While hindlimb surface 
temperature remained elevated up to 4 hours after treatment, it was independent on the 
day of heating. Comparable temperatures recorded between the days of treatment 
indicated that temperature retention does not increase with additional days of heating, 
and heat-enhanced temperature effects occur within the first 4 hours post-heating.  
Results in this study suggest heat-enhanced linear growth is enabled by changes 
in vasculature since blood flow positively correlates with skin temperature (Carter et al., 
2014; Senay et al., 1963; Song et al., 1989; Turner, 2001). However, the means by 
which heat-induced changes in vasculature occur remain unknown. In addition to the 
transport and delivery of essential nutrients and hormones, the vascular system also 
has a role in the delivery of heat (Scholander, 1955; Serrat et al., 2008; Serrat, 2014b). 
Therefore, vasculature has the potential to facilitate limb growth through the delivery of 
warm blood to the growth plate and module temperature-sensitive genes and pathways.  
During endochondral ossification, hypertrophic chondrocytes secrete angiogenic 
factors that initiate vascular invasion and recruitment of bone absorbing and forming 
cells that replace mineralized cartilage with bone (van der Eerden et al., 2003; 
Filipowska et al., 2017; Gerber et al., 1999b; Horner et al., 1999; Hunziker, 1994b; 
Maes et al., 2004; Zelzer & Olsen, 2005). The key regulator involved in this process of 
endochondral ossification is vascular endothelial growth factor (VEGF) (Emons et al., 
2010; Gerber et al., 1999b). Other factors expressed in the growth plate, such as IGF1 
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(Ahmed & Farquharson, 2010; Álvarez-García et al., 2010), have also been shown to 
stimulate VEGF and induce vascular invasion.  
One method for assessing heat-induced changes in vasculature at the site of the 
growth plate is to study expression of angiogenic factors (VEGF and CD31) in 
hypertrophic chondrocytes with heat-treatment. A preliminary study collected (non-
quantitated) images of the proximal tibial growth plate from mice treated for 7 days from 
3-4 weeks of age dual stained with fluorescent antibodies against VEGF (magenta) and 
CD31 (yellow) (Fig. 31). Expression of angiogenic markers (CD31 and VEGF) appeared 
to increase in the hypertrophic zone on heat-treated sides. However, a method for 
standardizing and quantifying these images is necessary to determine significance.  
Another methodology for studying vascular changes at the growth plate is by 
multiphoton microscopy (MPM). MPM is a novel method of in vivo live animal imaging 
(Zipfel et al., 2003) and can be used to fluorescently label and track transport of small 
molecules into the growth plate (Serrat & Ion, 2017). Serrat et al. (2009, 2010, 2014a) 
have already shown that temperature increases solute uptake into the growth plate. By 
fluorescently labeling specific regulators or linear growth (such as IGF1 and VEGF), this 
method could be used in future studies to determine if targeted limb heating increases 
vascular transport of these molecules to the growth plate to promote heat-enhanced 
limb elongation. Although vasculature stands out as a key player in facilitating the heat-
enhanced limb growth response, it is also possible that heat may modulate 
temperature-sensitive genes and pathways through more direct mechanisms as an 







Figure 33. Expression of VEGF and CD31 Appeared to Increase in the Growth 
Plate on the Heat-Treated Sides  
Left-right comparison of proximal tibial growth plate from mice treated for 7 days from 3-
4 weeks of age. A greater trend in positive immunofluorescent staining for VEGF 
(magenta) and CD31 (yellow) was observed on the heat-treated sides. Sections were 
stained using immunohistochemistry methods and primary antibodies were detected by 
double immunofluorescence (IF). Mouse monoclonal antibody against VEGF (1:50, 
ThermoFisher Scientific, MA1-16629) and rabbit polyclonal antibody against CD31(1:50, 
abcam, ab28364) were detected by the VectaFluor Duet double labeling kit (Vector 
Laboratories, DK-8818) using Dylight® 488 anti-rabbit IgG and Dylight® 594 anti-mouse 
IgG. Since using a mouse primary antibody on mouse tissue, the Vector M.O.M. kit 
(Vector Laboratories, MP-2400) was used to eliminate high background staining. 
Imaged using the Leica DM2500 optical microscope and filters blue (DAPI), green 
(CD31) and red (VEGF) to detect fluorescence. Exposure was adjusted uniformly for 
both CD31 and VEGF, but DAPI was taken at a lower exposure (a great deal brighter in 
comparison). The same section of sample was taken at 20X for each filter for 









While results from this extensive preliminary study support our hypothesis that 
skin temperature of heat-treated limbs will remain elevated for an extended time 
following treatment, future studies are necessary to further validate the connection 
between increased blood flow and linear growth. These studies will be important for 
determining if the duration of elevated skin temperature is associated with an increased 
blood supply to the growth plate. The results from this chapter preface future studies 
into possible mechanisms of the targeted heating-model, as it suggests a heat-induced 





CHAPTER VIII: CONCLUDING REMARKS AND FUTURE DIRECTIONS 
 
 Bone elongation disorders, whether congenital or acquired in origin, can lead to 
painful musculoskeletal disabilities in adulthood (Gurney, 2002). Intervention is 
recommended for children during critical stages of postnatal longitudinal bone growth. 
Existing treatment options to correct left-right asymmetry in limb length involve invasive 
surgery and/or drug regimens, which are often only partially effective (Gurney, 2002; 
Hasler & Krieg, 2012; Niedzielski et al., 2016; Pendleton et al., 2013; Sabharwal et al., 
2015; Stevens, 2016). Therefore, it is important to find alternative, less invasive 
treatment options for bone lengthening. Previous studies in weanling mice 
demonstrated that after 14 days of targeted limb heating (40°C) on one side of the body, 
femoral length (1.3%) and tibial elongation rate (>12%) increased on heat-treated sides 
(Serrat et al., 2015). The goal of this dissertation was to build upon an established 
method using targeted limb heating as a potential non-invasive alternative to enhance 
bone lengthening.  
The epiphyseal growth plate is the main site of longitudinal growth and the main 
regulator of local cartilage growth is IGF1. Therefore, investigation focused on the 
effects of temperature on chondrocyte morphology and IGF1 action in the growth plate. 
It was hypothesized that exposure to warm temperature augments the actions of 
IGF1 in the growth plate and permanently increases length of the extremities. The 
central aims of the study were 1) determine if IGF1 enhances bone elongation in heat-
treated extremities and 2) determine potential vasculature modifications and long-term 
extent of left-right limb length asymmetries resulting from unilateral heat-treatment.  
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 The application of the model for targeted limb heating (unilateral heating model) 
and its functional impact is described in Chapter 2. X-ray and weight bearing data 
indicated that even small discrepancies in limb length (nearly 1%) have a functional 
impact on hindlimb weight distribution (nearly 20%) in young mice. These findings set 
the foundation for following experiments using the unilateral heating model as a means 
to test the overall hypothesis. The impact of heat-treatment on the cellular level of the 
growth plate had previously been unexplored. Others have determined that the main 
contributing factors to longitudinal growth include the rate of chondrocyte proliferation 
and hypertrophy (Cooper et al., 2013; Farnum, 2007, Hunziker et al., 1987; Hunziker & 
Schenk, 1989; Hunziker, 1994b; Kember, 1993; Rolian, 2008; Walker & Kember, 1972; 
Wilsman et al., 1996a,b, 2008). It was expected that targeted limb heating would be 
accompanied by an increase in bone elongation, chondrocyte proliferation (assessed by 
PNCA expression in proliferative zone), hypertrophic zone height, and expression of 
IGF1 signaling (IGF1R, pIGF1R, pAkt) in growth plate chondrocytes. Mice treated for 7 
days from 3-4 weeks of age (determined in Chapter 2 and 3 to be an efficient age range 
for heat-induced bone elongation), femoral length (1.7%), tibial elongation rate (7.7%), 
hypertrophic zone height (8.6%) and chondrocyte proliferation (8.6%) increased on 
heat-treated sides of saline-injected controls (Chapter 3). There was also an increase in 
IGF1R (14.5%) and pIGF1R (7.7%) expression in the proliferative zone demonstrating 
heat-enhanced IGF1 activity in the growth plate (Chapter 5). Left-right limb length 
asymmetry, along with enhanced growth plate kinetics was also observed in mice 
administered a low dose of IGF1 (2.5 mg/kg, once daily) in conjunction with targeted 
limb heating. However, advanced bone elongation compared to heat alone (saline-
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injected controls) was only observed when IGF1 was administered with 14 days of heat-
treatment (Chapter 4).   
There was no heat-induced increase in the parameters assessing linear bone 
growth when IGF1 activity was blocked in JB1 injected mice and levels were low in 
GHR-/- mice (Chapter 5). The overall gain in mass, one physiological outcome 
subjective to changes in IGF1, did not differ between groups suggesting targeted limb 
heating affects local regulation of IGF1 in growth plate chondrocytes. Future studies 
may re-examine the potential differences between male and female mice that may be 
observed with heat-enhanced IGF1 activity in the growth plate. While previous studies 
showed no differences in heat-enhanced bone elongation between sexes (Serrat et al., 
2015) these mice were not administered IGF1.  
 In the preliminary investigation of heat-induced changes in vascular supply, skin 
temperature was measured by infrared thermal imaging. Limb surface temperatures 
were recorded prior to, and at various times following, unilateral heat-treatment. It was 
concluded that limb surface temperature remained elevated (1.2%) on the heat-treated 
sides up to 4 hrs post treatment (Chapter 7) but this heat-retention was not 
accumulative after consecutive days of heating. These results suggest that the retention 
in skin temperature may be due to an increase in blood flow that normalizes after 4 
hours of heat-treatment. To verify if there is a true correlation between the observed 
retention in limb temperature and increased blood flow, experiments to quantify blood 
flow (such as the Doppler method) would need to be conducted in conjunction with 
thermal imaging. In vivo multiphoton microcopy would also be useful to quantify if 
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increased blood flow correlates to increased delivery of growth enhancing molecules to 
the growth plate.  
An additional study to determine heat-enhanced changes to vascular supply 
observed angiogenic factors (VEGF and CD31) in hypertrophic chondrocytes by 
immunohistochemistry (IHC) analysis. Images seem to indicate an increase in VEGF 
and CD31 expression in hypertrophic chondrocytes signifying a heat-induced increase 
in angiogenesis in the growth plate (Chapter 7). Future studies will be necessary to 
quantify expression levels and to determine if increased expression of angiogenic 
markers is a result of heat-induced increases in transport of signaling molecules, or a 
result of temperature-sensitive genes and pathways (either directly or by indirect 
delivery of warm-blood through the vasculature). 
Long-term effects of heat-treatment were also assessed by the heat-induced left-
right asymmetries in limb length sustained at skeletal maturity (12 weeks of age) 
(Chapter 6). Femoral length was increased on heat-treated sides of saline (0.5%) and 
IGF1-injected (1.0%) after 7 days of unilateral heat-treatment. Heat-treated femora were 
also increased in saline (0.6%) and IGF-injected (1.0%) mice after 14 days of heating. 
While femoral length differential was observed at skeletal maturity at both durations of 
treatment, these differences were only statistically significant in mice administered IGF1 
during heat-treatment. Tibial length increase on heat-treated sides (0.8%) was also 
maintained in IGF1-injected mice at the 12 week of age endpoint, but only following 14 
days of treatment. Further studies will need to be done to understand how IGF1 
administration in conjunction with heating elicits a more permanent limb lengthening 
effect compared to saline control mice. Next steps of this study will also be to collect x-
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ray images and weight bearing data (as described in Chapter 2) at skeletal maturity to 
provide translation relevance.  
The purpose of this study was to build upon the established method using 
targeted limb heating. The findings reviewed in the chapters of this dissertation have 
achieved this by determining that heat-enhanced growth is dependent on IGF1 and its 
local regulation of growing cartilage, which may involve changes to vasculature supply. 
While aware that other factors play a role in regulating longitudinal bone growth, IGF1 
was the focus of these studies since it has been shown to be essential for normal linear 
growth. Throughout this dissertation the role of IGF1, GH and VEGF have been 
described in detail to regulate longitudinal bone growth in the growth plate (Fig. 34). 
Both endocrine (GH and IGF1) and autocrine/paracrine (IGF1 and VEGF) actions of 
these factors have shown to be important in regulating linear growth. However future 
studies will be needed to determine how heat-treatment affects GH and VEGF, as well 
as other factors that regulate chondrocytes of the growth plate, including the Ihh/PThrP 





Figure 34. Diagram Summarizes the Action of Important Factors in the Different 
Zones of the Growth Plate  
(A) Demonstrates regions of the growth plate in which growth hormone receptor (GHR), 
insulin-like growth factor 1 receptor (IGF1R), IGF1 and VEGF are expressed. (B) 
Indicates the effects of GH, IGF1 and VEGF on growth plate chondrocytes. Illustration 
focuses on main factors discussed in this dissertation and excludes other endocrine and 
autocrine/paracrine factors that also regulate the growth plate. Illustration based on 
Mackie et al. (2008).  
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Filling gaps in these studies mentioned above would be beneficial for expanding 
upon the unilateral limb-heating model in the mouse. However, further studies using a 
larger animal model will be fundamental to advancing toward the ultimate goal of 
translating these methods clinically to humans in the hopes to develop an alternative, 
non-invasive treatment to enhance linear growth in children with bone lengthening 
disorders. The next step would be to use the targeted limb heating approach using 
larger animal models to work towards answering questions such as: how does 40°C 
heat-treatment translate into a larger animal? Is 40-minutes long enough to warm the 
entire limb and elicit lengthening effects (considering the threshold of heat-tolerance in 
larger animals)? What is the optimal period of postnatal growth in larger animals for 
heat-treatment (such as the comparable toddler to elementary school age in humans)? 
What device can be used to administer localized heat (such as a heating cuff)? This 
device would help control for uniform heating as an alternative to warming the entire 
side of the body done in mice. Continuing these studies using the targeted heating 
model may lead to new approaches to increase bone lengthening in children with linear 
growth disorders that would otherwise cause painful, chronic musculoskeletal conditions 
in adulthood. Summaries of the concluding remarks (Table 18) and future directions 
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APPENDIX B: LIST OF ABBREVIATIONS 
 
ABC…avidin-biotin complex 
ALS…acid labile subunit 
BMP…bone morphogenic protein 
BrdU…bromodeoxyuridine 
CD31…cluster of differentiation 31 
DAPI…4’,6-diamidino-2-phenylindole  
EDTA…ethylenediaminetetraacetic acid 
ERK…extracellular receptor kinase 
FGF…fibroblast growth factor 
GH…growth hormone 
GHR-/-…growth hormone receptor knockout  
GnRH…gonadotropin releasing hormone 
GP…growth plate 
H2O2…hydrogen peroxide  
HSP…heat-shock protein 
HZ…hypertrophic zone of growth plate cartilage 
IF…immunofluorescence 
IGF1…insulin-like growth factor 1 
IGF1R…insulin-like growth factor 1 receptor 
IGF2…insulin-like growth factor 2  





LID…liver IGF1-deficient  
LLD…limb length discrepancy 
MAPK… mitogen-activated protein kinase 
MPM…multiphoton microscopy 
OTC…oxytetracycline 
pAkt…phosphorylated Akt  
PBS…phosphate buffered solution 
PCNA…proliferating cell nuclear antigen 
PECAM1 (CD31)…platelet endothelial cell adhesion molecule 
PI-3…phosphatidylinositol-3  
PI3K…phosphoinositide 3-kinase 
pIGF1R…phosphorylated insulin-like growth factor 1 receptor 
PTHrP…parathyroid hormone-related protein 
PZ…proliferative zone of growth plate cartilage 





TKI…tyrosine kinase inhibitors 
TRα1…thyroid hormone receptor alpha 1  
TRβ…thyroid hormone receptor beta  
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VEGF…vascular endothelial growth factor 
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